@NP	Ex Vivo	1
@NP	Adenoviral Vector-Mediated Neurotrophin Gene Transfer	9
@NP	Olfactory Ensheathing Glia	66
@NP	Effects	94
@NP	Rubrospinal Tract Regeneration	105
@NP	Lesion Size	137
@NP	Functional Recovery after Implantation in the Injured Rat	154
@NP	Functional Recovery	154
@NP	Implantation in the Injured Rat	180
@NP	Implantation	180
@NP	the Injured Rat	196
@NP	Spinal Cord Marc J.	212
@NP	Ruitenberg ,1 * Giles W.	233
@NP	Ruitenberg	233
@NP	,1 * Giles W.	243
@NP	,1	243
@NP	Giles W.	247
@NP	Plant ,2,3 * Frank P.	256
@NP	Plant	256
@NP	,2,3 * Frank P.	261
@NP	,2,3	261
@NP	Frank P.	267
@NP	T.	276
@NP	Hamers ,4 Joke Wortel ,1 Bas Blits ,1 Paul A.	279
@NP	Hamers	279
@NP	,4 Joke Wortel ,1 Bas Blits ,1 Paul A.	285
@NP	Dijkhuizen ,1 Willem Hendrik Gispen ,4 Gerard J.	322
@NP	Dijkhuizen ,1	322
@NP	Willem Hendrik Gispen	335
@NP	,4 Gerard J.	356
@NP	Primary OEG	1124
@NP	AdV vectors encoding rat brain-derived neurotrophic factor -LRB- BDNF -RRB-	1157
@NP	AdV vectors	1157
@NP	rat brain-derived neurotrophic factor -LRB- BDNF -RRB-	1178
@NP	rat brain-derived neurotrophic factor	1178
@NP	BDNF	1217
@NP	neurotrophin-3 -LRB- NT-3 -RRB-	1224
@NP	neurotrophin-3	1224
@NP	NT-3	1240
@NP	bacterial marker protein betta-galactosidase -LRB- LacZ -RRB-	1250
@NP	bacterial marker protein betta-galactosidase	1250
@NP	LacZ	1296
@NP	adult Fischer rats	1334
@NP	unilateral transection of the dorsolateral funiculus	1368
@NP	unilateral transection	1368
@NP	the dorsolateral funiculus	1394
@NP	animals	1432
@NP	a total of 2x10 ^	1449
@NP	a total	1449
@NP	2x10 ^	1460
@NP	5 OEG	1465
@NP	transduction	1494
@NP	neurotrophin-encoding AdV vector , AdV-LacZ , or no vector	1512
@NP	neurotrophin-encoding AdV vector	1512
@NP	AdV-LacZ	1546
@NP	no vector	1559
@NP	4 months after injury	1587
@NP	4 months	1587
@NP	injury	1602
@NP	lesion volumes	1610
@NP	allOEGimplanted rats	1641
@NP	size	1691
@NP	implantation of neurotrophin-encoding AdV vector-transduced OEG	1702
@NP	implantation	1702
@NP	neurotrophin-encoding AdV vector-transduced OEG	1718
@NP	All OEG grafts	1767
@NP	neurofilament-positive axons	1799
@NP	AdV vector-mediated expression of BDNF by implanted cells	1833
@NP	AdV vector-mediated expression	1833
@NP	BDNF by implanted cells	1867
@NP	BDNF	1867
@NP	implanted cells	1875
@NP	the rubrospinal tract	1940
@NP	Behavioral analysis	1963
@NP	OEG-implanted rats	1997
@NP	better locomotion	2026
@NP	horizontal rope walking	2051
@NP	unimplanted lesioned controls	2080
@NP	Recovery of hind limb function	2111
@NP	Recovery	2111
@NP	hind limb function	2123
@NP	implantation of OEG that were transduced with a BDNF	2166
@NP	implantation	2166
@NP	OEG	2182
@NP	a BDNF	2212
@NP	NT-3-encoding AdV vector	2223
@NP	Hind limb performance during horizontal rope locomotion	2249
@NP	Hind limb performance	2249
@NP	horizontal rope locomotion	2278
@NP	lesion size	2333
@NP	neuroprotective effects of OEG implants	2362
@NP	neuroprotective effects	2362
@NP	OEG implants	2389
@NP	the level of functional recovery	2417
@NP	the level	2417
@NP	functional recovery	2430
@NP	our results	2457
@NP	genetic engineering of OEG	2486
@NP	genetic engineering	2486
@NP	OEG	2509
@NP	a cell that was more effective in promoting axonal outgrowth	2534
@NP	a cell	2534
@NP	axonal outgrowth	2578
@NP	enhanced recovery after injury	2618
@NP	enhanced recovery	2618
@NP	injury	2642
@NP	sparing of spinal tissue	2662
@NP	sparing	2662
@NP	spinal tissue	2673
@NP	Introduction Impairment in voluntary motor function after spinal trauma	2689
@NP	Introduction Impairment	2689
@NP	voluntary motor function after spinal trauma	2716
@NP	voluntary motor function	2716
@NP	spinal trauma	2747
@NP	disruption	2790
@NP	descending motor pathways at the injury site -LRB- Nathan , 1994 -RRB-	2804
@NP	descending motor pathways	2804
@NP	the injury site -LRB- Nathan , 1994 -RRB-	2833
@NP	the injury site	2833
@NP	Nathan	2850
@NP	1994	2858
@NP	such damage	2871
@NP	very little regenerative response	2884
@NP	a permanent loss of function and paralysis	2939
@NP	a permanent loss	2939
@NP	function and paralysis	2959
@NP	This paucity of regeneration in the adult mammalian CNS	2983
@NP	This paucity	2983
@NP	regeneration in the adult mammalian CNS	2999
@NP	regeneration	2999
@NP	the adult mammalian CNS	3015
@NP	a negative balance	3063
@NP	factors	3090
@NP	axon growth	3122
@NP	review	3139
@NP	Schwab and Bartholdi , 1996 ; Fournier and Strittmatter , 2001	3151
@NP	Schwab and Bartholdi , 1996	3151
@NP	Schwab and Bartholdi	3151
@NP	1996	3173
@NP	Fournier and Strittmatter , 2001	3179
@NP	Fournier and Strittmatter	3179
@NP	2001	3206
@NP	Neurotrophic factor delivery	3213
@NP	inhibition	3283
@NP	regeneration	3306
@NP	spinal motor pathways	3322
@NP	the corticospinal tract -LRB- CST -RRB- and rubrospinal tract -LRB- RST -RRB-	3353
@NP	the corticospinal tract	3353
@NP	CST	3378
@NP	rubrospinal tract	3387
@NP	RST	3406
@NP	review	3416
@NP	Jones	3428
@NP	et al. , 2001 ; Murray and Fischer , 2001	3434
@NP	et al.	3434
@NP	2001 ; Murray and Fischer , 2001	3442
@NP	2001	3442
@NP	Murray and Fischer , 2001	3448
@NP	Murray and Fischer	3448
@NP	2001	3468
@NP	Neurotrophins	3475
@NP	their beneficial effects	3508
@NP	neuroprotection and neurite outgrowth	3536
@NP	Local delivery of neurotrophins	3575
@NP	Local delivery	3575
@NP	neurotrophins	3593
@NP	pathological events	3622
@NP	a regenerative response	3653
@NP	Schnell	3695
@NP	et al. , 1994	3703
@NP	et al.	3703
@NP	1994	3711
@NP	Tetzlaff et al. , 1994 -RRB- and chronic -LRB- Houle and Ye , 1999	3717
@NP	Tetzlaff et al. , 1994 -RRB-	3717
@NP	Tetzlaff	3717
@NP	et al.	3726
@NP	1994	3734
@NP	chronic -LRB- Houle and Ye , 1999	3744
@NP	chronic	3744
@NP	Ye	3763
@NP	1999	3767
@NP	Kwon et al. , 2002	3773
@NP	Kwon	3773
@NP	et al. , 2002	3778
@NP	et al.	3778
@NP	2002	3786
@NP	addition to intraparenchymal infusions	3815
@NP	addition	3815
@NP	intraparenchymal infusions	3827
@NP	genetically modified cells that deliver neurotrophins	3855
@NP	genetically modified cells	3855
@NP	neurotrophins	3895
@NP	Engineered fibroblasts -LRB- Grill et al. , 1997 ; Liu et al. , 1999 -RRB-	3928
@NP	Engineered fibroblasts	3928
@NP	Grill	3952
@NP	et al. , 1997 ; Liu et al. , 1999	3958
@NP	et al.	3958
@NP	1997 ; Liu et al.	3966
@NP	1997	3966
@NP	Liu et al.	3972
@NP	Liu	3972
@NP	et al.	3976
@NP	1999	3984
@NP	Schwann cells -LRB- Menei et al. , 1998 -RRB-	3991
@NP	Schwann cells	3991
@NP	Menei	4006
@NP	et al. , 1998	4012
@NP	et al.	4012
@NP	1998	4020
@NP	pieces of peripheral nerve	4031
@NP	pieces	4031
@NP	peripheral nerve	4041
@NP	Blits et al. , 2000	4059
@NP	Blits	4059
@NP	et al.	4065
@NP	2000	4073
@NP	regeneration	4104
@NP	injury	4123
@NP	much research	4141
@NP	the use	4170
@NP	olfactory ensheathing glia	4181
@NP	OEG	4209
@NP	advantages over other cellular conduits	4228
@NP	advantages	4228
@NP	other cellular conduits	4244
@NP	review	4273
@NP	Franklin and Barnett , 2000 ; Plant et al. , 2000	4285
@NP	Franklin and Barnett , 2000	4285
@NP	Franklin and Barnett	4285
@NP	2000	4307
@NP	Plant et al. , 2000	4313
@NP	Plant	4313
@NP	et al. , 2000	4319
@NP	et al.	4319
@NP	2000	4327
@NP	the adult olfactory neuroepithelium	4337
@NP	dying receptor neurons	4374
@NP	a compartment of stem cells	4415
@NP	a compartment	4415
@NP	stem cells	4432
@NP	the basal region of the epithelium -LRB- Farbman , 1992 -RRB-	4446
@NP	the basal region	4446
@NP	the epithelium -LRB- Farbman , 1992 -RRB-	4466
@NP	the epithelium	4466
@NP	Farbman	4482
@NP	1992	4491
@NP	The ability	4498
@NP	new primary olfactory neurons	4513
@NP	their axons	4555
@NP	a CNS environment	4572
@NP	the presence of OEG -LRB- Doucette , 1990 , 1991 -RRB-	4618
@NP	the presence	4618
@NP	OEG -LRB- Doucette , 1990 , 1991 -RRB-	4634
@NP	OEG	4634
@NP	Doucette	4639
@NP	1990	4649
@NP	1991	4655
@NP	These cells uniquely present	4662
@NP	These cells	4662
@NP	Schwann cell-like and astrocyte-like characteristics -LRB- for review ,	4696
@NP	Schwann	4696
@NP	cell-like and astrocyte-like characteristics -LRB- for review ,	4704
@NP	cell-like and astrocyte-like characteristics	4704
@NP	review	4754
@NP	Ramon-Cueto and Avila , 1998	4766
@NP	Ramon-Cueto and Avila	4766
@NP	1998	4789
@NP	great potential	4812
@NP	the damaged spinal cord	4838
@NP	Li	4863
@NP	et al.	4866
@NP	1997 , 1998	4874
@NP	1997	4874
@NP	1998	4880
@NP	Ramon-Cueto et al. , 1998	4886
@NP	Ramon-Cueto	4886
@NP	et al. , 1998	4898
@NP	et al.	4898
@NP	1998	4906
@NP	Barnett et al. , 2000	4912
@NP	Barnett	4912
@NP	et al. , 2000	4920
@NP	et al.	4920
@NP	2000	4928
@NP	Ramon-Cueto et al. , 2000	4934
@NP	Ramon-Cueto	4934
@NP	et al. , 2000	4946
@NP	et al.	4946
@NP	2000	4954
@NP	Lu et al.	4960
@NP	Lu	4960
@NP	et al.	4963
@NP	2001a	4971
@NP	not all axonal populations	4988
@NP	OEG implants -LRB- Gudino-Cabrera et al. , 2000 -RRB-	5025
@NP	OEG implants	5025
@NP	Gudino-Cabrera	5039
@NP	et al. , 2000	5054
@NP	et al.	5054
@NP	2000	5062
@NP	Additional adenoviral	5069
@NP	AdV	5092
@NP	vector-mediated neurotrophin expression	5097
@NP	their regeneration-supporting properties	5151
@NP	endogenous neurotrophic factor expression by OEG	5201
@NP	endogenous neurotrophic factor expression	5201
@NP	OEG	5246
@NP	Boruch	5258
@NP	et al. , 2001 ; Woodhall et al. , 2001	5265
@NP	et al.	5265
@NP	2001 ; Woodhall et al.	5273
@NP	2001	5273
@NP	Woodhall et al.	5279
@NP	Woodhall	5279
@NP	et al.	5288
@NP	2001	5296
@NP	AdVvector-mediated gene transfer	5302
@NP	OEG results	5338
@NP	transient transgene expression	5353
@NP	≈ 30 d after implantation in the lesioned rat spinal cord	5388
@NP	implantation in the lesioned rat	5400
@NP	implantation	5400
@NP	the lesioned rat	5416
@NP	Ruitenberg	5446
@NP	et al. , 2002	5457
@NP	et al.	5457
@NP	2002	5465
@NP	The present experiment	5472
@NP	a new approach	5506
@NP	spinal cord repair	5524
@NP	ex vivo AdV	5555
@NP	vector-transduced OEG implants	5567
@NP	an attempt to create more conducive conditions for RST regeneration	5601
@NP	more conducive conditions for RST regeneration	5622
@NP	more conducive conditions	5622
@NP	RST regeneration	5652
@NP	We	5670
@NP	the effects	5682
@NP	AdV vector-mediated hypersecretion	5697
@NP	brain-derived neurotrophic factor -LRB- BDNF -RRB- and neurotrophin-3	5735
@NP	brain-derived neurotrophic factor -LRB- BDNF -RRB-	5735
@NP	brain-derived neurotrophic factor	5735
@NP	BDNF	5770
@NP	neurotrophin-3	5780
@NP	NT-3	5796
@NP	two putative RST neurotrophic factors	5803
@NP	Kobayashi	5842
@NP	et al. , 1997 ; Liebl et al. , 2001	5852
@NP	et al.	5852
@NP	1997 ; Liebl et al.	5860
@NP	1997	5860
@NP	Liebl et al.	5866
@NP	Liebl	5866
@NP	et al.	5872
@NP	2001	5880
@NP	functional recovery and RST regeneration	5890
@NP	cervical injury	5937
@NP	Anatomical , electrophysiological , and functional analysis	5954
@NP	Anatomical	5954
@NP	electrophysiological , and functional analysis	5966
@NP	regeneration	6031
@NP	animals over a 4 month observation period	6047
@NP	animals	6047
@NP	a 4 month observation period	6060
@NP	Materials and Methods Recombinant AdV stock production .	6090
@NP	Materials and Methods	6090
@NP	Materials	6090
@NP	Methods	6104
@NP	Recombinant AdV stock production	6112
@NP	Recombinant AdV	6112
@NP	stock production	6128
@NP	The production	6146
@NP	first generation E1-deleted adenoviral vector stocks	6164
@NP	the bacterial marker enzyme betta-galactosidase -LRB- betta-gal ; AdV-LacZ -RRB-	6226
@NP	the bacterial marker enzyme betta-galactosidase	6226
@NP	betta-gal ; AdV-LacZ	6275
@NP	betta-gal	6275
@NP	AdV-LacZ	6286
@NP	Hermens	6297
@NP	et al. , 1997	6305
@NP	et al.	6305
@NP	1997	6313
@NP	rat NT-3 -LRB- AdV-NT-3 -RRB- -LRB- Dijkhuizen et al. , 1997 -RRB-	6322
@NP	rat NT-3 -LRB- AdV-NT-3 -RRB-	6322
@NP	rat NT-3	6322
@NP	AdV-NT-3	6332
@NP	Dijkhuizen	6343
@NP	et al. , 1997	6354
@NP	et al.	6354
@NP	1997	6362
@NP	detail	6401
@NP	the construction of an AdV vector-encoding BDNF	6413
@NP	the construction	6413
@NP	an AdV vector-encoding BDNF	6433
@NP	total RNA	6462
@NP	adult rat brain	6490
@NP	First strand cDNA	6507
@NP	reverse transcriptase	6547
@NP	Invitrogen	6570
@NP	Grand Island	6582
@NP	NY	6596
@NP	oligo-dT primers	6604
@NP	BDNF cDNA	6636
@NP	the total cDNA	6665
@NP	a PCR	6684
@NP	an upstream sense primer	6696
@NP	5	6721
@NP	CCC GGA ATT CGC CAC CAT GAC CAT CCT TTT CCT TAC	6724
@NP	T-3 ' and downstream antisense primer	6772
@NP	T-3	6772
@NP	downstream antisense primer	6781
@NP	5	6809
@NP	TTT AGA	6812
@NP	ATT CCT ATC TTC CCC TTT TAA TTG GT-3 '	6820
@NP	Amersham Biosciences	6859
@NP	Piscataway	6881
@NP	NJ	6893
@NP	Primer sets	6898
@NP	an EcoR1 site and a Kozak sequence -LRB- GCCACC ; Kozak , 1987 -RRB-	6934
@NP	an EcoR1 site	6934
@NP	a Kozak sequence -LRB- GCCACC ; Kozak , 1987 -RRB-	6952
@NP	a Kozak sequence	6952
@NP	GCCACC ; Kozak , 1987	6970
@NP	GCCACC	6970
@NP	Kozak , 1987	6978
@NP	Kozak	6978
@NP	1987	6985
@NP	front of the translation startcodon ATG	7010
@NP	front	7010
@NP	the translation startcodon ATG	7019
@NP	The PCR product	7051
@NP	the expression plasmid pcDNA-I/Amp -LRB- Invitrogen -RRB-	7089
@NP	the expression plasmid pcDNA-I/Amp	7089
@NP	Invitrogen	7125
@NP	downstream of the human cytomegalovirus -LRB- CMV -RRB- promoter	7137
@NP	downstream	7137
@NP	the human cytomegalovirus -LRB- CMV -RRB- promoter	7151
@NP	CMV	7178
@NP	Nucleic acid sequencing	7193
@NP	the PCR product	7243
@NP	rat BDNF cDNA using the United States Biochemicals sequencing kit	7262
@NP	rat BDNF cDNA	7262
@NP	the United States Biochemicals sequencing kit	7282
@NP	United States Biochemicals , Cleveland , OH	7329
@NP	United States Biochemicals	7329
@NP	Cleveland	7357
@NP	OH	7368
@NP	BDNF cDNA	7379
@NP	the AdV-targeting plasmid pAd309 dlE1.sl / SalI	7403
@NP	the AdV-targeting plasmid pAd309 dlE1.sl	7403
@NP	SalI	7445
@NP	the plasmid pAd-BDNF	7461
@NP	All targeting plasmids	7483
@NP	LacZ , BDNF , or NT-3	7516
@NP	a transgene expression cassette	7561
@NP	the CMV promoter	7598
@NP	transgene expression and an SV-40 splice donor	7624
@NP	transgene expression	7624
@NP	an SV-40 splice donor	7649
@NP	acceptor site and polyadenylation sequence downstream of the gene of interest	7671
@NP	acceptor site and polyadenylation sequence downstream	7671
@NP	the gene of interest	7728
@NP	the gene	7728
@NP	interest	7740
@NP	Replication-deficient E1-deleted AdV vectors	7750
@NP	standard procedures -LRB- Akli et al. , 1993 -RRB-	7815
@NP	standard procedures	7815
@NP	Akli	7836
@NP	et al. , 1993	7841
@NP	et al.	7841
@NP	1993	7849
@NP	brief	7859
@NP	AdV-targeting plasmid	7866
@NP	SalI digestion	7906
@NP	plasmid	7943
@NP	ClaI	7979
@NP	XbaI-digested Ad5 DNA	7989
@NP	911 producer cells -LRB- Fallaux et al. , 1996 -RRB-	8016
@NP	911 producer cells	8016
@NP	Fallaux	8036
@NP	et al. , 1996	8044
@NP	et al.	8044
@NP	1996	8052
@NP	The following day	8059
@NP	cells	8078
@NP	0.66 % agar-containing medium -LRB- Invitrogen -RRB-	8103
@NP	0.66 % agar-containing medium	8103
@NP	0.66 %	8103
@NP	Invitrogen	8133
@NP	8 d	8152
@NP	lytic plaques	8157
@NP	PCR	8206
@NP	Plaque-purified recombinant AdV vector	8211
@NP	911 cells	8271
@NP	two rounds of CsCl density gradient centrifugation	8309
@NP	two rounds	8309
@NP	CsCl density gradient centrifugation	8323
@NP	Recombinant AdV vector particles	8361
@NP	the gradient	8414
@NP	TS buffer	8445
@NP	25mM Tris-HCl	8456
@NP	0.7 mM Na2HPO4	8471
@NP	137mM NaCl	8486
@NP	6mM KCl	8498
@NP	1.1 mM MgCl2	8507
@NP	0.9 mM CaCl2	8521
@NP	pH 7.4	8535
@NP	small aliquots	8557
@NP	80 °C in TS buffer	8575
@NP	80 °C	8575
@NP	TS buffer	8583
@NP	10 % glycerol	8604
@NP	Viral stock titers	8618
@NP	a plaque assay on 911 cells	8656
@NP	a plaque assay	8656
@NP	911 cells	8674
@NP	plaque-forming units per milliliter -LRB- pfu/ml -RRB-	8701
@NP	plaque-forming units	8701
@NP	milliliter -LRB- pfu/ml -RRB-	8726
@NP	milliliter	8726
@NP	pfu/ml	8738
@NP	All stock titers used	8747
@NP	All stock titers	8747
@NP	the range of 1010 pfu/ml	8777
@NP	the range	8777
@NP	1010 pfu/ml	8790
@NP	use	8810
@NP	recombinant AdV vector stocks	8815
@NP	the absence	8863
@NP	replication-competent adenovirus as described previously	8878
@NP	replication-competent adenovirus as	8878
@NP	Hermens	8936
@NP	et al. , 1997	8944
@NP	et al.	8944
@NP	1997	8952
@NP	Culturing of OEG .	8959
@NP	Culturing	8959
@NP	OEG	8972
@NP	The isolation of OEG from the olfactory bulb nerve layer	8977
@NP	The isolation	8977
@NP	OEG from the olfactory bulb nerve layer	8994
@NP	OEG	8994
@NP	the olfactory bulb nerve layer	9003
@NP	Yan et al. , 2001	9065
@NP	Yan	9065
@NP	et al.	9069
@NP	2001	9077
@NP	adult female Fischer F344 rats	9093
@NP	intraperitoneal injection	9139
@NP	a lethal dose	9168
@NP	Nembutal -LRB- Rhoˆne-Me ' rieux , Pinkenba , QLD , Australia -RRB-	9185
@NP	Nembutal	9185
@NP	Rhoˆne-Me ' rieux , Pinkenba , QLD , Australia	9196
@NP	Rhoˆne-Me ' rieux	9196
@NP	Rhoˆne-Me '	9196
@NP	Pinkenba , QLD , Australia	9213
@NP	The olfactory bulbs	9256
@NP	Leibovitz 's -15 -LRB- L-15 -RRB- medium -LRB- Sigma , St Louis , MO -RRB-	9318
@NP	Leibovitz 's	9318
@NP	-15 -LRB- L-15 -RRB- medium -LRB- Sigma , St Louis , MO -RRB-	9329
@NP	-15 -LRB- L-15 -RRB- medium	9329
@NP	Sigma	9348
@NP	St Louis	9355
@NP	MO	9365
@NP	The pia	9370
@NP	a microscope	9411
@NP	fine Dumont forceps	9430
@NP	the ventral olfactory nerve and glomerular layers	9457
@NP	the ventral olfactory nerve	9457
@NP	glomerular layers	9489
@NP	the rest of the bulb	9532
@NP	the rest	9532
@NP	the bulb	9544
@NP	1mm3 pieces	9566
@NP	tissue blocks	9593
@NP	0.25 % trypsin -LRB- Invitrogen -RRB-	9627
@NP	0.25 % trypsin	9627
@NP	Invitrogen	9642
@NP	50 mg/ml DNase -LRB- Invitrogen -RRB- at 37 °C for 60 min	9665
@NP	50 mg/ml DNase -LRB- Invitrogen -RRB-	9665
@NP	50 mg/ml DNase	9665
@NP	Invitrogen	9681
@NP	37 °C for 60 min	9696
@NP	37 °C	9696
@NP	60 min	9705
@NP	continual shaking	9717
@NP	Trypsinization	9736
@NP	DMEM -LRB- Sigma -RRB-	9773
@NP	DMEM	9773
@NP	Sigma	9779
@NP	Ham 's F-12 -LRB- DMEM/F -12 ; 1:1 mixture ; Sigma -RRB-	9790
@NP	Ham 's F-12	9790
@NP	Ham 's	9790
@NP	DMEM/F -12	9802
@NP	1:1 mixture ; Sigma	9813
@NP	1:1 mixture	9813
@NP	Sigma	9826
@NP	10 % fetal bovine serum -LRB- FBS ; df-10S ; Invitrogen -RRB-	9851
@NP	10 % fetal bovine serum	9851
@NP	FBS	9875
@NP	df-10S ; Invitrogen	9880
@NP	df-10S	9880
@NP	Invitrogen	9888
@NP	50 mg/ml gentamicin -LRB- Invitrogen -RRB-	9904
@NP	50 mg/ml gentamicin	9904
@NP	Invitrogen	9925
@NP	The suspension	9938
@NP	poly-L-lysinecoated 10 cm dishes	9996
@NP	10	10016
@NP	Six to seven days after the initial plating , OEG	10030
@NP	Six	10030
@NP	seven days after the initial plating , OEG	10037
@NP	seven days	10037
@NP	the initial plating , OEG	10054
@NP	the initial plating	10054
@NP	OEG	10075
@NP	contaminated cells	10098
@NP	immunoaffinity using the p75 neurotrophin receptor -LRB- p75NTR -RRB-	10120
@NP	immunoaffinity	10120
@NP	the p75 neurotrophin receptor -LRB- p75NTR -RRB-	10141
@NP	the p75 neurotrophin receptor	10141
@NP	p75NTR	10172
@NP	this	10185
@NP	10cmPetri dishes -LRB- Scot Scientific , Perth , WA , Australia -RRB-	10191
@NP	10cmPetri dishes	10191
@NP	Scot Scientific	10209
@NP	Perth	10226
@NP	WA , Australia	10233
@NP	4 °C	10276
@NP	goat antimouse antibodies	10285
@NP	1:100	10312
@NP	ICN Biomedicals , Seven Hills , NSW , Australia	10319
@NP	ICN Biomedicals	10319
@NP	Seven Hills	10336
@NP	NSW	10349
@NP	Australia	10354
@NP	several washes	10372
@NP	the dishes	10388
@NP	with p75NTR monoclonal antibody	10414
@NP	with p75NTR	10414
@NP	p75NTR	10419
@NP	Dr.	10470
@NP	P.	10474
@NP	Wood , University of Miami School of Medicine , Miami , FL -RRB- in L-15 medium	10477
@NP	Wood , University of Miami School of Medicine , Miami , FL -RRB-	10477
@NP	Wood , University of Miami School of Medicine , Miami	10477
@NP	Wood , University	10477
@NP	Miami School of Medicine , Miami	10497
@NP	Miami School	10497
@NP	Medicine , Miami	10513
@NP	FL	10530
@NP	L-15 medium	10537
@NP	5 % FBS for 2 hr at 4 °C	10567
@NP	5 % FBS	10567
@NP	2 hr at 4 °C	10578
@NP	2 hr	10578
@NP	4 °C	10586
@NP	Unbound antibody	10591
@NP	several washings	10623
@NP	L-15 medium	10645
@NP	The cells in primary culture	10658
@NP	The cells	10658
@NP	primary culture	10671
@NP	trypsinization	10709
@NP	centrifugation	10737
@NP	L-15 medium	10772
@NP	a 10 ml suspension of olfactory bulb cells	10791
@NP	a 10 ml suspension	10791
@NP	olfactory bulb cells	10813
@NP	pretreated dishes	10850
@NP	a density of 4	10871
@NP	a density	10871
@NP	4	10884
@NP	10 ^ 5 cells per dish	10888
@NP	10 ^ 5 cells	10888
@NP	dish	10903
@NP	30 min at 4 °C	10912
@NP	30 min	10912
@NP	4 °C	10922
@NP	Unbound cells	10927
@NP	the dishes	10959
@NP	several washes	10977
@NP	L-15 medium	10997
@NP	The attached cells	11010
@NP	the dishes	11059
@NP	a cell scraper -LRB- Sarstedt , Newton , NC -RRB-	11076
@NP	a cell scraper	11076
@NP	Sarstedt	11092
@NP	Newton	11102
@NP	NC	11110
@NP	df-10S	11147
@NP	cells	11164
@NP	poly-Llysine - coated 10 cm dishes	11192
@NP	poly-Llysine	11192
@NP	coated 10 cm dishes	11206
@NP	coated	11206
@NP	10 cm dishes	11213
@NP	df-10S	11239
@NP	mitogens -LRB- 20 µg/ml pituitary extract and 2 µM forskolin ; Sigma -RRB-	11257
@NP	mitogens	11257
@NP	20 µg/ml pituitary extract and 2 µM forskolin ; Sigma	11267
@NP	20 µg/ml pituitary extract	11267
@NP	20 µg/ml	11267
@NP	pituitary extract	11276
@NP	2 µM forskolin ; Sigma	11298
@NP	2 µM forskolin	11298
@NP	Sigma	11314
@NP	Transduction of OEG cultures with AdV vectors .	11322
@NP	Transduction	11322
@NP	OEG cultures	11338
@NP	AdV vectors	11356
@NP	The methods for optimal transduction of primary OEG	11369
@NP	The methods	11369
@NP	optimal transduction of primary OEG	11385
@NP	optimal transduction	11385
@NP	primary OEG	11409
@NP	AdV	11427
@NP	vector-mediated gene transfer	11431
@NP	Ruitenberg et al. , 2002	11491
@NP	Ruitenberg	11491
@NP	et al.	11502
@NP	2002	11510
@NP	cells	11526
@NP	poly-L-lysine-coated six-well plates	11549
@NP	a density of 105 cells per well	11589
@NP	a density	11589
@NP	105 cells per well	11602
@NP	105 cells	11602
@NP	OEG	11622
@NP	overnight with df-10S supplemented with mitogens -LRB- see above -RRB-	11640
@NP	overnight with df-10S	11640
@NP	overnight	11640
@NP	df-10S	11655
@NP	mitogens	11680
@NP	The following day	11702
@NP	the medium	11721
@NP	df-10S	11750
@NP	a lowered mitogen concentration	11768
@NP	2 µg/ml pituitary extract and 0.2 µM forskolin	11801
@NP	2 µg/ml	11801
@NP	pituitary extract and 0.2 µM forskolin	11809
@NP	pituitary extract	11809
@NP	0.2 µM forskolin	11831
@NP	OEG proliferation	11861
@NP	AdV vectors	11888
@NP	the host cell genome	11922
@NP	proliferation of transduced OEG	11944
@NP	proliferation	11944
@NP	OEG	11972
@NP	the loss	11989
@NP	episomally located viral DNA and , consequently , transgene expression	12001
@NP	episomally located viral DNA and , consequently , transgene	12001
@NP	episomally located viral DNA	12001
@NP	transgene	12049
@NP	Recombinant AdV vector encoding betta-gal , BDNF , or NT-3	12071
@NP	Recombinant AdV vector	12071
@NP	betta-gal , BDNF , or NT-3	12103
@NP	betta-gal	12103
@NP	BDNF	12114
@NP	NT-3	12123
@NP	each	12141
@NP	a multiplicity of infection -LRB- moi -RRB- of 100	12156
@NP	a multiplicity	12156
@NP	infection -LRB- moi -RRB- of 100	12174
@NP	infection -LRB- moi -RRB-	12174
@NP	infection	12174
@NP	moi	12185
@NP	100	12193
@NP	the transduction	12211
@NP	virtually all cultured cells -LRB- Ruitenberg et al. , 2002 -RRB-	12231
@NP	virtually all	12231
@NP	cells -LRB- Ruitenberg et al. , 2002 -RRB-	12254
@NP	cells	12254
@NP	Ruitenberg	12261
@NP	et al. , 2002	12272
@NP	et al.	12272
@NP	2002	12280
@NP	Three days	12287
@NP	infection	12304
@NP	OEG cultures	12315
@NP	4 % paraformaldehyde -LRB- PFA -RRB- and 0.2 % glutaraldehyde	12344
@NP	4 % paraformaldehyde -LRB- PFA -RRB-	12344
@NP	4 % paraformaldehyde	12344
@NP	PFA	12365
@NP	0.2 % glutaraldehyde	12374
@NP	PBS	12397
@NP	10 min at room temperature -LRB- RT -RRB-	12405
@NP	10 min	12405
@NP	room temperature -LRB- RT -RRB-	12415
@NP	room temperature	12415
@NP	RT	12433
@NP	OEG cultures	12449
@NP	hybridization analysis	12508
@NP	Giger	12548
@NP	et al. -LRB- 1996 -RRB-	12554
@NP	et al.	12554
@NP	1996	12562
@NP	digoxigenin	12575
@NP	DIG	12588
@NP	antisense cRNA probes	12601
@NP	betta-gal , BDNF , or NT-3	12636
@NP	betta-gal	12636
@NP	BDNF	12647
@NP	NT-3	12656
@NP	Neurotrophin production from	12662
@NP	Neurotrophin production	12662
@NP	OEG	12702
@NP	Conditioned medium	12707
@NP	OEG cultures	12756
@NP	the levels of secreted AdV vector-derived BDNF and NT-3 via an ELISA	12782
@NP	the levels	12782
@NP	AdV vector-derived BDNF and NT-3 via an ELISA	12805
@NP	AdV vector-derived BDNF	12805
@NP	NT-3 via an ELISA	12833
@NP	NT-3	12833
@NP	an ELISA	12842
@NP	Woodhall	12868
@NP	et al. -LRB- 2001 -RRB-	12877
@NP	et al.	12877
@NP	2001	12885
@NP	cultures of OEG	12903
@NP	cultures	12903
@NP	OEG	12915
@NP	Three days	12953
@NP	infection	12970
@NP	the medium	12981
@NP	the cultures	13010
@NP	24 hr	13037
@NP	determination of net production levels per day	13053
@NP	determination	13053
@NP	net production levels per day	13070
@NP	net production levels	13070
@NP	day	13096
@NP	Samples of conditioned medium	13101
@NP	Samples	13101
@NP	conditioned medium	13112
@NP	control	13142
@NP	OEG cultures	13165
@NP	dry ice -- ethanol	13201
@NP	-80 °C	13231
@NP	additional processing	13243
@NP	The Emax immunoassay system -LRB- Promega , Leiden , The Netherlands -RRB-	13266
@NP	The Emax immunoassay system	13266
@NP	Promega	13295
@NP	Leiden	13304
@NP	The Netherlands	13312
@NP	the levels of neurotrophic factor protein in OEGconditioned medium	13351
@NP	the levels	13351
@NP	neurotrophic factor protein in OEGconditioned medium	13365
@NP	neurotrophic factor protein	13365
@NP	OEGconditioned medium	13396
@NP	the instructions of the manufacturer	13431
@NP	the instructions	13431
@NP	the manufacturer	13451
@NP	The amount of secreted neurotrophic factor	13469
@NP	The amount	13469
@NP	neurotrophic factor	13492
@NP	nanograms	13529
@NP	BDNF or NT-3	13542
@NP	a transduced OEG culture -LRB- 10 5 cells -RRB- per day	13568
@NP	a	13568
@NP	OEG culture -LRB- 10 5 cells -RRB- per day	13581
@NP	OEG culture -LRB- 10 5 cells -RRB-	13581
@NP	OEG culture	13581
@NP	10 5 cells	13594
@NP	day	13610
@NP	Biological activity of AdV vector-derived neurotrophins .	13615
@NP	Biological activity	13615
@NP	AdV vector-derived neurotrophins	13638
@NP	recombinant BDNF and NT-3 protein	13693
@NP	recombinant BDNF	13693
@NP	NT-3 protein	13714
@NP	we	13752
@NP	their effect	13763
@NP	neurite outgrowth	13779
@NP	embryonic dorsal root ganglion -LRB- DRG -RRB- explants	13802
@NP	Dijkhuizen	13864
@NP	et al. -LRB- 1997 -RRB-	13875
@NP	et al.	13875
@NP	1997	13883
@NP	OEG -LRB- 10 ^ 4 cells -RRB-	13899
@NP	OEG	13899
@NP	10 ^ 4 cells	13904
@NP	10 ^	13904
@NP	4 cells	13907
@NP	poly-L-lysine-coated 12 mm glass coverslips	13933
@NP	AdV-LacZ , AdV-BDNF , AdV-NT-3 , or no virus	13995
@NP	AdV-LacZ	13995
@NP	AdV-BDNF	14005
@NP	AdV-NT-3	14015
@NP	no virus	14028
@NP	Three days	14072
@NP	AdV vector-mediated transduction of OEG cultures	14089
@NP	AdV vector-mediated transduction	14089
@NP	OEG cultures	14125
@NP	embryonic DRGs	14139
@NP	timed pregnant female rats	14172
@NP	embryonic day -LRB- E -RRB- 14 pregnant females	14209
@NP	embryonic day -LRB- E -RRB-	14209
@NP	14 pregnant females	14227
@NP	an intraperitoneal overdose of Nembutal	14262
@NP	an intraperitoneal overdose	14262
@NP	Nembutal	14293
@NP	the entire litter	14325
@NP	Cesarean section	14366
@NP	wet icecooled L-15 medium	14402
@NP	E14 lumbar DRGs	14429
@NP	rat embryos	14482
@NP	ice-cold L-15 medium	14508
@NP	DRGs	14539
@NP	DMEM/F -12 medium -LRB- 1:1 mixture -RRB-	14577
@NP	DMEM/F -12 medium	14577
@NP	1:1 mixture	14595
@NP	the medium from OEG cultures	14613
@NP	the medium	14613
@NP	OEG cultures	14629
@NP	aspiration	14657
@NP	Single DRGs	14669
@NP	50 l of DMEM/F -12 medium	14698
@NP	50 l	14698
@NP	DMEM/F -12 medium	14706
@NP	top of AdV vector-transduced OEG monolayers	14737
@NP	top	14737
@NP	AdV vector-transduced OEG monolayers	14744
@NP	Cocultures of OEG and DRG explants	14782
@NP	Cocultures	14782
@NP	OEG and DRG explants	14796
@NP	an additional 24 hr in a CO2 incubator -LRB- 5 % -RRB-	14832
@NP	an additional 24 hr	14832
@NP	a CO2 incubator -LRB- 5 % -RRB-	14855
@NP	a CO2 incubator	14855
@NP	5 %	14872
@NP	37 °C	14879
@NP	neurite outgrowth	14898
@NP	cocultures	14917
@NP	4 % PFA in PBS	14944
@NP	4 % PFA	14944
@NP	PBS	14954
@NP	30 min	14962
@NP	cultures	14976
@NP	several times	15010
@NP	Tris-buffered saline -LRB- TBS ; 10 mM Tris-HCl , 135 mM NaCl -RRB- , pH 7.4	15029
@NP	Tris-buffered saline -LRB- TBS ; 10 mM Tris-HCl , 135 mM NaCl -RRB-	15029
@NP	Tris-buffered saline	15029
@NP	TBS ; 10 mM Tris-HCl , 135 mM NaCl	15051
@NP	TBS	15051
@NP	10 mM Tris-HCl , 135 mM NaCl	15056
@NP	10 mM Tris-HCl	15056
@NP	135 mM NaCl	15072
@NP	pH 7.4	15086
@NP	TBS containing 0.3 % Triton X-100 and 5 % FBS	15117
@NP	TBS	15117
@NP	0.3 % Triton X-100 and 5 % FBS	15132
@NP	0.3 % Triton X-100	15132
@NP	5 % FBS	15154
@NP	Cultures	15162
@NP	overnight with the mouse monoclonal antibody 2H3	15191
@NP	overnight	15191
@NP	the mouse monoclonal antibody 2H3	15206
@NP	rat neurofilament -LRB- NF -RRB-	15248
@NP	rat neurofilament	15248
@NP	NF	15267
@NP	1:1000	15272
@NP	Developmental Studies Hybridoma Bank , University of Iowa , Iowa City , IA	15280
@NP	Developmental Studies Hybridoma Bank , University	15280
@NP	Iowa , Iowa City , IA	15332
@NP	4 °C	15356
@NP	The following day	15361
@NP	cultures	15380
@NP	three times	15401
@NP	TBS	15418
@NP	Cy3-conjugated secondary antibody -LSB- 1:400	15441
@NP	Cy3-conjugated secondary antibody	15441
@NP	1:400	15476
@NP	DAM	15502
@NP	Cy3	15507
@NP	Jackson ImmunoResearch	15512
@NP	West Grove , PA -RSB-	15536
@NP	West Grove	15536
@NP	PA	15548
@NP	cocultures	15562
@NP	Vectashield -LRB- Vector Laboratories , Burlingame , CA -RRB-	15589
@NP	Vectashield	15589
@NP	Vector Laboratories	15602
@NP	Burlingame	15623
@NP	CA	15635
@NP	Digital photographic images of neurite outgrowth from each DRG explant	15657
@NP	Digital photographic images	15657
@NP	neurite outgrowth from each DRG explant	15688
@NP	neurite outgrowth	15688
@NP	each DRG explant	15711
@NP	a Zeiss -LRB- Thornwood , NY -RRB- confocal laser-scanning microscope	15753
@NP	a Zeiss	15753
@NP	Thornwood	15762
@NP	NY	15773
@NP	confocal laser-scanning microscope	15777
@NP	CLSM	15813
@NP	Preparation of OEG for spinal implantation .	15820
@NP	Preparation	15820
@NP	OEG	15835
@NP	spinal implantation	15843
@NP	Suspensions of OEG for implantation purposes	15864
@NP	Suspensions	15864
@NP	OEG for implantation purposes	15879
@NP	OEG	15879
@NP	implantation purposes	15887
@NP	Ruitenberg et al. , 2002	15948
@NP	Ruitenberg	15948
@NP	et al.	15959
@NP	2002	15967
@NP	Primary p75NTR-purified OEG	15974
@NP	poly - L-lysine-coated 6 cm dishes	16019
@NP	poly	16019
@NP	L-lysine-coated 6 cm dishes	16025
@NP	6	16041
@NP	a density of 10 ^ 6 cells per plate	16056
@NP	a density	16056
@NP	10 ^ 6 cells per plate	16069
@NP	10 ^ 6 cells	16069
@NP	plate	16084
@NP	overnight in df-10S containing 2 µg/ml of pituitary extract and 0.2 µM forskolin	16100
@NP	overnight	16100
@NP	df-10S containing 2 µg/ml of pituitary extract and 0.2 µM forskolin	16113
@NP	df-10S	16113
@NP	2 µg/ml of pituitary extract and 0.2 µM forskolin	16131
@NP	2 µg/ml	16131
@NP	pituitary extract and 0.2 µM forskolin	16142
@NP	pituitary extract	16142
@NP	0.2 µM forskolin	16164
@NP	The following day	16182
@NP	the medium	16201
@NP	fresh medium	16230
@NP	no AdV vector	16261
@NP	108 pfu	16278
@NP	moi , 100	16287
@NP	moi	16287
@NP	100	16292
@NP	AdV-LacZ , AdV-BDNF , AdV-NT-3 , or AdV-BDNF	16297
@NP	AdV-NT-3 , respectively	16344
@NP	AdV-NT-3	16344
@NP	the cells	16372
@NP	72 hr	16396
@NP	OEG cultures	16403
@NP	10 µg/ml of Hoechst 33342	16442
@NP	10 µg/ml	16442
@NP	Hoechst 33342	16454
@NP	bis-benzimide ; Sigma	16473
@NP	bis-benzimide	16473
@NP	Sigma	16488
@NP	several times	16519
@NP	L-15 medium	16538
@NP	the cells	16557
@NP	trypsinization	16584
@NP	serum-free DMEM/F -12 medium	16619
@NP	Cells	16648
@NP	low-speed centrifugation	16671
@NP	the appropriate volume of DMEM/F -12 medium	16735
@NP	the appropriate volume	16735
@NP	DMEM/F -12 medium	16761
@NP	a suspension of 105OEGper microliter	16788
@NP	a suspension	16788
@NP	105OEGper microliter	16804
@NP	The viability of OEG suspensions	16853
@NP	The viability	16853
@NP	OEG suspensions	16870
@NP	the percentage of dead cells using Trypan blue staining	16913
@NP	the percentage	16913
@NP	dead cells using Trypan blue staining	16931
@NP	dead cells	16931
@NP	Trypan blue staining	16948
@NP	all cases	16973
@NP	the viability of OEG suspensions before implantation	16984
@NP	the viability	16984
@NP	OEG suspensions before implantation	17001
@NP	OEG suspensions	17001
@NP	implantation	17024
@NP	≈ 95 %	17041
@NP	Suspensions	17047
@NP	wet ice	17077
@NP	surgery	17092
@NP	Experimental design .	17101
@NP	A total of 68 adult female Fischer F344 rats	17122
@NP	A total	17122
@NP	68 adult female Fischer F344 rats	17133
@NP	175	17168
@NP	200 gm ; Harlan-Olac , Oxon , UK	17173
@NP	200 gm	17173
@NP	Harlan-Olac , Oxon , UK	17181
@NP	this experiment	17217
@NP	All rats	17234
@NP	standard conditions	17261
@NP	a 12 hr light/dark cycle	17296
@NP	ad libitum access to water and food	17330
@NP	ad libitum access	17330
@NP	water and food	17351
@NP	All experimental procedures	17367
@NP	accordance	17413
@NP	the guidelines	17429
@NP	the local animal welfare committee for use and care of laboratory animals	17447
@NP	the local animal welfare committee	17447
@NP	use and care of laboratory animals	17486
@NP	use and care	17486
@NP	laboratory animals	17502
@NP	Body weight of experimental animals	17522
@NP	Body weight	17522
@NP	experimental animals	17537
@NP	the experiment as a general measure of health	17579
@NP	the experiment	17579
@NP	a general measure of health	17597
@NP	a general measure	17597
@NP	health	17618
@NP	Animals	17626
@NP	six experimental groups	17652
@NP	Experimental group 1 -LRB- n = 10 -RRB- , which serves as a control ,	17677
@NP	Experimental group 1	17677
@NP	n	17699
@NP	10	17703
@NP	a control	17724
@NP	a unilateral transection	17752
@NP	the dorsolateral funiculus of the cervical spinal cord	17780
@NP	the dorsolateral funiculus	17780
@NP	the cervical spinal cord	17810
@NP	Rats	17836
@NP	experimental	17844
@NP	groups 2 , 3 , 4 , 5 , and 6	17857
@NP	a similar spinal cord lesion but also an	17891
@NP	a similar spinal cord lesion	17891
@NP	an	17929
@NP	either control or AdV vector-transduced OEG	17943
@NP	control	17950
@NP	AdV vector-transduced OEG	17961
@NP	Animals in groups 2 and 3	17988
@NP	Animals	17988
@NP	groups 2 and 3	17999
@NP	an	18023
@NP	uninfected OEG -LRB- n = 10 -RRB- or AdV-LacZ-transduced OEG -LRB- n = 12 -RRB-	18037
@NP	uninfected OEG	18037
@NP	n	18053
@NP	10	18057
@NP	AdV-LacZ-transduced OEG	18064
@NP	n	18089
@NP	12	18093
@NP	These groups	18112
@NP	additional controls	18135
@NP	groups 4 , 5 , and 6	18159
@NP	groups	18159
@NP	4 , 5 , and 6	18166
@NP	OEG	18179
@NP	infection	18201
@NP	AdV vectors encoding BDNF or NT-3 before implantation	18216
@NP	AdV vectors	18216
@NP	BDNF or NT-3	18237
@NP	implantation	18257
@NP	Rats in experimental groups 4 and 5	18271
@NP	Rats	18271
@NP	experimental groups 4 and 5	18279
@NP	experimental groups	18279
@NP	an	18316
@NP	AdV-BDNF -LRB- n = 12 -RRB- or AdV-NT-3-transduced -LRB- n = 12 -RRB- OEG	18330
@NP	AdV-BDNF -LRB- n = 12 -RRB-	18330
@NP	AdV-BDNF	18330
@NP	n	18340
@NP	12	18344
@NP	AdV-NT-3-transduced -LRB- n = 12 -RRB- OEG	18351
@NP	n = 12	18372
@NP	n	18372
@NP	= 12	18373
@NP	group 6	18400
@NP	OEG	18409
@NP	infection	18431
@NP	a 1:1 mixture of BDNF - and NT-3-encoding AdV vector	18446
@NP	a 1:1 mixture	18446
@NP	BDNF	18463
@NP	NT-3-encoding AdV vector	18473
@NP	the lesioned spinal cord -LRB- n = 12 -RRB-	18528
@NP	the lesioned spinal cord	18528
@NP	n	18554
@NP	12	18558
@NP	All rats	18563
@NP	4 months for recovery of hind limb performance	18595
@NP	4 months	18595
@NP	recovery of hind limb performance	18608
@NP	recovery	18608
@NP	hind limb performance	18620
@NP	Rubrospinal projections in these animals	18643
@NP	Rubrospinal projections	18643
@NP	these animals	18670
@NP	dextran amine -LRB- BDA -RRB- as a tracer	18735
@NP	dextran amine -LRB- BDA -RRB-	18735
@NP	dextran amine	18735
@NP	BDA	18750
@NP	a tracer	18758
@NP	2 weeks	18767
@NP	the animals	18782
@NP	Rubrospinal motor-evoked potentials -LRB- MEPs -RRB-	18807
@NP	Rubrospinal motor-evoked potentials	18807
@NP	MEPs	18844
@NP	all experimental animals	18868
@NP	perfusion	18900
@NP	regeneration of RST axons and integrity of descending spinal pathways in general	18919
@NP	regeneration	18919
@NP	RST axons and integrity of descending spinal pathways in general	18935
@NP	RST axons and integrity	18935
@NP	spinal pathways	18973
@NP	Seven days	19001
@NP	implantation	19018
@NP	two animals	19032
@NP	groups 3 -- 6	19060
@NP	groups	19060
@NP	3 -- 6	19067
@NP	transgene expression	19089
@NP	Surgical procedures .	19111
@NP	Surgical	19111
@NP	procedures	19120
@NP	Implantation	19132
@NP	OEG into a unilateral cervical transection injury model involving the RST	19148
@NP	OEG	19148
@NP	a unilateral cervical transection injury model involving the RST	19157
@NP	a unilateral cervical transection injury model	19157
@NP	the RST	19214
@NP	detail -LRB- Ruitenberg et al. , 2002 -RRB-	19250
@NP	detail	19250
@NP	Ruitenberg	19258
@NP	et al. , 2002	19269
@NP	et al.	19269
@NP	2002	19277
@NP	brief	19287
@NP	rats	19294
@NP	intramuscular injection	19327
@NP	ketamine	19354
@NP	100 mg/kg of body weight ; Nimatek , Eurovet , Bladel , The Netherlands	19364
@NP	100 mg/kg	19364
@NP	body weight ; Nimatek , Eurovet , Bladel , The Netherlands	19377
@NP	body weight	19377
@NP	Nimatek , Eurovet , Bladel , The Netherlands	19390
@NP	Nimatek , Eurovet , Bladel ,	19390
@NP	The Netherlands	19416
@NP	xylazine	19437
@NP	10 mg/kg of body weight ; Bayer , Leverkussen , Germany	19447
@NP	10 mg/kg	19447
@NP	body weight ; Bayer , Leverkussen , Germany	19459
@NP	body weight	19459
@NP	Bayer , Leverkussen , Germany	19472
@NP	Access to the spinal cord	19502
@NP	Access	19502
@NP	the spinal cord	19512
@NP	dorsal laminectomy of the fourth cervical vertebra	19545
@NP	dorsal laminectomy	19545
@NP	the fourth cervical vertebra	19567
@NP	splitting the neck musculature	19602
@NP	splitting	19602
@NP	the neck musculature	19612
@NP	the spinal cord	19644
@NP	a small incision	19661
@NP	both dura and pia mater using a sharpened 30 ga needle	19695
@NP	both dura and pia mater	19695
@NP	a sharpened 30 ga needle	19725
@NP	30	19737
@NP	identification of the dorsal root entry zone and midline of the spinal cord	19757
@NP	identification of the dorsal root entry zone	19757
@NP	identification	19757
@NP	the dorsal root entry zone	19775
@NP	midline of the spinal cord	19806
@NP	midline	19806
@NP	the spinal cord	19817
@NP	the left dorsolateral funiculus of the spinal cord	19834
@NP	the left dorsolateral funiculus	19834
@NP	the spinal cord	19869
@NP	a pair of microscissors	19903
@NP	a pair	19903
@NP	microscissors	19913
@NP	1mmventral to the spinal surface , taking care not to damage the dorsal	19938
@NP	1mmventral	19938
@NP	the spinal surface	19952
@NP	care	19979
@NP	the dorsal	19998
@NP	Such a lesion	20016
@NP	complete transection of the RST projection area	20042
@NP	complete transection	20042
@NP	the RST projection area	20066
@NP	the spinal gray matter	20111
@NP	OEG suspensions	20141
@NP	1 mm distance , both proximal and distal , from the lesion cavity	20184
@NP	1 mm distance	20184
@NP	the lesion cavity	20230
@NP	a Harvard microinjection apparatus	20254
@NP	Each injection	20290
@NP	105 cells	20315
@NP	removal of the injector	20332
@NP	removal	20332
@NP	the injector	20343
@NP	muscles and skin	20357
@NP	separate layers	20389
@NP	All animals	20406
@NP	a postoperative subcutaneous injection of 2 ml physiological salt solution	20427
@NP	a postoperative subcutaneous injection	20427
@NP	2 ml physiological salt solution	20469
@NP	2 ml	20469
@NP	blood loss and Finadyne	20520
@NP	flunixinum	20545
@NP	2.4 mg/kg of body weight for 3 d ; Schering-Plough , Brussels	20557
@NP	2.4 mg/kg of body weight for 3 d	20557
@NP	2.4 mg/kg	20557
@NP	body weight for 3 d	20570
@NP	body weight	20570
@NP	3 d	20586
@NP	Schering-Plough , Brussels	20591
@NP	Schering-Plough	20591
@NP	Brussels	20608
@NP	Belgium	20618
@NP	pain	20639
@NP	the end of surgical procedures	20648
@NP	the end	20648
@NP	surgical procedures	20659
@NP	the viability of OEG suspensions used for implantation	20680
@NP	the viability	20680
@NP	OEG suspensions used for implantation	20697
@NP	OEG suspensions	20697
@NP	implantation	20722
@NP	between 90 and 95 %	20748
@NP	determined by Trypan blue staining	20771
@NP	Trypan	20785
@NP	Locomotor analysis .	20807
@NP	Locomotor	20807
@NP	analysis	20817
@NP	surgery	20833
@NP	spinal cord-injured rats	20842
@NP	a period of 7 d	20895
@NP	a period	20895
@NP	7 d	20907
@NP	the assessment of locomotor capacity	20918
@NP	the assessment	20918
@NP	locomotor capacity	20936
@NP	Functional performance of the impaired hind limb	20956
@NP	Functional performance	20956
@NP	the impaired hind limb	20982
@NP	the Basso -- Beattie -- Bresnahan -LRB- BBB -RRB- locomotor rating scale	21026
@NP	Basso -- Beattie -- Bresnahan -LRB- BBB -RRB-	21030
@NP	Basso -- Beattie -- Bresnahan	21030
@NP	Beattie	21036
@NP	BBB	21055
@NP	Basso	21084
@NP	et al. , 1995	21090
@NP	et al.	21090
@NP	1995	21098
@NP	horizontal rope walking -LRB- Kim et al. , 2001 -RRB-	21115
@NP	horizontal rope walking	21115
@NP	Kim	21140
@NP	et al. , 2001	21144
@NP	et al.	21144
@NP	2001	21152
@NP	both cases	21162
@NP	gait analysis of spinal cord-injured rats	21174
@NP	gait analysis	21174
@NP	spinal cord-injured rats	21191
@NP	two independent investigators that were blinded to the treatment of the animal	21250
@NP	two independent investigators	21250
@NP	the treatment of the animal	21301
@NP	the treatment	21301
@NP	the animal	21318
@NP	The first functional assay , the BBB rating score ,	21330
@NP	The first functional assay	21330
@NP	the BBB rating score	21358
@NP	21 operational definitions	21396
@NP	several aspects involved in the locomotion of quadrupedal animals	21432
@NP	several aspects	21432
@NP	the locomotion of quadrupedal animals	21460
@NP	the locomotion	21460
@NP	quadrupedal animals	21478
@NP	behavioral deficits	21534
@NP	partial spinal cord hemisection models	21557
@NP	horizontal rope walking	21597
@NP	more specific aspects such as posture and balance	21639
@NP	more specific aspects	21639
@NP	posture and balance	21669
@NP	gait	21696
@NP	this test	21705
@NP	animals	21716
@NP	a 1.25-meter-long rope -LRB- diameter , 4 cm -RRB-	21752
@NP	a 1.25-meter-long rope	21752
@NP	diameter , 4 cm	21776
@NP	diameter	21776
@NP	4 cm	21786
@NP	one platform to another	21797
@NP	one platform	21797
@NP	another	21813
@NP	the gait of the animal	21827
@NP	the gait	21827
@NP	the animal	21839
@NP	this task	21888
@NP	hind limb weight support	21899
@NP	precise paw placement	21925
@NP	adaptable balance	21952
@NP	Animals	21985
@NP	a period of 5 weeks	22013
@NP	a period	22013
@NP	5 weeks	22025
@NP	the start of the experiment , such	22040
@NP	the start	22040
@NP	the experiment , such	22053
@NP	the experiment	22053
@NP	such	22069
@NP	a constant rope locomotion performance	22079
@NP	Trained animals	22132
@NP	the rope	22156
@NP	an occasional minor slip	22178
@NP	no	22207
@NP	Rats	22217
@NP	their general performance	22238
@NP	rope locomotion	22271
@NP	a deficit rating scale defined as follows : -LRB- 0 -RRB- normal rope locomotion	22293
@NP	a deficit rating scale defined as follows	22293
@NP	a deficit rating scale	22293
@NP	-LRB- 0 -RRB- normal rope locomotion	22336
@NP	-LRB- 0 -RRB- normal rope	22336
@NP	0	22337
@NP	locomotion	22352
@NP	rare minor deficits	22368
@NP	normal locomotion	22402
@NP	occasional lesion deficits ; -LRB- 2 -RRB- able to cross the rope	22425
@NP	occasional lesion deficits	22425
@NP	-LRB- 2 -RRB- able to cross the rope	22453
@NP	able	22457
@NP	the rope	22471
@NP	obvious lesion deficits such as inability	22489
@NP	obvious lesion deficits	22489
@NP	inability	22521
@NP	consistent weight-supported limb placement during traverse	22543
@NP	consistent weight-supported limb placement	22543
@NP	traverse	22593
@NP	-LRB- 3 -RRB- great difficulty to cross the rope	22606
@NP	great difficulty	22610
@NP	the rope	22636
@NP	frequent	22646
@NP	ratings	22686
@NP	rats	22695
@NP	two conditioning trials	22711
@NP	forelimb and hindlimb placement	22766
@NP	general balance and posture	22812
@NP	traverse	22847
@NP	they	22860
@NP	the rope	22877
@NP	all rats	22887
@NP	a stationary lateral view	22922
@NP	us	22958
@NP	the `` total error/step '' ratio	22974
@NP	This quantitative analysis method	23004
@NP	the number of	23056
@NP	the number	23056
@NP	rope traverse	23093
@NP	these data	23113
@NP	a total error/step ratio	23125
@NP	the following	23180
@NP	number of slips + 2 -LRB- number of falls -RRB-	23196
@NP	number of slips	23196
@NP	number	23196
@NP	2 -LRB- number of falls -RRB-	23214
@NP	2	23214
@NP	number of falls	23216
@NP	number	23216
@NP	total number	23234
@NP	steps	23250
@NP	Each rat	23257
@NP	three times	23279
@NP	final scores	23296
@NP	the mean of three independent observations -LRB- quantitative analysis -RRB-	23321
@NP	the mean	23321
@NP	three independent observations -LRB- quantitative analysis -RRB-	23333
@NP	three independent observations	23333
@NP	quantitative analysis	23365
@NP	the cumulative deficit score	23391
@NP	three runs -LRB- maximum deficit score of 9 -RRB-	23423
@NP	three runs	23423
@NP	maximum deficit score of 9	23435
@NP	maximum deficit score	23435
@NP	9	23460
@NP	Kim et al. -LRB- 2001 -RRB-	23477
@NP	Kim et al.	23477
@NP	Kim	23477
@NP	et al.	23481
@NP	2001	23489
@NP	RST axon tracing .	23496
@NP	RST axon	23496
@NP	Anterograde labeling of the RST	23514
@NP	Anterograde labeling	23514
@NP	the RST	23538
@NP	Antal et al. , 1992	23585
@NP	Antal	23585
@NP	et al.	23591
@NP	1992	23599
@NP	biotin	23612
@NP	dextran conjugates -LRB- 10 % BDA , 10,000 molecular weight in PBS -RRB-	23619
@NP	dextran conjugates	23619
@NP	10 % BDA , 10,000 molecular weight in PBS	23639
@NP	10 %	23639
@NP	BDA , 10,000 molecular weight in PBS	23643
@NP	BDA	23643
@NP	10,000 molecular weight in PBS	23648
@NP	10,000 molecular weight	23648
@NP	PBS	23675
@NP	Molecular Probes	23681
@NP	Leiden	23699
@NP	The Netherlands	23707
@NP	a neuronal tracer	23727
@NP	perfusion	23758
@NP	brief	23772
@NP	a small hole	23779
@NP	the skull	23807
@NP	deep ketamine	23823
@NP	xylazine anesthesia while the animal was held in a stereotaxic frame	23837
@NP	xylazine anesthesia	23837
@NP	the animal	23863
@NP	a stereotaxic frame	23886
@NP	Glass pipettes with a tip diameter of 60 µm	23907
@NP	Glass pipettes	23907
@NP	a tip diameter of 60 µm	23927
@NP	a tip diameter	23927
@NP	60 µm	23945
@NP	BDA tracer	23968
@NP	the red nucleus	24014
@NP	iontophoresis	24036
@NP	The stereotaxic	24051
@NP	tracer delivery	24083
@NP	horizontal skull position , 6 mm posterior and 0.7 mm lateral	24110
@NP	horizontal skull position	24110
@NP	6 mm posterior	24137
@NP	0.7 mm lateral	24155
@NP	bregma and 6.8 mmdeep from the dorsal surface of the brain	24172
@NP	bregma	24172
@NP	6.8 mmdeep from the dorsal surface of the brain	24183
@NP	6.8 mmdeep	24183
@NP	the dorsal surface of the brain	24198
@NP	the dorsal surface	24198
@NP	the brain	24220
@NP	A positive direct current of 6 µA -LRB- Vmax , 30 V -RRB-	24231
@NP	A positive direct current	24231
@NP	6 µA -LRB- Vmax , 30 V -RRB-	24260
@NP	6 µA	24260
@NP	Vmax , 30 V	24266
@NP	Vmax	24266
@NP	30 V	24272
@NP	a pulse duration of 5 sec followed by 5 sec intervals for a period of 20 min	24292
@NP	a pulse duration	24292
@NP	5 sec followed by 5 sec intervals for a period of 20 min	24312
@NP	5 sec	24312
@NP	5 sec intervals for a period of 20 min	24330
@NP	5 sec intervals	24330
@NP	a period of 20 min	24350
@NP	a period	24350
@NP	20 min	24362
@NP	The current	24370
@NP	the injector	24408
@NP	place for 5 min	24433
@NP	place	24433
@NP	5 min	24443
@NP	diffusion ofBDAfrom	24458
@NP	the injection spot	24478
@NP	Polarity of the current	24498
@NP	Polarity	24498
@NP	the current	24510
@NP	the careful withdrawal of the glass capillary and suturing of the skin	24552
@NP	the careful withdrawal of the glass capillary	24552
@NP	the careful withdrawal	24552
@NP	the glass capillary	24578
@NP	suturing of the skin	24602
@NP	suturing	24602
@NP	the skin	24614
@NP	Electrophysiology	24624
@NP	the end of the experiment	24646
@NP	the end	24646
@NP	the experiment	24657
@NP	conclusion of the behavioral analysis at 4 months after injury	24679
@NP	conclusion	24679
@NP	the behavioral analysis at 4 months after injury	24693
@NP	the behavioral analysis	24693
@NP	4 months after injury	24720
@NP	4 months	24720
@NP	injury	24735
@NP	rubrospinal MEPs	24743
@NP	Lankhorst et al. , 1999	24799
@NP	Lankhorst	24799
@NP	et al.	24809
@NP	1999	24817
@NP	possible RST axon regeneration	24835
@NP	animals	24876
@NP	0.4 ml/kg of body weight	24923
@NP	0.4 ml/kg	24923
@NP	body weight	24936
@NP	i.m. ; Janssen Pharmaceutical LTD , Grove , Oxford , UK	24949
@NP	i.m.	24949
@NP	Janssen Pharmaceutical LTD , Grove , Oxford , UK	24955
@NP	0.315 mg/ml of fentanyl citrate and 10 mg/ml of fluanisone	25013
@NP	0.315 mg/ml of fentanyl citrate	25013
@NP	0.315 mg/ml	25013
@NP	fentanyl citrate	25028
@NP	10 mg/ml of fluanisone	25049
@NP	10 mg/ml	25049
@NP	fluanisone	25061
@NP	Hypnorm injections	25073
@NP	every 30 min	25106
@NP	induction of the anesthesia	25125
@NP	induction	25125
@NP	the anesthesia	25138
@NP	the animals	25168
@NP	a neuromuscular blockade	25229
@NP	pancronium bromide	25259
@NP	1.25 mg/kg of body weight , i.v. ; Organon , Oss , The Netherlands	25279
@NP	1.25 mg/kg of body weight	25279
@NP	1.25 mg/kg	25279
@NP	body weight	25293
@NP	i.v. ; Organon	25306
@NP	i.v.	25306
@NP	Organon	25312
@NP	Oss , The Netherlands	25321
@NP	Oss	25321
@NP	The Netherlands	25326
@NP	Rubrospinal MEPs	25344
@NP	direct bipolar stimulation	25378
@NP	SNEX-100x ; 20 mm ; Bilaney Consultants , Dusseldorf , Germany	25406
@NP	SNEX-100x	25406
@NP	20 mm ; Bilaney Consultants , Dusseldorf , Germany	25417
@NP	20 mm	25417
@NP	Bilaney Consultants , Dusseldorf , Germany	25424
@NP	Bilaney Consultants	25424
@NP	Dusseldorf , Germany	25445
@NP	the lesioned right red nucleus	25469
@NP	stereotaxic	25501
@NP	tracer delivery	25532
@NP	vertebra C5	25568
@NP	an epidurally located bipolar recording electrode	25584
@NP	thin gold plates	25648
@NP	an interpolar distance of 5 mm	25674
@NP	an interpolar distance	25674
@NP	5 mm	25700
@NP	Threshold values	25706
@NP	the applied voltage	25773
@NP	All MEPs used for analysis	25794
@NP	All MEPs	25794
@NP	analysis	25812
@NP	twice the threshold value	25838
@NP	potentials	25887
@NP	the lesioned red nucleus and not	25916
@NP	part , the result of cross-stimulation of the intact RST	25953
@NP	part	25953
@NP	the result of cross-stimulation of the intact RST	25959
@NP	the result	25959
@NP	cross-stimulation of the intact RST	25973
@NP	cross-stimulation	25973
@NP	the intact RST	25994
@NP	the right lateral funiculus	26010
@NP	the level of vertebrae C3	26056
@NP	the level	26056
@NP	vertebrae C3	26069
@NP	Such a lesion	26083
@NP	the RST	26118
@NP	the left red nucleus	26147
@NP	the MEP signal that was attributable to stimulation of the right red nucleus	26178
@NP	the MEP signal	26178
@NP	stimulation of the right red nucleus	26218
@NP	stimulation	26218
@NP	the right red nucleus	26233
@NP	recording of rubrospinal MEPs	26274
@NP	recording	26274
@NP	rubrospinal MEPs	26287
@NP	animals	26305
@NP	transcardial perfusion	26328
@NP	100 ml of saline followed by 300 ml of ice-cold 4 % PFA in PBS	26356
@NP	100 ml	26356
@NP	saline followed by 300 ml of ice-cold 4 % PFA in PBS	26366
@NP	saline	26366
@NP	300 ml of ice-cold 4 % PFA in PBS	26385
@NP	300 ml	26385
@NP	ice-cold 4 % PFA in PBS	26395
@NP	ice-cold 4 % PFA	26395
@NP	PBS	26414
@NP	Brains and spinal cords	26419
@NP	Brains	26419
@NP	spinal cords	26430
@NP	4 % PFA solution	26492
@NP	0.1 % PFA in PBS	26523
@NP	0.1 % PFA	26523
@NP	PBS	26535
@NP	0.01 %	26550
@NP	4 °C until additional use	26564
@NP	4 °C	26564
@NP	additional use	26574
@NP	MEP analysis	26594
@NP	a total of 1024 traces	26608
@NP	a total	26608
@NP	1024 traces	26619
@NP	the signal/noise ratio	26656
@NP	the mean trace	26687
@NP	deviations from the signal baseline	26703
@NP	deviations	26703
@NP	the signal baseline	26719
@NP	a peak	26758
@NP	the top-valley voltage difference	26768
@NP	at least three times as large	26806
@NP	the SD of the noise	26839
@NP	the SD	26839
@NP	the noise	26849
@NP	The amplitude and latency of the first -LRB- monosynaptic -RRB- positive peak	26860
@NP	The amplitude and latency	26860
@NP	the first -LRB- monosynaptic -RRB- positive peak	26889
@NP	the summed amplitudes	26940
@NP	all peaks	26965
@NP	the first 5 msec	26982
@NP	stimulus artifact	27000
@NP	the analysis	27066
@NP	Histological analysis .	27080
@NP	transgene expression 7 d	27115
@NP	transgene expression	27115
@NP	implantation	27146
@NP	horizontal sections through the cervical spinal cord	27160
@NP	horizontal sections	27160
@NP	the cervical spinal cord	27188
@NP	a cryostat	27225
@NP	standard in situ hybridization using DIGlabeled cRNA	27253
@NP	standard	27253
@NP	hybridization	27270
@NP	DIGlabeled cRNA	27290
@NP	antisense probes	27306
@NP	BDNF or NT-3 mRNA	27331
@NP	Consecutive sections	27350
@NP	p75NTR	27396
@NP	the nature of transgene-expressing cells	27415
@NP	the nature	27415
@NP	transgene-expressing cells	27429
@NP	astrocyte marker	27460
@NP	glial fibrillary acidic protein	27477
@NP	GFAP	27510
@NP	1:5000 ; Dako , Glostrup , Denmark	27516
@NP	1:5000	27516
@NP	Dako , Glostrup , Denmark	27524
@NP	perfusion of the experimental animals , at 4 months after injury	27556
@NP	perfusion	27556
@NP	the experimental animals , at 4 months after injury	27569
@NP	the experimental animals	27569
@NP	4 months	27598
@NP	injury	27613
@NP	fixed spinal cords -LRB- cervical region , C2 -- C6 -RRB-	27621
@NP	fixed spinal cords	27621
@NP	cervical region , C2 -- C6	27641
@NP	cervical region , C2	27641
@NP	C6	27661
@NP	several times	27677
@NP	PBS	27696
@NP	10 % gelatin -LRB- Difco , Detroit , MI -RRB-	27713
@NP	10 % gelatin	27713
@NP	Difco	27726
@NP	Detroit	27733
@NP	MI	27742
@NP	48 hr in 4 % PFA solution	27765
@NP	48 hr	27765
@NP	4 % PFA solution	27774
@NP	4 °C -LRB- Griffioen et al. , 1992 -RRB-	27793
@NP	4 °C	27793
@NP	Griffioen	27798
@NP	et al. , 1992	27808
@NP	et al.	27808
@NP	1992	27816
@NP	Four series of consecutive horizontal vibratome sections -LRB- 40µm -RRB-	27823
@NP	Four series	27823
@NP	consecutive horizontal vibratome sections -LRB- 40µm -RRB-	27838
@NP	consecutive horizontal vibratome sections	27838
@NP	40µm	27881
@NP	PBS	27899
@NP	serial vials	27920
@NP	BDA-traced RST axons	27934
@NP	quantification purposes	27975
@NP	two alternate series	28011
@NP	the horizontal spinal cord sections -LRB- 50 % of all sections -RRB-	28035
@NP	the horizontal spinal cord sections	28035
@NP	50 % of all sections	28072
@NP	50 %	28072
@NP	all sections	28079
@NP	brief	28097
@NP	sections	28104
@NP	three times	28125
@NP	TBS	28140
@NP	irreversible blocking of endogenous peroxidase activity	28157
@NP	irreversible blocking	28157
@NP	endogenous peroxidase activity	28182
@NP	10 % methanol and 3 % H2O2	28218
@NP	10 % methanol	28218
@NP	3 % H2O2	28235
@NP	TBS for 1 hr at RT.	28246
@NP	TBS	28246
@NP	1 hr at RT.	28254
@NP	1 hr	28254
@NP	RT.	28262
@NP	sections	28280
@NP	three times	28301
@NP	30 min	28331
@NP	TBS supplemented with 5 % FBS and 0.3 % Triton X-100	28343
@NP	TBS	28343
@NP	5 % FBS and 0.3 % Triton X-100	28365
@NP	5 % FBS	28365
@NP	0.3 % Triton X-100	28376
@NP	Sections	28395
@NP	overnight	28424
@NP	avidin	28439
@NP	biotin	28446
@NP	peroxidase complex	28453
@NP	4 °C	28475
@NP	1	28480
@NP	800 avidin plus 1:800 biotin	28483
@NP	800 avidin	28483
@NP	1:800 biotin	28499
@NP	PK-6100 Elite Vectastain ABC-kit	28513
@NP	PK-6100 Elite	28513
@NP	Vectastain ABC-kit	28527
@NP	Vector Laboratories , Burlingame , CA	28547
@NP	Vector Laboratories	28547
@NP	Burlingame , CA	28568
@NP	The following day	28585
@NP	sections	28604
@NP	three times	28625
@NP	TBS	28640
@NP	tyramid -LRB- 1:1000 ; Dako -RRB- for 10 min	28676
@NP	tyramid -LRB- 1:1000 ; Dako -RRB-	28676
@NP	tyramid	28676
@NP	1:1000 ; Dako	28685
@NP	1:1000	28685
@NP	Dako	28693
@NP	10 min	28703
@NP	TBS containing 0.01 % H2O2 to allow signal amplification	28713
@NP	TBS	28713
@NP	0.01 %	28728
@NP	H2O2 to allow signal amplification	28734
@NP	H2O2	28734
@NP	signal amplification	28748
@NP	Sections	28770
@NP	three times	28797
@NP	ABC reagent	28828
@NP	1 hr at RT.	28844
@NP	1 hr	28844
@NP	RT.	28852
@NP	several washes	28862
@NP	sections	28878
@NP	3,3	28905
@NP	diaminobenzidine tetrahydrochloride -LRB- DAB -RRB- in 50 mM Tris-HCl	28910
@NP	diaminobenzidine tetrahydrochloride -LRB- DAB -RRB-	28910
@NP	diaminobenzidine tetrahydrochloride	28910
@NP	DAB	28947
@NP	50 mM Tris-HCl	28955
@NP	pH 7.4	28971
@NP	0.01 % H2O2	28990
@NP	0.2 mg/ml of -LRB- NH4 -RRB- 2 *	29005
@NP	0.2 mg/ml	29005
@NP	NH4	29019
@NP	2	29023
@NP	SO4 *	29025
@NP	SO4	29025
@NP	NiSO4 resulting in a dark purple precipitate	29029
@NP	NiSO4	29029
@NP	a dark purple precipitate	29048
@NP	Sections	29075
@NP	series of ethanol , cleared in xylene ,	29123
@NP	series	29123
@NP	ethanol , cleared in xylene ,	29133
@NP	ethanol	29133
@NP	xylene	29153
@NP	Entellan -LRB- Merck , Amsterdam , The Netherlands -RRB-	29185
@NP	Entellan	29185
@NP	Merck	29195
@NP	Amsterdam	29202
@NP	The Netherlands	29213
@NP	the spatial relationship	29251
@NP	BDA-traced RST axons with the lesion and implantation site	29279
@NP	BDA-traced RST axons	29279
@NP	the lesion and implantation site	29305
@NP	camera lucida drawings	29339
@NP	representative sections through the injured dorsolateral funiculus	29365
@NP	representative sections	29365
@NP	the injured dorsolateral funiculus	29397
@NP	The third set of sections	29443
@NP	The third set	29443
@NP	sections	29460
@NP	more detail	29492
@NP	the spatial relationship	29504
@NP	BDA-traced RST axons	29532
@NP	the glial scar using DAB double staining as described previously	29557
@NP	the glial scar	29557
@NP	DAB double staining	29578
@NP	Buijs	29623
@NP	et al. , 1999	29629
@NP	et al.	29629
@NP	1999	29637
@NP	this end	29647
@NP	free-floating sections	29657
@NP	overnight with ABC reagent	29729
@NP	overnight	29729
@NP	ABC reagent	29744
@NP	RST axons	29772
@NP	the DAB color reaction	29789
@NP	three washes	29828
@NP	TBS	29846
@NP	a 10 min incubation	29862
@NP	10 % methanol and 3 % H2O2	29887
@NP	10 % methanol	29887
@NP	3 % H2O2	29904
@NP	TBS	29923
@NP	peroxidase activity	29936
@NP	Sections	29957
@NP	overnight	29986
@NP	a rabbit polyclonal antibody against GFAP -LRB- 1:5000 ; Dako -RRB-	30001
@NP	a rabbit polyclonal antibody	30001
@NP	GFAP -LRB- 1:5000 ; Dako -RRB-	30038
@NP	GFAP	30038
@NP	1:5000 ; Dako	30044
@NP	1:5000	30044
@NP	Dako	30052
@NP	4 °C	30061
@NP	The following day	30066
@NP	unbound antibodies	30085
@NP	multiple washings in TBS	30126
@NP	multiple washings	30126
@NP	TBS	30147
@NP	sections incubated with a horseradish peroxidaseconjugated secondary antibody	30156
@NP	sections	30156
@NP	a horseradish peroxidaseconjugated secondary antibody	30180
@NP	rabbit immunoglobulins -LRB- 1:200 ; Dako -RRB-	30256
@NP	rabbit immunoglobulins	30256
@NP	1:200 ; Dako	30280
@NP	1:200	30280
@NP	Dako	30287
@NP	Sections	30294
@NP	DAB as a chromogen but without the addition of -LRB- NH4 -RRB- 2 * SO4 * NISO4	30341
@NP	DAB as a chromogen but without the addition of -LRB- NH4 -RRB- 2 * SO4	30341
@NP	DAB	30341
@NP	a chromogen	30348
@NP	the addition of -LRB- NH4 -RRB- 2	30372
@NP	the addition	30372
@NP	NH4	30389
@NP	2	30393
@NP	SO4	30395
@NP	NISO4	30399
@NP	This	30406
@NP	the formation	30422
@NP	a brown immunoprecipitate	30439
@NP	dark purple-stained RST axons	30504
@NP	Sections	30535
@NP	gelatin-coated slides	30560
@NP	overnight	30592
@NP	RT.	30605
@NP	The sections	30609
@NP	0.2 %	30660
@NP	cresyl violet solution , dehydrated in ethanol ,	30665
@NP	cresyl violet solution	30665
@NP	ethanol	30703
@NP	Entellan	30736
@NP	The fourth and final set of vibratome sections	30765
@NP	The fourth and final set	30765
@NP	vibratome sections	30793
@NP	an impression of the severity of scar formation	30836
@NP	an impression	30836
@NP	the severity of scar formation	30853
@NP	the severity	30853
@NP	scar formation	30869
@NP	the lesion site at 4 months	30887
@NP	the lesion site	30887
@NP	4 months	30906
@NP	injury	30921
@NP	regenerating axons in the lesion area	30945
@NP	regenerating axons	30945
@NP	the lesion area	30967
@NP	this	30988
@NP	p75NTR immunoreactivity	30994
@NP	a general marker	31030
@NP	implantedOEGat	31060
@NP	the lesion site	31075
@NP	staining for NF or fibronectin	31109
@NP	staining	31109
@NP	NF or fibronectin	31122
@NP	The latter antibody	31141
@NP	p75NTR-negative meningeal cells and fibroblasts	31172
@NP	the lesion site -LRB- Pasterkamp et al. , 1999 -RRB-	31242
@NP	the lesion site	31242
@NP	Pasterkamp	31259
@NP	et al. , 1999	31270
@NP	et al.	31270
@NP	1999	31278
@NP	brief	31288
@NP	sections	31295
@NP	three times	31316
@NP	TBS and permeabilized with TBS containing 0.3 % Triton X-100	31333
@NP	TBS containing 0.3 %	31360
@NP	TBS	31360
@NP	0.3 %	31375
@NP	5 % FBS	31397
@NP	nonspecific binding of antibodies	31413
@NP	nonspecific binding	31413
@NP	antibodies	31436
@NP	Sections	31448
@NP	overnight with primary antibodies	31477
@NP	overnight	31477
@NP	primary antibodies	31492
@NP	p75NTR	31519
@NP	1:50 ; mouse monoclonal antibody clone 192 ; Chemicon , Harrow , UK	31527
@NP	1:50	31527
@NP	mouse monoclonal antibody clone 192 ; Chemicon , Harrow , UK	31533
@NP	mouse monoclonal antibody clone 192	31533
@NP	mouse monoclonal antibody	31533
@NP	clone 192	31559
@NP	Chemicon , Harrow , UK	31570
@NP	Chemicon	31570
@NP	Harrow , UK	31580
@NP	fibronectin -LRB- 1 : 50 ; rabbit polyclonal antibody ; Chemicon -RRB-	31596
@NP	fibronectin	31596
@NP	1 : 50 ; rabbit polyclonal antibody ; Chemicon	31609
@NP	1 : 50	31609
@NP	rabbit polyclonal antibody ; Chemicon	31616
@NP	rabbit polyclonal antibody	31616
@NP	Chemicon	31644
@NP	NF -LRB- 1:100 ; NF-200 ; Sigma -RRB-	31657
@NP	NF	31657
@NP	1:100	31661
@NP	NF-200 ; Sigma	31668
@NP	NF-200	31668
@NP	Sigma	31676
@NP	4 °C	31686
@NP	The following day	31691
@NP	sections	31710
@NP	TBS	31736
@NP	a mixture	31759
@NP	fluorophore-conjugated secondary antibodies	31772
@NP	1 hr	31820
@NP	RT	31828
@NP	swine	31832
@NP	DAM-Cy3	31859
@NP	1:400 ; Jackson ImmunoResearch	31868
@NP	1:400	31868
@NP	Jackson ImmunoResearch	31875
@NP	Sections	31900
@NP	slides	31925
@NP	Vectashield	31948
@NP	Digital photographic images	31961
@NP	a Zeiss CLSM device	32009
@NP	Quantification of RST axon numbers and lesion size .	32030
@NP	Quantification	32030
@NP	RST axon numbers and lesion size	32048
@NP	RST axon numbers	32048
@NP	lesion size	32069
@NP	regeneration or sprouting of traced RST axons	32094
@NP	regeneration or sprouting	32094
@NP	traced RST axons	32123
@NP	BDA-positive axonal profiles in the lesion area	32141
@NP	BDA-positive axonal profiles	32141
@NP	the lesion area	32173
@NP	Blits	32218
@NP	et al. -LRB- 2000 -RRB-	32224
@NP	et al.	32224
@NP	2000	32232
@NP	the proximal border of the scar	32246
@NP	the proximal border	32246
@NP	the scar	32269
@NP	a dark-field filter	32299
@NP	point 0	32338
@NP	Lesion borders	32348
@NP	a clear discontinuity	32379
@NP	normal spinal cord cytoarchitecture	32404
@NP	the absence	32441
@NP	spinal neurons , and a high density of small cells	32471
@NP	spinal neurons	32471
@NP	a high density of small cells	32491
@NP	a high density	32491
@NP	small cells	32509
@NP	OEG	32538
@NP	endogenous cells -LRB- e.g. , inflammatory cells -RRB-	32546
@NP	endogenous cells	32546
@NP	e.g. , inflammatory cells	32564
@NP	e.g.	32564
@NP	inflammatory cells	32570
@NP	spinal cord injury sites	32615
@NP	Takami	32666
@NP	et al. , 2002 ; Plant et al. , 2003	32673
@NP	et al.	32673
@NP	2002 ; Plant et al.	32681
@NP	2002	32681
@NP	Plant et al.	32687
@NP	Plant	32687
@NP	et al.	32693
@NP	2003	32701
@NP	Fiber counts	32708
@NP	fixed distances up to several millimeters proximal and distal to this point	32734
@NP	fixed distances	32734
@NP	several millimeters proximal and distal	32756
@NP	several millimeters	32756
@NP	this point	32799
@NP	this	32815
@NP	a 65 µm width frame	32821
@NP	the horizontal sections	32858
@NP	3 , 2 , 1.5 , 1 , 0.75 , 0.5 , 0.25 , and 0 mm proximal or distal	32885
@NP	3	32885
@NP	2	32888
@NP	1.5	32891
@NP	1	32896
@NP	0.75	32899
@NP	0.5	32905
@NP	0.25	32910
@NP	0 mm proximal or distal	32920
@NP	0 mm	32920
@NP	the proximal border of the lesion -LRB- point 0 -RRB-	32947
@NP	the proximal border	32947
@NP	the lesion -LRB- point 0 -RRB-	32970
@NP	the lesion	32970
@NP	point 0	32982
@NP	All BDA-positive axons visible within this frame	32992
@NP	All BDA-positive axons	32992
@NP	this frame	33030
@NP	200 magnification	33062
@NP	an independent investigator who was blinded to the treatment of the animals	33083
@NP	an independent investigator	33083
@NP	the treatment of the animals	33130
@NP	the treatment	33130
@NP	the animals	33147
@NP	variability in the tracing results	33175
@NP	variability	33175
@NP	the tracing results	33190
@NP	relative RST axon numbers	33211
@NP	the fiber	33267
@NP	each distance as a percentage of traced RST axons at 3 mm proximal to point 0	33287
@NP	each distance	33287
@NP	a percentage of traced RST axons at 3 mm proximal to point 0	33304
@NP	a percentage	33304
@NP	traced RST axons at 3 mm proximal to point 0	33320
@NP	traced RST axons	33320
@NP	3 mm proximal to point 0	33340
@NP	3 mm	33340
@NP	0	33363
@NP	possible counteracting effects	33376
@NP	different OEG implants on the ongoing secondary degeneration at the injury site	33410
@NP	different OEG implants	33410
@NP	the ongoing secondary degeneration at the injury site	33436
@NP	the ongoing secondary degeneration	33436
@NP	the injury site	33474
@NP	lesion volumes of all experimental animals	33491
@NP	lesion volumes	33491
@NP	all experimental animals	33509
@NP	a computerized image analysis station	33556
@NP	brief	33598
@NP	the same sections used for RST axon quantification	33605
@NP	the same sections	33605
@NP	RST axon quantification	33632
@NP	50 % of total sections	33674
@NP	50 %	33674
@NP	total sections	33681
@NP	darkfield microscopy	33716
@NP	the border of the damaged area	33742
@NP	the border	33742
@NP	the damaged area	33756
@NP	the same criteria	33794
@NP	lesion areas	33838
@NP	the observer	33871
@NP	the experimental treatment	33899
@NP	The outlined area	33927
@NP	scar-associated cells	33960
@NP	grafted OEG	33993
@NP	a rare occasion	34013
@NP	some small cysts	34030
@NP	unimplanted lesioned control animals	34072
@NP	The outlined areas of each animal	34111
@NP	The outlined areas	34111
@NP	each animal	34133
@NP	Microsoft -LRB- Seattle , WA -RRB- Excel	34177
@NP	Seattle	34188
@NP	WA	34197
@NP	the section thickness	34230
@NP	the total number of sections	34271
@NP	the total number	34271
@NP	sections	34291
@NP	Statistical analysis .	34301
@NP	Data	34323
@NP	histological analysis	34342
@NP	electrophysiology , as well as the calculated total error/step ratios ,	34368
@NP	electrophysiology	34368
@NP	the calculated total error/step ratios	34398
@NP	statistical differences between animal groups -LRB- p < 0.05 -RRB-	34456
@NP	statistical differences	34456
@NP	animal groups -LRB- p < 0.05 -RRB-	34488
@NP	animal groups	34488
@NP	p < 0.05	34504
@NP	p	34504
@NP	< 0.05	34507
@NP	<	34507
@NP	0.05	34509
@NP	two-way ANOVA	34521
@NP	hoc	34544
@NP	Newman -- Keuls tests	34548
@NP	Newman	34548
@NP	Keuls tests	34555
@NP	Functional data from the rope locomotion-rating scale -LRB- deficit scores -RRB-	34568
@NP	Functional data	34568
@NP	the rope locomotion-rating scale -LRB- deficit scores -RRB-	34589
@NP	the rope locomotion-rating scale	34589
@NP	deficit scores	34623
@NP	nonparametric Kruskall -- Wallis ANOVA test	34660
@NP	nonparametric Kruskall	34660
@NP	Wallis ANOVA test	34683
@NP	Wallis ANOVA	34683
@NP	test	34696
@NP	The Pearson correlation test	34702
@NP	there	34763
@NP	possible relationships between different outcome parameters	34774
@NP	possible relationships	34774
@NP	different outcome parameters	34805
@NP	p 0.01	34883
@NP	All data incorporated in the analysis	34893
@NP	All data	34893
@NP	the analysis	34918
@NP	animals that survived the entire study	34950
@NP	animals	34950
@NP	the entire study	34972
@NP	Results Figure 1 .	34991
@NP	Results	34991
@NP	Figure 1	34999
@NP	In vitro analysis of AdV vector-mediated transgene expression .	35009
@NP	In vitro analysis	35009
@NP	AdV vector-mediated transgene expression	35030
@NP	, Conditioned medium from uninfected and AdV-LacZ -LRB- controls -RRB-	35073
@NP	, Conditioned medium	35073
@NP	uninfected and AdV-LacZ -LRB- controls -RRB-	35099
@NP	uninfected	35099
@NP	AdV-LacZ -LRB- controls -RRB-	35114
@NP	AdV-LacZ	35114
@NP	controls	35124
@NP	OEG cultures -LRB- 10 5 cells -RRB-	35180
@NP	OEG cultures	35180
@NP	10 5 cells	35194
@NP	the presence of BDNF and NT-3	35223
@NP	the presence	35223
@NP	BDNF and NT-3	35239
@NP	ELISA techniques	35259
@NP	Bars	35277
@NP	averages SEM -LRB- n = 4 -RRB-	35291
@NP	averages SEM	35291
@NP	n	35305
@NP	4	35307
@NP	4 d after transduction	35314
@NP	4 d	35314
@NP	transduction	35324
@NP	low levels of BDNF -LRB- ≈ 0.5 ng -RRB-	35338
@NP	low levels of BDNF	35338
@NP	low levels	35338
@NP	BDNF	35352
@NP	≈ 0.5 ng	35358
@NP	≈	35358
@NP	0.5 ng	35359
@NP	medium taken from control OEG cultures over a 24 hr time period	35390
@NP	medium	35390
@NP	control OEG cultures over a 24 hr time period	35408
@NP	control OEG cultures	35408
@NP	a 24 hr time period	35434
@NP	NT-3	35463
@NP	N.D.	35488
@NP	Transduction of OEG cultures with neurotrophin-encoding AdV vectors	35495
@NP	Transduction	35495
@NP	OEG cultures with neurotrophin-encoding AdV vectors	35511
@NP	OEG cultures	35511
@NP	neurotrophin-encoding AdV vectors	35529
@NP	high levels of recombinant BDNF and NT-3 , secreted into the culture medium	35575
@NP	high levels	35575
@NP	recombinant BDNF and NT-3	35590
@NP	the culture medium	35631
@NP	a net rate of 43.8 ± 6.8 ng and 50.8 ± 3.7 ng/10	35653
@NP	a net rate	35653
@NP	43.8 ± 6.8 ng and 50.8 ± 3.7 ng/10	35667
@NP	43.8 ± 6.8 ng	35667
@NP	43.8 ±	35667
@NP	6.8 ng	35672
@NP	50.8 ± 3.7 ng/10	35683
@NP	50.8 ±	35683
@NP	3.7 ng/10	35688
@NP	^ 5 cells per day	35697
@NP	^ 5 cells	35697
@NP	day	35710
@NP	B -- E , Biological activity of AdV vector-derived BDNF and NT-3	35729
@NP	B	35729
@NP	E , Biological activity of AdV vector-derived BDNF and NT-3	35731
@NP	E , Biological activity	35731
@NP	AdV vector-derived BDNF and NT-3	35757
@NP	AdV vector-derived BDNF	35757
@NP	NT-3	35785
@NP	a 24 hr coculture experiment of transduced OEG and E14 DRG explants	35807
@NP	a 24 hr coculture experiment	35807
@NP	OEG and E14 DRG explants	35850
@NP	This	35876
@NP	visualization of the additional effect of transgenic neurotrophin expression	35889
@NP	visualization	35889
@NP	the additional effect of transgenic neurotrophin expression	35906
@NP	the additional effect	35906
@NP	transgenic neurotrophin expression	35931
@NP	the neurite outgrowthpromoting properties of OEG	35969
@NP	the neurite outgrowthpromoting properties	35969
@NP	OEG	36014
@NP	Similar moderate outgrowth of neurites	36019
@NP	Similar moderate outgrowth	36019
@NP	neurites	36049
@NP	DRG explants	36076
@NP	top	36103
@NP	uninfected -LRB- B -RRB- or AdV-LacZ-transduced -LRB- C -RRB- OEG cultures	36110
@NP	uninfected -LRB- B -RRB-	36110
@NP	AdV-LacZ-transduced -LRB- C -RRB- OEG cultures	36129
@NP	C	36151
@NP	This	36168
@NP	AdV vector infection itself	36188
@NP	AdV vector infection	36188
@NP	the growth-promoting properties of these cells	36230
@NP	the growth-promoting properties	36230
@NP	these cells	36265
@NP	Robust neurite outgrowth	36278
@NP	DRG explants	36321
@NP	OEG transducedwithanAdVvector	36350
@NP	encodingBDNF -LRB- D -RRB- orNT-3 -LRB- E -RRB-	36381
@NP	encodingBDNF -LRB- D -RRB- orNT-3	36381
@NP	encodingBDNF -LRB- D -RRB-	36381
@NP	encodingBDNF	36381
@NP	D	36394
@NP	E	36404
@NP	ThisdemonstratesthatAdVvector-derived neurotrophins	36407
@NP	OEG in biologically active form	36478
@NP	OEG	36478
@NP	biologically active form	36485
@NP	these	36520
@NP	OEG	36537
@NP	neurite outgrowth	36574
@NP	culture	36595
@NP	Scale bar : -LRB- in E -RRB- B -- E , 1 mm .	36604
@NP	Scale bar : -LRB- in E -RRB- B	36604
@NP	Scale bar	36604
@NP	Scale	36604
@NP	bar	36610
@NP	E	36619
@NP	E , 1 mm	36624
@NP	E	36624
@NP	1 mm	36627
@NP	Figure 2 .	36634
@NP	Figure	36634
@NP	2	36641
@NP	In vivo analysis of AdV vector-mediated neurotrophin expression	36644
@NP	In vivo analysis	36644
@NP	AdV vector-mediated neurotrophin expression	36664
@NP	OEG	36722
@NP	implantation	36732
@NP	the lesioned spinal cord	36748
@NP	7 d after implantation	36777
@NP	7 d	36777
@NP	implantation	36787
@NP	many cells expressing high levels of BDNF and NT-3 mRNA	36801
@NP	many cells	36801
@NP	high levels of BDNF and NT-3 mRNA	36823
@NP	high levels	36823
@NP	BDNF and NT-3 mRNA	36838
@NP	the lesion area	36874
@NP	Animals	36891
@NP	uninfected or AdV-LacZ-transduced OEG	36914
@NP	control implants	36953
@NP	such neurotrophin mRNA expression at the injury site	36987
@NP	such neurotrophin mRNA expression	36987
@NP	the injury site	37024
@NP	Transgene-expressing cells	37041
@NP	the host spinal cord bridging the injury site	37094
@NP	the host spinal cord	37094
@NP	the injury site	37124
@NP	Histological analysis of adjacent sections	37141
@NP	Histological analysis	37141
@NP	adjacent sections	37166
@NP	these cells	37196
@NP	the confines	37229
@NP	p75 NTR immunoreactivity	37245
@NP	them	37288
@NP	OEG.Someadditional labeling for p75 NTR -LRB- Schwann cells -RRB-	37306
@NP	OEG.Someadditional labeling	37306
@NP	p75 NTR -LRB- Schwann cells -RRB-	37338
@NP	p75 NTR	37338
@NP	Schwann cells	37347
@NP	the lateral edges of the spinal cord	37375
@NP	the lateral edges	37375
@NP	the spinal cord	37396
@NP	the level of the dorsal root -LRB- dr -RRB- entry zone -LRB- dashed line -RRB-	37416
@NP	the level	37416
@NP	the dorsal root -LRB- dr -RRB- entry zone -LRB- dashed line -RRB-	37429
@NP	the dorsal root -LRB- dr -RRB- entry zone	37429
@NP	dorsal root -LRB- dr -RRB-	37433
@NP	dorsal root	37433
@NP	dr	37446
@NP	line	37469
@NP	Visualization of the developing glial scar	37476
@NP	Visualization	37476
@NP	the developing glial scar	37493
@NP	the vast majority of transgene-expressing cells	37531
@NP	the vast majority	37531
@NP	transgene-expressing cells	37552
@NP	the lesion center	37594
@NP	GFAP-positive reactive astrocytes	37630
@NP	Scale bar , 100µm .	37665
@NP	Scale bar	37665
@NP	100µm	37676
@NP	Figure 3 .	37684
@NP	Figure	37684
@NP	3	37691
@NP	Immunohistochemical characterization	37694
@NP	the lesion area	37734
@NP	4 months	37753
@NP	injury	37768
@NP	A , B , Staining for fibronectin -LRB- green -RRB-	37776
@NP	A , B , Staining for fibronectin	37776
@NP	A , B , Staining	37776
@NP	B	37779
@NP	fibronectin	37795
@NP	a marker	37827
@NP	scar-associated meningeal cells and fibroblasts in the lesion area	37849
@NP	scar-associated meningeal cells and fibroblasts	37849
@NP	the lesion area	37900
@NP	immunohistochemistry for p75 NTR -LRB- red -RRB-	37934
@NP	immunohistochemistry	37934
@NP	p75 NTR -LRB- red -RRB-	37959
@NP	p75 NTR	37959
@NP	red	37968
@NP	a general antigenic marker for implanted OEG	37976
@NP	a general antigenic marker	37976
@NP	implanted OEG	38007
@NP	A , In unimplanted controls , fibronectin	38022
@NP	unimplanted controls	38028
@NP	the lesion area	38086
@NP	only little immunoreactivity for p75 NTR	38107
@NP	only little immunoreactivity	38107
@NP	p75 NTR	38140
@NP	Fibronectin-positive cells	38149
@NP	the lesion gap	38195
@NP	virtually no cystic cavity formation	38215
@NP	Most of the p75 NTR-stained cells	38266
@NP	Most	38266
@NP	the p75 NTR-stained cells	38274
@NP	typical bipolar Schwann cell morphology	38310
@NP	inset	38351
@NP	a higher magnification of the outlined area	38360
@NP	a higher magnification	38360
@NP	the outlined area	38386
@NP	the lesion area	38433
@NP	the dorsal root	38454
@NP	B , Abundant and elevated p75 NTR immunoreactivity	38471
@NP	B	38471
@NP	Abundant	38474
@NP	elevated p75 NTR immunoreactivity	38487
@NP	the lesion area	38534
@NP	all OEG	38553
@NP	animals	38571
@NP	the endogenous Schwann cells present , grafted	38607
@NP	the endogenous Schwann cells	38607
@NP	cells	38653
@NP	the lesioned spinal cord	38674
@NP	C	38700
@NP	D	38703
@NP	Representative confocal microscope images	38706
@NP	the lesion center of an unimplanted control	38751
@NP	the lesion center	38751
@NP	an unimplanted control	38772
@NP	typical OEG-implanted rat , respectively	38799
@NP	typical OEG-implanted rat	38799
@NP	higher magnification	38843
@NP	Immunohistochemistry for p75 NTR -LRB- red -RRB-	38865
@NP	Immunohistochemistry for p75 NTR	38865
@NP	Immunohistochemistry	38865
@NP	p75 NTR	38890
@NP	red	38899
@NP	staining	38922
@NP	neurofilament -LRB- green -RRB- to visualize all axons present in this area	38935
@NP	all axons	38970
@NP	this area	38991
@NP	C , Few axons	39002
@NP	the lesion center	39032
@NP	unimplanted controls -LRB- arrows -RRB-	39053
@NP	unimplanted controls	39053
@NP	arrows	39075
@NP	some of them displaying typical end bulb-like structures -LRB- arrowhead -RRB-	39084
@NP	some	39084
@NP	them	39092
@NP	typical end bulb-like structures -LRB- arrowhead -RRB-	39108
@NP	typical end bulb-like structures	39108
@NP	arrowhead	39142
@NP	D	39154
@NP	all OEG-implanted rats	39160
@NP	numerous NF-positive axons	39184
@NP	the graft area	39225
@NP	bipolar p75 NTR-positive cells -LRB- arrows -RRB-	39261
@NP	bipolar p75 NTR-positive cells	39261
@NP	arrows	39293
@NP	This	39302
@NP	several unidentified populations of spinal axons	39322
@NP	several unidentified populations	39322
@NP	spinal axons	39358
@NP	the OEG implantation site	39403
@NP	Scale bars	39430
@NP	Scale	39430
@NP	bars	39436
@NP	A , B , 100µm	39442
@NP	A	39442
@NP	B	39445
@NP	100µm	39448
@NP	25µm	39461
@NP	Figure 4 .	39468
@NP	Figure	39468
@NP	4	39475
@NP	The regenerative response	39478
@NP	lesioned RST axons	39507
@NP	different types of AdV vector-transduced OEG implants 4 months	39529
@NP	different types	39529
@NP	AdV vector-transduced OEG implants	39548
@NP	4 months	39583
@NP	injury	39598
@NP	All experimental animals	39606
@NP	BDA , which was iontophoretically applied 2 weeks before perfusion	39648
@NP	BDA	39648
@NP	2 weeks	39689
@NP	perfusion	39704
@NP	Representative photomicrographs	39715
@NP	horizontal sections through the cervical spinal cord	39750
@NP	horizontal sections	39750
@NP	the cervical spinal cord	39778
@NP	anterograde BDA-traced RST axons	39808
@NP	reactive GFAP-positive astrocytes -LRB- brown -RRB-	39853
@NP	reactive GFAP-positive astrocytes	39853
@NP	brown	39888
@NP	the lesion and OEG implantation site	39898
@NP	DAB double staining	39936
@NP	cresyl violet counterstaining -LRB- blue -RRB-	39974
@NP	cresyl violet counterstaining	39974
@NP	blue	40005
@NP	tissue cytoarchitecture	40031
@NP	all cases	40059
@NP	the injury	40099
@NP	lines	40123
@NP	graft	40138
@NP	host interfaces	40145
@NP	A , C , Traced RST axons proximal to the lesion in an unimplanted control animal	40162
@NP	A , C ,	40162
@NP	C	40165
@NP	RST axons	40175
@NP	the lesion in an unimplanted control animal	40197
@NP	the lesion	40197
@NP	an unimplanted control animal	40211
@NP	C	40242
@NP	Higher magnification	40245
@NP	the outlined area in A	40269
@NP	the outlined area	40269
@NP	A	40290
@NP	RST axons -LRB- arrows -RRB-	40306
@NP	RST axons	40306
@NP	arrows	40317
@NP	the lesion area -LRB- asterisk -RRB-	40349
@NP	the lesion area	40349
@NP	asterisk	40366
@NP	all	40381
@NP	the proximal border of the scar delineated by GFAP-positive astrocytes	40396
@NP	the proximal border	40396
@NP	the scar delineated by GFAP-positive astrocytes	40419
@NP	the scar	40419
@NP	GFAP-positive astrocytes	40442
@NP	B	40468
@NP	Termination	40471
@NP	lesioned BDA-traced RST axons	40486
@NP	the lesion site after implantation of AdV-LacZ-transduced OEG	40519
@NP	the lesion site	40519
@NP	implantation of AdV-LacZ-transduced OEG	40541
@NP	implantation	40541
@NP	AdV-LacZ-transduced OEG	40557
@NP	No sprouting of the RST into the graft and lesion area	40582
@NP	No sprouting	40582
@NP	the RST into the graft and lesion area	40598
@NP	the RST	40598
@NP	the graft and lesion area	40611
@NP	D , E	40651
@NP	D	40651
@NP	E	40654
@NP	Higher magnifications of the corresponding areas outlined in B	40657
@NP	Higher magnifications	40657
@NP	the corresponding areas outlined in B	40682
@NP	the corresponding areas	40682
@NP	B	40718
@NP	end bulb-like axon endings	40729
@NP	the proximal graft -- host boundary -LRB- arrows -RRB-	40759
@NP	the proximal graft	40759
@NP	host boundary	40779
@NP	arrows	40794
@NP	Similar distribution patterns of traced RST axons	40803
@NP	Similar distribution patterns	40803
@NP	traced RST axons	40836
@NP	OEG	40869
@NP	no or AdV-NT-3 vector	40898
@NP	no	40898
@NP	AdV-NT-3 vector	40904
@NP	implantation	40927
@NP	F	40941
@NP	J	40943
@NP	RST axon	40946
@NP	representative animals	40968
@NP	implantation of AdV-BDNF-transduced OEG	40997
@NP	implantation	40997
@NP	AdV-BDNF-transduced OEG	41013
@NP	F , RST axon regeneration into the graft	41038
@NP	F , RST axon regeneration	41038
@NP	the graft	41068
@NP	The dashed line	41092
@NP	the rostral graft -- host interface as	41118
@NP	the rostral graft	41118
@NP	host interface as	41137
@NP	host interface	41137
@NP	dark-field microscopy	41172
@NP	asterisk , blood vessel ; wm , white matter	41202
@NP	asterisk	41202
@NP	blood vessel ; wm	41212
@NP	blood vessel	41212
@NP	wm	41226
@NP	white matter	41230
@NP	the graft	41292
@NP	host interface -LRB- arrows -RRB- with some axons	41303
@NP	host interface -LRB- arrows -RRB-	41303
@NP	host interface	41303
@NP	arrows	41319
@NP	some axons	41332
@NP	the central core of the lesion and implantation site	41354
@NP	the central core	41354
@NP	the lesion and implantation site	41374
@NP	arrowhead	41408
@NP	G , Traced RST axons deeper in the graft -LRB- arrows -RRB- .	41420
@NP	G	41420
@NP	RST axons	41430
@NP	the graft -LRB- arrows -RRB-	41450
@NP	the graft	41450
@NP	arrows	41461
@NP	H , BDA-labeled RST axons at the caudal graft -- host interface .	41469
@NP	H , BDA-labeled RST axons at the caudal graft	41469
@NP	H	41469
@NP	BDA-labeled RST axons at the caudal graft	41472
@NP	BDA-labeled RST axons	41472
@NP	the caudal graft	41497
@NP	host interface	41515
@NP	I	41531
@NP	Higher magnification	41534
@NP	the outlined area in G	41558
@NP	the outlined area	41558
@NP	G	41579
@NP	undirectional growth of RST axons -LRB- arrow -RRB-	41590
@NP	undirectional growth	41590
@NP	RST axons -LRB- arrow -RRB-	41614
@NP	RST axons	41614
@NP	arrow	41625
@NP	J , Higher magnification of corresponding area in H.	41633
@NP	J , Higher magnification of corresponding area	41633
@NP	J	41633
@NP	Higher magnification of corresponding area	41636
@NP	Higher magnification	41636
@NP	corresponding area	41660
@NP	H.	41682
@NP	Few axons	41685
@NP	the graft	41715
@NP	the host spinal cord -LRB- arrow -RRB-	41750
@NP	the host spinal cord	41750
@NP	arrow	41772
@NP	Scale bars : A , 220µm ; B , C , F -- H , 92µm ; D , E , 36µm ; I , J , 23µm .	41780
@NP	Scale bars	41780
@NP	A , 220µm	41792
@NP	A	41792
@NP	220µm	41795
@NP	B , C , F	41802
@NP	B	41802
@NP	C	41805
@NP	F	41808
@NP	H , 92µm	41810
@NP	H	41810
@NP	92µm	41813
@NP	D , E , 36µm	41819
@NP	D	41819
@NP	E	41822
@NP	36µm	41825
@NP	I , J , 23µm	41831
@NP	I	41831
@NP	J	41834
@NP	23µm	41837
@NP	Figure 5 .	41844
@NP	Figure	41844
@NP	5	41851
@NP	Graphic representation	41854
@NP	the regenerative response of BDA-traced RST axons	41880
@NP	the regenerative response	41880
@NP	BDA-traced RST axons	41909
@NP	implantation	41936
@NP	AdV vectortransduced OEG 4 months after injury	41952
@NP	AdV vectortransduced OEG	41952
@NP	4 months	41977
@NP	injury	41992
@NP	Top , Schematic representation	42000
@NP	spinal cord lesion model and OEG injection sites	42033
@NP	RN , Red nucleus .	42083
@NP	RN	42083
@NP	Red nucleus	42087
@NP	Camera lucida drawings	42100
@NP	representative animals	42131
@NP	each experimental group	42159
@NP	the distribution pattern of BDA-traced RST axons -LRB- black -RRB-	42199
@NP	the distribution pattern	42199
@NP	BDA-traced RST axons -LRB- black -RRB-	42227
@NP	BDA-traced RST axons	42227
@NP	their collaterals	42260
@NP	the spinal cord gray matter -LRB- light gray area -RRB-	42281
@NP	the spinal cord gray matter	42281
@NP	light gray area	42310
@NP	the injury site -LRB- gray area -RRB-	42330
@NP	the injury site	42330
@NP	gray area	42347
@NP	The latter	42359
@NP	both scar-associated cells	42380
@NP	OEG	42421
@NP	NTs , BDNF plus NT-3 .	42426
@NP	NTs	42426
@NP	BDNF plus NT-3	42431
@NP	BDNF	42431
@NP	NT-3	42441
@NP	Scale bar , 450µm .	42447
@NP	Scale bar	42447
@NP	450µm	42458
@NP	Figure 6 .	42466
@NP	Figure	42466
@NP	6	42473
@NP	Quantitative analysis	42476
@NP	the regenerative response of lesioned RST axons	42501
@NP	the regenerative response	42501
@NP	lesioned RST axons	42530
@NP	implantation	42555
@NP	different types of AdV vector-transduced OEG	42571
@NP	different types	42571
@NP	AdV vector-transduced OEG	42590
@NP	variability in RST-tracing efficiency	42635
@NP	variability	42635
@NP	RST-tracing efficiency	42650
@NP	fiber counts at 3 mm proximal to the lesion	42674
@NP	fiber counts	42674
@NP	3 mm proximal to the lesion	42690
@NP	3 mm	42690
@NP	the lesion	42707
@NP	100 %	42730
@NP	all other points calculated	42740
@NP	all other points	42740
@NP	relative percentages	42780
@NP	Data	42802
@NP	averages ± SEM	42824
@NP	averages	42824
@NP	SEM	42834
@NP	The shaded area	42839
@NP	the outer confines of the distribution pattern of BDA-traced RST axon	42866
@NP	the outer confines	42866
@NP	the distribution pattern of BDA-traced RST axon	42888
@NP	the distribution pattern	42888
@NP	BDA-traced RST axon	42916
@NP	the control groups	42946
@NP	`` lesion only '' and uninfected or AdV-LacZ-transduced OEG , respectively	42966
@NP	`` lesion only '' and uninfected or AdV-LacZ-transduced OEG	42966
@NP	lesion only	42967
@NP	uninfected or AdV-LacZ-transduced OEG	42984
@NP	Top	43038
@NP	No statistically significant differences in the number of RST fibers	43049
@NP	No statistically significant differences	43049
@NP	the number of RST fibers	43093
@NP	the number	43093
@NP	RST fibers	43107
@NP	implantation	43135
@NP	uninfected OEG	43151
@NP	p	43168
@NP	0.52	43170
@NP	AdV-LacZ-transduced OEG	43179
@NP	p = 0.12	43205
@NP	p =	43205
@NP	0.12	43207
@NP	Top	43228
@NP	Implantation of AdV-NT-3-transduced OEG	43240
@NP	Implantation	43240
@NP	AdV-NT-3-transduced OEG	43256
@NP	a regenerative response of lesioned RST axons	43295
@NP	a regenerative response	43295
@NP	lesioned RST axons	43322
@NP	animals	43355
@NP	no implant or a graft of uninfected or AdV-LacZ-transduced OEG , respectively	43384
@NP	no	43384
@NP	a graft of uninfected or AdV-LacZ-transduced OEG , respectively	43398
@NP	a graft	43398
@NP	uninfected or AdV-LacZ-transduced OEG , respectively	43409
@NP	uninfected or AdV-LacZ-transduced OEG	43409
@NP	controls ; p > 0.28	43462
@NP	controls	43462
@NP	p > 0.28	43472
@NP	p >	43472
@NP	p	43472
@NP	0.28	43474
@NP	Bottom	43481
@NP	Quantification	43502
@NP	the regenerative response	43520
@NP	RST axons after implantation of AdV-BDNF-transduced OEG or OEG	43549
@NP	RST axons	43549
@NP	implantation of AdV-BDNF-transduced OEG or OEG	43565
@NP	implantation	43565
@NP	AdV-BDNF-transduced OEG or OEG	43581
@NP	both BDNF and NT-3-encoding AdV vectors	43628
@NP	BDNF	43633
@NP	NT-3-encoding AdV vectors	43642
@NP	RST axon counts	43669
@NP	RST axon	43669
@NP	these grafts	43699
@NP	axonal dieback	43722
@NP	RST axons	43773
@NP	the lesion area -LRB- p < 0.0001 -RRB-	43788
@NP	the lesion area	43788
@NP	p < 0.0001	43806
@NP	p	43806
@NP	< 0.0001	43807
@NP	<	43807
@NP	0.0001	43808
@NP	No significant differences	43817
@NP	these two groups -LRB- p = 0.33 -RRB-	43863
@NP	these two groups	43863
@NP	p	43882
@NP	0.33	43884
@NP	coexpression of BDNF and NT-3	43907
@NP	coexpression	43907
@NP	BDNF and NT-3	43923
@NP	no synergistic	43941
@NP	effect	43973
@NP	RST outgrowth	43983
@NP	Figure 7 .	43999
@NP	Figure	43999
@NP	7	44006
@NP	OEG implants	44009
@NP	lesion size	44029
@NP	implantation in the lesioned rat spinal cord	44047
@NP	implantation	44047
@NP	the lesioned rat spinal cord	44063
@NP	A , Example of lesion size determination in an OEG	44093
@NP	A , Example of lesion size determination	44093
@NP	Example	44096
@NP	lesion	44107
@NP	an OEG	44136
@NP	animal using dark-field microscopy	44153
@NP	animal	44153
@NP	dark-field microscopy	44166
@NP	Top	44189
@NP	Adiscontinuity	44193
@NP	normal spinal cord cytoarchitecture and a high density of small cells	44211
@NP	normal spinal cord cytoarchitecture	44211
@NP	a high density of small cells	44251
@NP	a high density	44251
@NP	small cells	44269
@NP	the injury site	44294
@NP	the borders of the damaged area	44326
@NP	the borders	44326
@NP	the damaged area	44341
@NP	Bottom	44359
@NP	Computerized image analysis picture	44367
@NP	the outlined damaged -LRB- shaded -RRB- area to determine lesion size	44411
@NP	the	44411
@NP	shaded	44433
@NP	area to determine lesion size	44441
@NP	lesion size	44459
@NP	gm , Gray matter ; wm , white matter .	44472
@NP	gm , Gray matter	44472
@NP	gm	44472
@NP	Gray matter	44476
@NP	wm , white matter	44489
@NP	wm	44489
@NP	white matter	44493
@NP	B	44507
@NP	Graphic representation	44510
@NP	lesion volumes	44541
@NP	cubic millimeters -LRB- average ± SEM -RRB-	44559
@NP	cubic millimeters	44559
@NP	average ± SEM	44578
@NP	average	44578
@NP	± SEM	44586
@NP	A consistent trend toward smaller lesion volumes	44594
@NP	A consistent trend	44594
@NP	smaller lesion volumes	44620
@NP	all OEG-implanted animals	44656
@NP	Significant reduction in lesion size	44683
@NP	Significant reduction	44683
@NP	lesion size	44708
@NP	implantation of AdV-BDNF	44741
@NP	implantation	44741
@NP	AdV-BDNF	44757
@NP	AdV-NT-3	44768
@NP	AdV-BDNF	44782
@NP	AdV-NT-3-transduced OEG , respectively	44796
@NP	AdV-NT-3-transduced OEG	44796
@NP	Asterisks	44835
@NP	statistically significant differences -LRB- p < 0.05 -RRB-	44854
@NP	statistically significant differences	44854
@NP	p < 0.05	44894
@NP	p	44894
@NP	< 0.05	44897
@NP	<	44897
@NP	0.05	44899
@NP	lesioned unimplanted controls	44910
@NP	Figure 8 .	44942
@NP	Figure	44942
@NP	8	44949
@NP	Four examples	44952
@NP	representative rubrospinal MEP recordings	44969
@NP	an intact and lesioned control	45016
@NP	AdV vector-transduced OEG implantation	45057
@NP	unilateral transection of the dorsolateral funiculus	45103
@NP	unilateral transection	45103
@NP	the dorsolateral funiculus	45129
@NP	a significant decrease -LRB- p < 0.001 -RRB- in the amplitude of the first peak	45157
@NP	a significant decrease -LRB- p < 0.001 -RRB-	45157
@NP	a significant decrease	45157
@NP	p < 0.001	45182
@NP	p	45182
@NP	< 0.001	45183
@NP	<	45183
@NP	0.001	45185
@NP	the amplitude of the first peak	45195
@NP	the amplitude	45195
@NP	the first peak	45212
@NP	all groups	45243
@NP	age-matched unlesioned control animals -LRB- arrow -RRB-	45268
@NP	age-matched unlesioned control animals	45268
@NP	arrow	45308
@NP	No treatment-based statistical differences in amplitude of this peak	45316
@NP	No treatment-based statistical differences	45316
@NP	amplitude of this peak	45362
@NP	amplitude	45362
@NP	this peak	45375
@NP	experimental groups	45405
@NP	the absence of robust and functional RST regeneration	45442
@NP	the absence	45442
@NP	robust and functional RST regeneration	45457
@NP	Calibration : 10µV , 1 msec .	45497
@NP	Calibration	45497
@NP	10µV , 1 msec	45510
@NP	10µV	45510
@NP	1 msec	45516
@NP	Figure 9 .	45525
@NP	Figure	45525
@NP	9	45532
@NP	OEG implants	45535
@NP	recovery of hindlimb function	45556
@NP	recovery	45556
@NP	hindlimb function	45568
@NP	horizontal rope walking	45593
@NP	A	45618
@NP	Photographs	45621
@NP	video recordings	45647
@NP	experimental animals	45672
@NP	the rope	45702
@NP	4 months	45711
@NP	injury	45726
@NP	Top , Typical example of a slip and fall from the rope	45734
@NP	Top , Typical example	45734
@NP	a slip and fall from the rope	45758
@NP	a slip and fall	45758
@NP	the rope	45779
@NP	unimplanted lesioned controls	45811
@NP	Bottom , All OEG-implanted rats	45842
@NP	Bottom	45842
@NP	All OEG-implanted rats	45850
@NP	better functional performance -LRB- fewer slips and falls -RRB-	45877
@NP	better functional performance	45877
@NP	fewer slips and falls	45908
@NP	fewer	45908
@NP	horizontal rope locomotion	45938
@NP	addition	45969
@NP	implantation of neurotrophin-encoding AdV	45979
@NP	implantation	45979
@NP	neurotrophin-encoding AdV	45995
@NP	OEG	46038
@NP	better general body posture during task performance	46054
@NP	better general body posture	46054
@NP	task performance	46089
@NP	This	46107
@NP	better paw placement	46135
@NP	the body and elevated trunk position and tail position -LRB- bottom right -RRB-	46162
@NP	the body	46162
@NP	elevated trunk position and tail position -LRB- bottom right -RRB-	46175
@NP	elevated trunk position and tail position	46175
@NP	bottom right	46218
@NP	other OEG-implanted rats -LRB- bottom left -RRB-	46246
@NP	other OEG-implanted rats	46246
@NP	bottom left	46272
@NP	bottom	46272
@NP	B , Mean deficit scores	46286
@NP	B	46286
@NP	Mean deficit scores	46289
@NP	SEM	46310
@NP	each experimental group	46333
@NP	up to 16 weeks	46357
@NP	injury	46378
@NP	Unilateral transection of the dorsolateral funiculus	46386
@NP	Unilateral transection	46386
@NP	the dorsolateral funiculus	46412
@NP	severe functional impairments of the ipsilateral hindlimb 7 d	46451
@NP	severe functional impairments	46451
@NP	the ipsilateral hindlimb 7 d	46484
@NP	the ipsilateral hindlimb	46484
@NP	injury	46519
@NP	Monitoring	46527
@NP	the left -LRB- ipsilateral -RRB- hindlimb during horizontal rope locomotion	46541
@NP	the left -LRB- ipsilateral -RRB- hindlimb	46541
@NP	ipsilateral	46551
@NP	horizontal rope locomotion	46580
@NP	recovery of function	46621
@NP	recovery	46621
@NP	function	46633
@NP	all OEG-implanted animal groups	46654
@NP	the first postoperative weeks	46693
@NP	4 weeks	46729
@NP	hardly any improvement in deficit score	46745
@NP	hardly any improvement	46745
@NP	deficit score	46771
@NP	a significant main treatment effect	46800
@NP	all OEG-implanted animal groups	46851
@NP	p	46885
@NP	≤ 0.0002	46886
@NP	No differences	46896
@NP	uninfected and AdV-LacZ-transduced OEG implanted rats -LRB- p = 0.99 -RRB-	46930
@NP	uninfected and AdV-LacZ-transduced OEG	46930
@NP	rats -LRB- p = 0.99 -RRB-	46979
@NP	rats	46979
@NP	p	46986
@NP	0.99	46990
@NP	AdV vector-directed neurotrophin expression	46997
@NP	AdV	46997
@NP	vector-directed neurotrophin expression	47001
@NP	a significantly enhanced main effect of the treatment -LRB- p < 0.00002 -RRB-	47053
@NP	a significantly enhanced main effect	47053
@NP	the treatment -LRB- p < 0.00002 -RRB-	47093
@NP	the treatment	47093
@NP	p < 0.00002	47109
@NP	p	47109
@NP	< 0.00002	47111
@NP	<	47111
@NP	0.00002	47112
@NP	all other groups	47135
@NP	no differences	47161
@NP	these groups -LRB- p > 0.53 -RRB-	47198
@NP	these groups	47198
@NP	p > 0.53	47213
@NP	p	47213
@NP	> 0.53	47214
@NP	>	47214
@NP	0.53	47215
@NP	C	47222
@NP	total error/step ratios -LRB- average ± SEM -RRB-	47236
@NP	total error/step ratios	47236
@NP	average ± SEM	47261
@NP	average	47261
@NP	± SEM	47269
@NP	4 months	47275
@NP	implantation	47290
@NP	A statistically significant reduction in error score	47304
@NP	A statistically significant reduction	47304
@NP	error score	47345
@NP	asterisk ; fewer	47358
@NP	asterisk	47358
@NP	fewer	47368
@NP	p <	47391
@NP	p	47391
@NP	0.0002	47394
@NP	all OEG-implanted rats	47415
@NP	unimplanted lesioned controls	47452
@NP	no difference	47490
@NP	uninfected and AdV-LacZ-transduced OEG implants -LRB- p = 0.57 -RRB-	47522
@NP	uninfected and AdV-LacZ-transduced OEG implants	47522
@NP	p	47572
@NP	0.57	47574
@NP	Implantation of neurotrophin-encoding AdV vector-transduced OEG	47581
@NP	Implantation	47581
@NP	neurotrophin-encoding AdV vector-transduced OEG	47597
@NP	a further improvement	47657
@NP	hindlimb function	47682
@NP	fewer slips and no falls	47701
@NP	fewer	47701
@NP	implantation	47768
@NP	AdV-NT-3 -LRB- p = 0.02 -RRB-	47784
@NP	AdV-NT-3	47784
@NP	p	47795
@NP	0.02	47797
@NP	AdV-BDNF plus NT-3 -LRB- p = 0.009 ; double asterisks -RRB-	47806
@NP	AdV-BDNF	47806
@NP	NT-3	47820
@NP	p	47827
@NP	= 0.009 ; double asterisks	47828
@NP	= 0.009	47828
@NP	double asterisks	47836
@NP	OEG	47865
@NP	No statistical differences	47870
@NP	these groups -LRB- p > 0.64 -RRB-	47919
@NP	these groups	47919
@NP	p > 0.64	47934
@NP	p	47934
@NP	> 0.64	47936
@NP	>	47936
@NP	0.64	47938
@NP	D , Functional performance of the impaired hindlimb	47945
@NP	D	47945
@NP	Functional performance of the impaired hindlimb	47948
@NP	Functional performance	47948
@NP	the impaired hindlimb	47974
@NP	lesion size	48012
@NP	Scatter graph	48025
@NP	calculated total error/step ratios plotted against accompanying lesion volumes	48042
@NP	calculated total error/step ratios	48042
@NP	accompanying lesion volumes	48093
@NP	the existence	48127
@NP	a positive correlation between hindlimb function and lesion size	48144
@NP	a positive correlation	48144
@NP	hindlimb function and lesion size	48175
@NP	Pearson 's correlation test	48226
@NP	Pearson 's	48226
@NP	In vitro analysis	48255
@NP	transgenic neurotrophin expression Transduction	48276
@NP	primary p75NTR-purified OEG cultures	48327
@NP	first-generation E1-deleted adenoviral vectors	48369
@NP	high levels of transgene expression	48428
@NP	high levels	48428
@NP	transgene expression	48443
@NP	many cells	48467
@NP	determined by in situ hybridization	48481
@NP	3 d after infection -LRB- data not shown -RRB-	48520
@NP	3 d	48520
@NP	infection	48530
@NP	data not shown	48541
@NP	data	48541
@NP	Numerous cells	48558
@NP	high levels of betta-gal , BDNF , or NT-3 mRNA	48583
@NP	high levels	48583
@NP	betta-gal , BDNF , or NT-3 mRNA	48598
@NP	signs of toxicity or cytopathological effects	48651
@NP	signs	48651
@NP	toxicity or cytopathological effects	48660
@NP	No staining for any of the transgenes	48698
@NP	No staining	48698
@NP	any of the transgenes	48714
@NP	any	48714
@NP	the transgenes	48721
@NP	uninfected OEG	48752
@NP	control cultures	48782
@NP	hybridization	48808
@NP	sense probe	48827
@NP	Conditioned medium from transduced OEG cultures	48840
@NP	the presence	48905
@NP	neurotrophins BDNF and NT-3	48921
@NP	an ELISA assay 4 d	48955
@NP	transduction with AdV vectors -LRB- Fig. 1A -RRB-	48980
@NP	transduction	48980
@NP	AdV vectors -LRB- Fig. 1A -RRB-	48998
@NP	AdV vectors	48998
@NP	Fig. 1A	49011
@NP	Low levels of BDNF	49021
@NP	Low levels	49021
@NP	BDNF	49035
@NP	medium samples	49057
@NP	n	49073
@NP	4	49077
@NP	control -LRB- 0.45 ± 0.17 ng/105 cells per day -RRB- or AdVLacZ	49091
@NP	control -LRB- 0.45 ± 0.17 ng/105 cells per day -RRB-	49091
@NP	control	49091
@NP	0.45 ± 0.17 ng/105 cells per day	49100
@NP	0.45 ±	49100
@NP	0.17 ng/105 cells per day	49107
@NP	0.17 ng/105 cells	49107
@NP	day	49129
@NP	AdVLacZ	49137
@NP	OEG cultures -LRB- 0.57 ± 0.13 ng/105 cells per day -RRB-	49157
@NP	OEG cultures	49157
@NP	0.57 ± 0.13 ng/105 cells per day	49171
@NP	0.57 ±	49171
@NP	0.13 ng/105 cells per day	49178
@NP	0.13 ng/105 cells	49178
@NP	day	49200
@NP	NT-3	49214
@NP	infection with AdVBDNF	49245
@NP	infection	49245
@NP	AdVBDNF	49260
@NP	an ≈	49269
@NP	the levels	49294
@NP	BDNF -LRB- 43.8 ± 6.8 ng -RRB- secreted from transduced OEG was observed	49308
@NP	BDNF	49308
@NP	43.8 ± 6.8 ng	49314
@NP	43.8 ±	49314
@NP	6.8 ng	49321
@NP	OEG was observed	49354
@NP	OEG	49354
@NP	ELISA analysis of medium samples taken from AdV-NT-3-transduced OEG cultures	49372
@NP	ELISA analysis	49372
@NP	medium samples taken from AdV-NT-3-transduced OEG cultures	49390
@NP	medium samples	49390
@NP	AdV-NT-3-transduced OEG cultures	49416
@NP	at least 50.8 ± 3.7 ng of recombinant NT-3	49463
@NP	at least 50.8 ± 3.7 ng	49463
@NP	recombinant NT-3	49487
@NP	105 cells per day	49522
@NP	105 cells	49522
@NP	day	49536
@NP	These results	49541
@NP	the time-point of implantation	49573
@NP	the time-point	49573
@NP	implantation	49591
@NP	high amounts of recombinant neurotrophin	49605
@NP	high amounts	49605
@NP	recombinant neurotrophin	49621
@NP	OEG	49665
@NP	an AdV	49685
@NP	vector-encoding BDNF or NT-3	49692
@NP	controls	49738
@NP	Biological activity of AdV	49748
@NP	Biological activity	49748
@NP	AdV	49771
@NP	BDNF and NT-3	49789
@NP	a coculture experiment	49823
@NP	this	49851
@NP	E14 DRG explants -LRB- n = 12 -RRB-	49857
@NP	E14 DRG explants	49857
@NP	n	49875
@NP	12	49879
@NP	top of an AdV vectortransduced monolayer of OEG	49902
@NP	top	49902
@NP	an AdV vectortransduced monolayer of OEG	49909
@NP	an AdV vectortransduced monolayer	49909
@NP	OEG	49946
@NP	the effect of transgenic neurotrophic factor production	49963
@NP	the effect	49963
@NP	transgenic neurotrophic factor production	49977
@NP	neurite outgrowth	50054
@NP	24 hr after the initial plating	50072
@NP	24 hr	50072
@NP	the initial plating	50084
@NP	Moderate extensions of neurites	50105
@NP	Moderate extensions	50105
@NP	neurites	50128
@NP	E14 DRG explants	50156
@NP	uninfected or AdV-LacZ-transduced OEG -LRB- Fig. 1B , C -RRB-	50194
@NP	uninfected or AdV-LacZ-transduced OEG	50194
@NP	Fig. 1B , C	50233
@NP	Fig. 1B	50233
@NP	C	50241
@NP	No visible differences in radial neurite outgrowth	50245
@NP	No visible differences	50245
@NP	radial neurite outgrowth	50271
@NP	these groups	50318
@NP	AdV vector infection	50348
@NP	the growthsupporting properties of OEG	50392
@NP	the growthsupporting properties	50392
@NP	OEG	50427
@NP	A robust outgrowth of neurites from DRG explants	50432
@NP	A robust outgrowth	50432
@NP	neurites from DRG explants	50454
@NP	neurites	50454
@NP	DRG explants	50468
@NP	OEG monolayers	50496
@NP	an AdV vector-encoding BDNF or NT-3 -LRB- Fig. 1D , E -RRB-	50532
@NP	an AdV vector-encoding BDNF	50532
@NP	NT-3 -LRB- Fig. 1D , E -RRB-	50563
@NP	NT-3	50563
@NP	Fig. 1D , E	50569
@NP	Fig. 1D	50569
@NP	E	50577
@NP	These results	50581
@NP	AdV vector-derived neurotrophins	50612
@NP	recombinant BDNF and NT-3	50687
@NP	recombinant BDNF	50687
@NP	NT-3	50708
@NP	OEG	50741
@NP	ELISA	50768
@NP	In vivo analysis of transgene expression	50775
@NP	In vivo analysis	50775
@NP	transgene expression	50795
@NP	7 d	50819
@NP	implantation	50829
@NP	transgene expression in OEG implants	50843
@NP	transgene expression	50843
@NP	OEG implants	50867
@NP	in situ hybridization and immunohistochemical characterization	50896
@NP	in situ hybridization	50896
@NP	hybridization	50904
@NP	immunohistochemical characterization	50922
@NP	the lesion area -LRB- Fig. 2 -RRB-	50962
@NP	the lesion area	50962
@NP	Fig. 2	50979
@NP	Numerous cells displaying typical bipolar OEG morphology	50988
@NP	Numerous cells	50988
@NP	typical bipolar OEG morphology	51014
@NP	the lesion area expressing high levels of BDNF or NT-3 mRNA	51062
@NP	the lesion area	51062
@NP	high levels of BDNF or NT-3 mRNA	51089
@NP	high levels	51089
@NP	BDNF or NT-3 mRNA	51104
@NP	No such staining	51123
@NP	unimplanted animals	51155
@NP	implantation of AdV-LacZtransduced OEG -LRB- data not shown -RRB-	51184
@NP	implantation	51184
@NP	AdV-LacZtransduced OEG	51200
@NP	data not shown	51224
@NP	data	51224
@NP	the identity of BDNF - and NT-3	51254
@NP	the identity	51254
@NP	BDNF - and NT-3	51270
@NP	cells	51297
@NP	adjacent sections	51304
@NP	the presence of Hoechstlabeled cells and immunoreactivity	51340
@NP	the presence	51340
@NP	Hoechstlabeled cells and immunoreactivity	51356
@NP	p75NTR , which is a marker for OEG	51402
@NP	p75NTR	51402
@NP	a marker for OEG	51419
@NP	a marker	51419
@NP	OEG	51432
@NP	No BDNF - or NT-3-expressing cells	51437
@NP	No BDNF	51437
@NP	NT-3-expressing cells	51449
@NP	the confines of p75NTR immunoreactivity and Hoechst distribution pattern	51492
@NP	the confines	51492
@NP	p75NTR immunoreactivity and Hoechst distribution pattern	51508
@NP	p75NTR immunoreactivity	51508
@NP	Hoechst distribution pattern	51536
@NP	them	51578
@NP	OEG	51602
@NP	The vast majority of BDNFand NT-3-positive cells	51607
@NP	The vast majority	51607
@NP	BDNFand NT-3-positive cells	51628
@NP	the inner core of the lesion	51672
@NP	the inner core	51672
@NP	the lesion	51690
@NP	the injury site	51711
@NP	GFAP staining that was used to visualize the developing glial scar	51744
@NP	GFAP staining	51744
@NP	the developing glial scar	51785
@NP	Some additional p75NTR labeling	51812
@NP	the lateral edges of the spinal cord close to or in the dorsal root itself	51860
@NP	the lateral edges	51860
@NP	the spinal cord close to or in the dorsal root itself	51881
@NP	the spinal cord close	51881
@NP	the dorsal root	51912
@NP	the presence of Schwann cells	51947
@NP	the presence	51947
@NP	Schwann cells	51963
@NP	Histological analysis Double staining for fibronectin and p75NTR	51978
@NP	Histological analysis Double staining	51978
@NP	fibronectin and p75NTR	52020
@NP	scar-associated cells , such as meningeal cells and fibroblasts ,	52065
@NP	scar-associated cells	52065
@NP	meningeal cells and fibroblasts	52096
@NP	OEG	52143
@NP	4 months after the injury	52165
@NP	4 months	52165
@NP	the injury	52180
@NP	abundant fibronectin expression	52192
@NP	unimplanted animals	52237
@NP	the scar	52269
@NP	only a minor immunoreactivity for p75NTR	52283
@NP	only a minor immunoreactivity	52283
@NP	p75NTR	52317
@NP	Fig. 3A	52343
@NP	The majority of these p75NTR-labeled cells	52353
@NP	The majority	52353
@NP	these p75NTR-labeled cells	52369
@NP	the more lateral part of the lesion	52409
@NP	the more lateral part	52409
@NP	the lesion	52434
@NP	the dorsal root entry zone	52455
@NP	Most of these cells	52483
@NP	Most	52483
@NP	these cells	52491
@NP	typical bipolar morphology -LRB- Fig. 3A , inset -RRB-	52513
@NP	typical bipolar morphology	52513
@NP	Fig. 3A , inset	52541
@NP	Fig. 3A	52541
@NP	they	52574
@NP	most likely Schwann cells	52584
@NP	the spinal cord	52633
@NP	the injury	52655
@NP	contrast	52670
@NP	high levels of p75NTR immunoreactivity	52680
@NP	high levels	52680
@NP	p75NTR immunoreactivity	52695
@NP	all	52736
@NP	animal groups	52750
@NP	many cells	52774
@NP	the injury site but not rostral or caudal	52788
@NP	the injury site	52788
@NP	rostral or caudal	52812
@NP	it -LRB- Fig. 3B -RRB-	52833
@NP	it	52833
@NP	Fig. 3B	52837
@NP	This	52847
@NP	implanted OEG	52867
@NP	the spinal cord for at least 4 months	52905
@NP	the spinal cord	52905
@NP	at least 4 months	52925
@NP	implantation	52949
@NP	only a few p75NTR-positive Schwann cells	52971
@NP	the spinal cord	53033
@NP	Clusters of aligned p75NTR-positive cells , presumably implanted OEG ,	53050
@NP	Clusters	53050
@NP	aligned p75NTR-positive cells	53062
@NP	OEG	53114
@NP	some endogenous Schwann cells	53133
@NP	small fibronectin-positive cells	53182
@NP	the meningeal sheets -LRB- Pasterkamp et al. , 1999 -RRB-	53241
@NP	the meningeal sheets	53241
@NP	Pasterkamp	53263
@NP	et al. , 1999	53274
@NP	et al.	53274
@NP	1999	53282
@NP	axonal staining	53308
@NP	few NFpositive axon-like structures	53325
@NP	the lesion area of unimplanted controls -LRB- Fig. 3C -RRB-	53375
@NP	the lesion area	53375
@NP	unimplanted controls -LRB- Fig. 3C -RRB-	53394
@NP	unimplanted controls	53394
@NP	Fig. 3C	53416
@NP	a dense network of NFpositive axons	53434
@NP	a dense network	53434
@NP	NFpositive axons	53453
@NP	OEG-implanted rats	53486
@NP	close association with p75NTR-positive cells -LRB- Fig. 3D -RRB-	53515
@NP	close association	53515
@NP	p75NTR-positive cells -LRB- Fig. 3D -RRB-	53538
@NP	p75NTR-positive cells	53538
@NP	Fig. 3D	53561
@NP	Anterograde tracing	53571
@NP	Anterograde	53571
@NP	implantation of OEG	53605
@NP	implantation	53605
@NP	OEG	53621
@NP	robust long-distance regeneration of RST fibers	53643
@NP	robust long-distance regeneration	53643
@NP	RST fibers	53680
@NP	any condition	53697
@NP	unimplanted animals	53715
@NP	the vast majority of traced RST axons -LRB- black -RRB-	53736
@NP	the vast majority	53736
@NP	traced RST axons -LRB- black -RRB-	53757
@NP	traced RST axons	53757
@NP	`` end bulb ''	53792
@NP	structures at the proximal border of the lesion site	53808
@NP	structures	53808
@NP	the proximal border of the lesion site	53822
@NP	the proximal border	53822
@NP	the lesion site	53845
@NP	the GFAP-positive -LRB- brown -RRB- area	53865
@NP	brown	53884
@NP	the central component of the scar tissue -LRB- Fig. 4A , C -RRB-	53924
@NP	the central component	53924
@NP	the scar tissue -LRB- Fig. 4A , C -RRB-	53949
@NP	the scar tissue	53949
@NP	Fig. 4A , C	53966
@NP	Fig. 4A	53966
@NP	C	53974
@NP	animals	53981
@NP	an	54003
@NP	uninfected , AdV-LacZ - or AdV-NT-3-transduced OEG , respectively	54017
@NP	uninfected , AdV-LacZ - or AdV-NT-3-transduced OEG	54017
@NP	no obvious difference in the distribution of RST axons	54081
@NP	no obvious difference	54081
@NP	the distribution of RST axons	54106
@NP	the distribution	54106
@NP	RST axons	54126
@NP	nonimplanted animals -LRB- Fig. 4B , D , E -RRB-	54163
@NP	nonimplanted animals	54163
@NP	Fig. 4B	54185
@NP	D	54193
@NP	E	54195
@NP	extensive BDNF-mediated sprouting of RST axons	54208
@NP	extensive BDNF-mediated	54208
@NP	RST axons	54245
@NP	animals	54271
@NP	an OEG	54293
@NP	that	54308
@NP	AdV-BDNF	54333
@NP	AdVNT	54365
@NP	3	54372
@NP	Sprouting of RST axons	54375
@NP	Sprouting	54375
@NP	RST axons	54388
@NP	the interface of the injury site and astrocytic scar -LRB- Fig. 4F -RRB-	54428
@NP	the interface	54428
@NP	the injury site and astrocytic scar -LRB- Fig. 4F -RRB-	54445
@NP	the injury site and astrocytic scar	54445
@NP	Fig. 4F	54482
@NP	many cases	54495
@NP	aberrant and undirectional sprouting of RST axons	54507
@NP	aberrant and undirectional sprouting	54507
@NP	RST axons	54547
@NP	Fig. 4G	54571
@NP	I	54579
@NP	Sprouting of RST axons	54583
@NP	Sprouting	54583
@NP	RST axons	54596
@NP	the lesion area	54634
@NP	a small number	54656
@NP	fibers	54674
@NP	the lesion and implantation site in the distal spinal cord	54698
@NP	the lesion and implantation site	54698
@NP	the distal spinal cord	54734
@NP	most of these axons	54767
@NP	most	54767
@NP	these axons	54775
@NP	close proximity of the injury site -LRB- Fig. 4H , J -RRB-	54801
@NP	close proximity	54801
@NP	the injury site -LRB- Fig. 4H , J -RRB-	54820
@NP	the injury site	54820
@NP	Fig. 4H , J	54837
@NP	Fig. 4H	54837
@NP	J	54845
@NP	each experimental group	54854
@NP	camera lucida drawings through the lesion area of a representative animal	54879
@NP	camera lucida drawings	54879
@NP	the lesion area of a representative animal	54910
@NP	the lesion area	54910
@NP	a representative animal	54929
@NP	the spatial relationship of traced RST axons	54981
@NP	the spatial relationship	54981
@NP	traced RST axons	55009
@NP	the lesion area -LRB- Fig. 5 -RRB-	55029
@NP	the lesion area	55029
@NP	Fig. 5	55046
@NP	Microscopic observations	55055
@NP	quantitative analysis of the regenerative response of rubrospinal neurons	55098
@NP	quantitative analysis	55098
@NP	the regenerative response of rubrospinal neurons	55123
@NP	the regenerative response	55123
@NP	rubrospinal neurons	55152
@NP	different OEG implants -LRB- Fig. 6 -RRB-	55175
@NP	different OEG implants	55175
@NP	Fig. 6	55199
@NP	Fiber counts of BDA-traced RST axons	55208
@NP	Fiber counts	55208
@NP	BDA-traced RST axons	55224
@NP	no statistical differences	55259
@NP	animal groups	55307
@NP	no treatment -LRB- n = 6 -RRB-	55342
@NP	no treatment	55342
@NP	n	55356
@NP	6	55358
@NP	uninfected OEG -LRB- p = 0.52 ; n = 9 -RRB- or AdVLacZ -	55380
@NP	uninfected OEG	55380
@NP	p = 0.52 ; n = 9	55397
@NP	p	55397
@NP	= 0.52 ; n = 9	55399
@NP	= 0.52	55399
@NP	n = 9	55407
@NP	n	55407
@NP	9	55411
@NP	AdVLacZ	55417
@NP	p = 0.12 ; n = 6	55443
@NP	p	55443
@NP	= 0.12 ; n = 6	55445
@NP	= 0.12	55445
@NP	=	55445
@NP	0.12	55447
@NP	n = 6	55453
@NP	n	55453
@NP	6	55457
@NP	AdV vector-mediated hypersecretion of NT-3 from transduced OEG	55475
@NP	AdV vector-mediated hypersecretion	55475
@NP	NT-3 from transduced OEG	55513
@NP	NT-3	55513
@NP	OEG	55534
@NP	growth of RST axons	55560
@NP	growth	55560
@NP	RST axons	55570
@NP	`` dieback '' -LRB- p ≥ 0.28 ; n = 7 -RRB-	55601
@NP	`` dieback ''	55601
@NP	p ≥	55613
@NP	0.28 ; n = 7	55615
@NP	0.28	55615
@NP	n = 7	55621
@NP	n	55621
@NP	7	55624
@NP	all cases	55631
@NP	a similar distribution pattern and dieback of RST axons	55642
@NP	a similar distribution pattern and dieback	55642
@NP	RST axons	55688
@NP	a consistent tendency toward limited local sprouting	55722
@NP	a consistent tendency	55722
@NP	limited local sprouting	55751
@NP	limited local	55751
@NP	these OEG implanted groups	55793
@NP	these OEG	55793
@NP	groups	55813
@NP	These data	55821
@NP	RST axons	55846
@NP	OEG implants	55885
@NP	an additional AdV vector-mediated expression of NT-3 by implanted cells	55903
@NP	an additional AdV vector-mediated expression	55903
@NP	NT-3 by implanted cells	55951
@NP	NT-3	55951
@NP	implanted cells	55959
@NP	a regenerative response of RST axons	55989
@NP	a regenerative response	55989
@NP	RST axons	56016
@NP	the histological observations	56044
@NP	a statistically significant BDNF-mediated sprouting of RST axons	56075
@NP	a statistically significant BDNF-mediated	56075
@NP	RST axons	56130
@NP	animal groups	56153
@NP	4 -LRB- p ≤ 0.0002 ; n = 5 -RRB- and 6 -LRB- p ≤ 0.004 ; n = 7 -RRB-	56167
@NP	4	56167
@NP	p ≤	56171
@NP	0.0002 ; n = 5	56175
@NP	0.0002	56175
@NP	n = 5	56183
@NP	n	56183
@NP	5	56187
@NP	6	56194
@NP	p ≤ 0.004 ; n = 7	56198
@NP	p	56198
@NP	≤ 0.004 ; n = 7	56200
@NP	≤ 0.004	56200
@NP	n = 7	56209
@NP	n	56209
@NP	7	56213
@NP	all other animal groups	56230
@NP	No statistical differences	56255
@NP	these two groups -LRB- p = 0.33 -RRB-	56301
@NP	these two groups	56301
@NP	p	56320
@NP	0.33	56324
@NP	coexpression of BDNF and NT-3	56347
@NP	coexpression	56347
@NP	BDNF and NT-3	56363
@NP	no synergistic	56381
@NP	effect	56413
@NP	the level of RST axon sprouting	56423
@NP	the level	56423
@NP	RST axon	56436
@NP	Volumetric analysis of the injury site	56456
@NP	Volumetric analysis	56456
@NP	the injury site	56479
@NP	a consistent trend toward smaller lesion volumes	56509
@NP	a consistent trend	56509
@NP	smaller lesion volumes	56535
@NP	all OEG implanted rats compared with controls -LRB- Fig. 7 -RRB-	56573
@NP	all OEG	56573
@NP	rats	56591
@NP	controls -LRB- Fig. 7 -RRB-	56610
@NP	controls	56610
@NP	Fig. 7	56620
@NP	no statistically significant differences	56638
@NP	unimplanted controls -LRB- n = 6 -RRB-	56684
@NP	unimplanted controls	56684
@NP	n	56706
@NP	6	56708
@NP	animals	56727
@NP	uninfected OEG	56750
@NP	p ≤ 0.08 ; n = 9	56767
@NP	p	56767
@NP	≤ 0.08 ; n = 9	56769
@NP	≤ 0.08	56769
@NP	n = 9	56777
@NP	n	56777
@NP	9	56781
@NP	AdV-LacZ-transduced OEG	56787
@NP	p	56813
@NP	= 0.11 ; n = 6	56815
@NP	= 0.11	56815
@NP	n = 6	56823
@NP	n	56823
@NP	6	56827
@NP	contrast	56848
@NP	lesion volumes	56858
@NP	half	56896
@NP	animals	56904
@NP	OEG implants transduced with AdV vectors encoding BDNF	56926
@NP	OEG implants	56926
@NP	AdV vectors	56955
@NP	BDNF	56976
@NP	p = 0.008 ; n = 5 -RRB-	56983
@NP	p = 0.008	56983
@NP	p	56983
@NP	0.008	56985
@NP	n = 5	56992
@NP	n	56992
@NP	5	56994
@NP	NT-3 -LRB- p = 0.01 ; n = 9 -RRB-	56998
@NP	NT-3	56998
@NP	p = 0.01 ; n = 9	57005
@NP	p = 0.01	57005
@NP	p	57005
@NP	0.01	57007
@NP	n = 9	57013
@NP	n	57013
@NP	9	57016
@NP	a mixture of both vectors -LRB- p = 0.004 ; n	57023
@NP	a mixture	57023
@NP	both vectors -LRB- p = 0.004 ; n	57036
@NP	vectors -LRB- p = 0.004	57041
@NP	vectors	57041
@NP	p = 0.004	57051
@NP	p	57051
@NP	0.004	57053
@NP	n	57060
@NP	= 7	57061
@NP	This	57066
@NP	AdV vector-mediated secretion of BDNF and NT-3	57086
@NP	AdV vector-mediated secretion	57086
@NP	BDNF and NT-3	57119
@NP	secondary degeneration of neural tissue	57146
@NP	secondary degeneration	57146
@NP	neural tissue	57172
@NP	experimental spinal cord injury	57192
@NP	MEP analysis	57225
@NP	unoperated age-matched controls	57241
@NP	unilateral stimulation of the red nucleus	57274
@NP	unilateral stimulation	57274
@NP	the red nucleus	57300
@NP	the recording of a few detectable peaks	57328
@NP	the recording	57328
@NP	a few detectable peaks	57345
@NP	the level of cervical vertebra C6 -LRB- Fig. 8 -RRB-	57371
@NP	the level	57371
@NP	cervical vertebra C6 -LRB- Fig. 8 -RRB-	57384
@NP	cervical vertebra C6	57384
@NP	Fig. 8	57406
@NP	The first peak	57415
@NP	the direct projection	57441
@NP	the red nucleus	57468
@NP	its amplitude -LRB- a direct measure for the number of RST axons -RRB-	57489
@NP	its amplitude	57489
@NP	a direct measure for the number of RST axons	57504
@NP	a direct measure	57504
@NP	the number of RST axons	57525
@NP	the number	57525
@NP	RST axons	57539
@NP	signifi	57553
@NP	transection of the dorsolateral funiculus -LRB- p < 0.001 -RRB-	57585
@NP	transection	57585
@NP	the dorsolateral funiculus -LRB- p < 0.001 -RRB-	57600
@NP	the dorsolateral funiculus	57600
@NP	p < 0.001	57629
@NP	p	57629
@NP	< 0.001	57632
@NP	<	57632
@NP	0.001	57634
@NP	The other detectable peaks	57642
@NP	unidentified descending spinal pathways	57689
@NP	MEP recording or part of the larger motor system that involves the red nucleus	57765
@NP	MEP recording or part	57765
@NP	the larger motor system that involves the red nucleus	57790
@NP	the larger motor system	57790
@NP	the red nucleus	57828
@NP	line with our histological observations	57848
@NP	line	57848
@NP	our histological observations	57858
@NP	no significant differences in rubrospinal MEP recordings	57889
@NP	no significant differences	57889
@NP	rubrospinal MEP recordings	57919
@NP	different experimental animal groups -LRB- p > 0.05 ; data not shown -RRB- ,	57963
@NP	different experimental animal groups	57963
@NP	p > 0.05 ; data not shown -RRB-	58002
@NP	p	58002
@NP	0.05	58006
@NP	data	58012
@NP	the absence of robust long-distance regeneration of axons	58040
@NP	the absence	58040
@NP	robust long-distance regeneration of axons	58055
@NP	robust long-distance regeneration	58055
@NP	axons	58092
@NP	OEG implants -LRB- Fig. 8 -RRB-	58105
@NP	OEG implants	58105
@NP	Fig. 8	58119
@NP	Analysis	58128
@NP	functional recovery Behavioral analysis	58140
@NP	spinal cord-injured rats during overground locomotion	58183
@NP	spinal cord-injured rats	58183
@NP	overground locomotion	58215
@NP	BBB score	58238
@NP	detectable functional deficits in the open field	58264
@NP	detectable functional deficits	58264
@NP	the open field	58298
@NP	a transient impairment	58323
@NP	the initial postoperative phase in both the left forelimb and hindlimb	58366
@NP	the initial postoperative phase	58366
@NP	both the left forelimb and hindlimb	58401
@NP	the left forelimb	58406
@NP	hindlimb	58428
@NP	animals	58438
@NP	the injury	58473
@NP	treatment -LRB- data not shown -RRB-	58498
@NP	treatment	58498
@NP	data not shown	58509
@NP	data	58509
@NP	This	58526
@NP	the BBB rating score	58549
@NP	an inappropriate assay	58573
@NP	evaluation	58600
@NP	hindlimb function recovery	58614
@NP	partial transection	58647
@NP	the dorsolateral funiculus , as stated previously	58670
@NP	the dorsolateral funiculus	58670
@NP	Kim	58720
@NP	et al. , 2001	58724
@NP	et al.	58724
@NP	2001	58732
@NP	contrast	58742
@NP	a persistent impairment in especially ipsilateral hindlimb function	58752
@NP	a persistent impairment	58752
@NP	especially ipsilateral hindlimb function	58779
@NP	horizontal rope walking	58840
@NP	the hindlimb or even a fall	58887
@NP	the hindlimb	58887
@NP	even a fall	58903
@NP	the rope -LRB- Fig. 9A -RRB-	58920
@NP	the rope	58920
@NP	Fig. 9A	58930
@NP	Such impairment	58940
@NP	pretraining of the animals	58979
@NP	pretraining	58979
@NP	the animals	58994
@NP	spinal injury	59013
@NP	all operated animals	59031
@NP	all	59031
@NP	animals	59044
@NP	remaining deficits in general locomotion and hindlimb performance	59053
@NP	remaining deficits	59053
@NP	general locomotion and hindlimb performance	59075
@NP	a statistically significant main treatment effect in deficit	59143
@NP	a statistically significant main treatment effect	59143
@NP	deficit	59196
@NP	scores was found -LRB- p ≤ 0.0002 -RRB-	59204
@NP	scores	59204
@NP	p	59223
@NP	≤ 0.0002	59225
@NP	Fig. 9B	59236
@NP	This	59246
@NP	allOEGimplanted rats	59266
@NP	a consistently improved locomotion	59291
@NP	the rope	59351
@NP	unimplanted control animals	59381
@NP	no differences in locomotor behavior	59423
@NP	no differences	59423
@NP	locomotor behavior	59441
@NP	animals	59479
@NP	an implant of uninfected or AdVLacZ - transduced OEG , respectively	59501
@NP	uninfected or AdVLacZ	59515
@NP	uninfected	59515
@NP	AdVLacZ	59529
@NP	OEG	59549
@NP	p	59569
@NP	0.99	59573
@NP	This	59580
@NP	ex vivo transduction of OEG itself	59603
@NP	ex vivo transduction	59603
@NP	OEG itself	59627
@NP	OEG	59627
@NP	AdV vector-mediated gene transfer	59645
@NP	AdV	59645
@NP	vector-mediated gene transfer	59649
@NP	the behavioral outcome	59703
@NP	addition	59730
@NP	rope locomotion behavior	59740
@NP	animals	59792
@NP	an OEG	59814
@NP	that	59829
@NP	a neurotrophin-encoding AdV vector	59854
@NP	p	59891
@NP	≤ 0.00002	59893
@NP	the fact that these rats made fewer errors during rope traverse	59916
@NP	the fact	59916
@NP	these rats	59930
@NP	fewer errors	59946
@NP	rope traverse	59966
@NP	other locomotion aspects , in particular body posture and hindpaw placement ,	59981
@NP	other locomotion aspects	59981
@NP	particular body posture and hindpaw placement	60010
@NP	these groups com	60074
@NP	animals	60103
@NP	control groups -LRB- lesion only or control OEG implant -RRB-	60116
@NP	control groups	60116
@NP	lesion only or control OEG implant	60132
@NP	lesion only	60132
@NP	OEG	60155
@NP	Fig. 9A	60169
@NP	These observations	60179
@NP	the significantly lower deficit scores	60216
@NP	all experimental groups	60278
@NP	no significant additional improvements in functional performance	60303
@NP	no significant additional improvements	60303
@NP	functional performance	60345
@NP	the first month	60385
@NP	surgery	60407
@NP	This	60416
@NP	recovery of function	60436
@NP	recovery	60436
@NP	function	60448
@NP	the first 4 weeks	60483
@NP	injury and OEG implantation	60507
@NP	total error/step ratios	60547
@NP	the behavioral data	60592
@NP	the deficit-scoring method -LRB- Fig. 9C -RRB-	60629
@NP	the deficit-scoring method	60629
@NP	Fig. 9C	60657
@NP	Significant treatment-based differences	60667
@NP	the experimental groups	60724
@NP	All OEG-implanted animal groups	60749
@NP	an improved recovery	60791
@NP	the injury	60818
@NP	significantly lower error scores	60842
@NP	fewer slips or falls	60876
@NP	fewer	60876
@NP	unimplanted lesioned control rats -LRB- p ≤ 0.0003 -RRB-	60903
@NP	unimplanted lesioned control rats	60903
@NP	p ≤ 0.0003	60939
@NP	p	60939
@NP	≤ 0.0003	60940
@NP	no statistical difference -LRB- p = 0.57 -RRB-	60957
@NP	no statistical difference	60957
@NP	p	60985
@NP	0.57	60989
@NP	horizontal rope locomotion performance	60998
@NP	rats that received an implant of either uninfected or AdVLacZ - transduced OEG	61053
@NP	rats	61053
@NP	an implant of either uninfected or AdVLacZ - transduced OEG	61072
@NP	either uninfected or AdVLacZ	61086
@NP	uninfected	61093
@NP	AdVLacZ	61107
@NP	OEG	61127
@NP	recovery	61141
@NP	animal groups	61166
@NP	OEG implants subjected to transduction with neurotrophin-encoding AdV vector	61194
@NP	OEG implants	61194
@NP	transduction	61220
@NP	neurotrophin-encoding AdV vector	61238
@NP	AdVLacZ - transducedOEGimplanted rats	61291
@NP	AdVLacZ	61291
@NP	transducedOEGimplanted rats	61300
@NP	fewer errors	61329
@NP	animals implanted with AdV-BDNF-transduced OEG	61359
@NP	animals	61359
@NP	AdV-BDNF-transduced OEG	61382
@NP	this	61411
@NP	statistical significance -LRB- p = 0.07 -RRB-	61435
@NP	statistical significance	61435
@NP	p	61462
@NP	0.07	61466
@NP	statistically significant improvements	61482
@NP	implantation	61541
@NP	AdV-NT-3OEG -LRB- p = 0.02 -RRB- or AdVBDNF / NT-3-transduced OEG	61557
@NP	AdV-NT-3OEG	61557
@NP	p	61570
@NP	0.02	61572
@NP	AdVBDNF	61581
@NP	NT-3-transduced OEG	61590
@NP	p = 0.009	61612
@NP	p	61612
@NP	= 0.009	61613
@NP	these data	61632
@NP	neurotrophin-encoding AdV	61660
@NP	OEG implants	61703
@NP	the best recovery	61723
@NP	injury	61747
@NP	all OEGimplanted animal groups	61763
@NP	unimplanted lesioned controls	61832
@NP	a significant positive correlation	61878
@NP	the error scores	61929
@NP	the impaired -LRB- left -RRB- hindpaw	61949
@NP	individual animals and accompanying lesion volumes	61980
@NP	individual animals	61980
@NP	accompanying lesion volumes	62003
@NP	Pearson 's correlation test ; r 0.632 ; p 0.001	62032
@NP	Pearson 's correlation test ; r 0.632 ; p	62032
@NP	Pearson 's correlation test	62032
@NP	Pearson 's	62032
@NP	r 0.632 ; p	62060
@NP	r 0.632	62060
@NP	p	62071
@NP	0.001	62073
@NP	Rats that performed well during horizontal rope walking	62081
@NP	Rats	62081
@NP	horizontal rope walking	62113
@NP	low error score	62138
@NP	relatively small lesions	62174
@NP	animals that slipped or fell from the rope more frequently	62208
@NP	animals	62208
@NP	the rope	62242
@NP	bigger lesion volumes -LRB- Fig. 9D -RRB-	62284
@NP	bigger lesion volumes	62284
@NP	Fig. 9D	62307
@NP	This	62317
@NP	possible neuroprotective effects	62336
@NP	BDNF and NT-3	62372
@NP	secondary degeneration	62401
@NP	the functional performance of animals	62447
@NP	the functional performance	62447
@NP	animals	62477
@NP	horizontal rope locomotion	62492
@NP	line	62543
@NP	the time course of recovery	62553
@NP	the time course	62553
@NP	recovery	62572
@NP	Discussion The present study uniquely	62583
@NP	Discussion	62583
@NP	The present study	62594
@NP	OEG implantation	62630
@NP	ex vivo AdV vector-mediated neurotrophin gene transfer	62652
@NP	ex vivo AdV	62652
@NP	vector-mediated neurotrophin gene transfer	62664
@NP	Quantitative histological and electrophysiological analysis	63445
@NP	OEG	63517
@NP	major long-distance RST regeneration	63536
@NP	the correlation between lesion size and functional performance	63585
@NP	the correlation	63585
@NP	lesion size and functional performance	63609
@NP	lesion size	63609
@NP	functional performance	63625
@NP	the recovery	63663
@NP	protective effects of OEG implants	63710
@NP	protective effects	63710
@NP	OEG implants	63732
@NP	the surrounding spinal cord	63748
@NP	Functional performance	63777
@NP	lesion size	63816
@NP	All OEG-implanted animals	63828
@NP	better functional performance	63864
@NP	horizontal rope walking	63901
@NP	rats receiving an implant of neurotrophin-encoding AdV vector-transduced OEG	63953
@NP	rats	63953
@NP	an	63968
@NP	neurotrophin-encoding AdV vector-transduced OEG	63982
@NP	Functional studies on the physiological role of the red nucleus	64031
@NP	Functional studies	64031
@NP	the physiological role of the red nucleus	64053
@NP	the physiological role	64053
@NP	the red nucleus	64079
@NP	its specific ablation	64118
@NP	persistent , although minor , deficits	64151
@NP	hindlimb functioning -LRB- Muir and Whishaw , 2000	64191
@NP	hindlimb functioning -LRB- Muir and Whishaw	64191
@NP	hindlimb functioning	64191
@NP	Muir and Whishaw	64213
@NP	Muir	64213
@NP	Whishaw	64222
@NP	2000	64231
@NP	This	64238
@NP	the observed impairments in hindlimb performance during horizontal rope walking	64257
@NP	the observed impairments	64257
@NP	hindlimb performance during horizontal rope walking	64285
@NP	hindlimb performance	64285
@NP	horizontal rope walking	64313
@NP	a loss of rubral input	64367
@NP	a loss	64367
@NP	rubral input	64377
@NP	Damage	64391
@NP	other motor pathways in the lateral funiculus -LRB- Holstege , 1991 -RRB- likely	64401
@NP	other motor pathways	64401
@NP	the lateral funiculus -LRB- Holstege , 1991 -RRB- likely	64425
@NP	the lateral funiculus -LRB- Holstege , 1991 -RRB-	64425
@NP	the lateral funiculus	64425
@NP	Holstege	64448
@NP	1991	64458
@NP	these remaining deficits	64486
@NP	The striking correlation between lesion size and functional performance	64512
@NP	The striking correlation	64512
@NP	lesion size and functional performance	64545
@NP	lesion size	64545
@NP	functional performance	64561
@NP	the degree of recovery	64599
@NP	the degree	64599
@NP	recovery	64613
@NP	the protective potential of OEG implants , which is a novel finding	64644
@NP	the protective potential	64644
@NP	OEG implants , which is a novel finding	64672
@NP	OEG implants	64672
@NP	a novel finding	64695
@NP	OEGmediated tissue sparing	64722
@NP	a contusion injury model -LRB- Takami et al. , 2002 ; Plant et al. , 2003 -RRB-	64771
@NP	a contusion injury model	64771
@NP	Takami	64797
@NP	et al. , 2002 ; Plant et al. , 2003	64804
@NP	et al.	64804
@NP	2002 ; Plant et al.	64812
@NP	2002	64812
@NP	Plant et al.	64818
@NP	Plant	64818
@NP	et al.	64824
@NP	2003	64832
@NP	it	64848
@NP	this also improved functional recovery	64885
@NP	A significant reduction in lesion size	64925
@NP	A significant reduction	64925
@NP	lesion size	64952
@NP	implantation of OEG transduced with neurotrophin-encoding AdV vectors	64985
@NP	implantation	64985
@NP	OEG transduced with neurotrophin-encoding AdV vectors	65001
@NP	OEG	65001
@NP	neurotrophin-encoding AdV vectors	65021
@NP	This	65056
@NP	BDNF and NT-3	65076
@NP	secondary tissue degeneration	65103
@NP	Such a restorative role for neurotrophins	65134
@NP	Such a restorative role	65134
@NP	neurotrophins	65162
@NP	BDNF	65201
@NP	tissue necrosis	65231
@NP	spinal cord injury -LRB- Novikova et al. , 1996 -RRB-	65253
@NP	spinal cord injury	65253
@NP	Novikova	65273
@NP	et al. , 1996	65282
@NP	et al.	65282
@NP	1996	65290
@NP	This feature	65297
@NP	spinal tissue sparing , in particular ventrolateral white matter ,	65331
@NP	spinal tissue sparing	65331
@NP	particular ventrolateral white matter	65357
@NP	the locomotor capacity	65425
@NP	spinal cord-injured rats -LRB- Schucht et al. , 2002 -RRB-	65451
@NP	spinal cord-injured rats	65451
@NP	Schucht	65477
@NP	et al. , 2002	65485
@NP	et al.	65485
@NP	2002	65493
@NP	both BDNF and NT-3	65513
@NP	oligodendrocyte proliferation and remyelination	65558
@NP	damaged axons -LRB- McTigue et al. , 1998 -RRB-	65609
@NP	damaged axons	65609
@NP	McTigue	65624
@NP	et al. , 1998	65632
@NP	et al.	65632
@NP	1998	65640
@NP	interest	65659
@NP	remaining deficits after injury	65676
@NP	remaining deficits	65676
@NP	injury	65701
@NP	demyelination of spared axons	65729
@NP	demyelination	65729
@NP	spared axons	65746
@NP	we	65770
@NP	lesion size	65790
@NP	impaired hindlimb performance	65833
@NP	This	65864
@NP	the idea	65878
@NP	neurotrophin-mediated tissue preservation	65892
@NP	implantation of AdV vector-transduced OEG in the subacute phase after injury	65940
@NP	implantation	65940
@NP	AdV vector-transduced OEG in the subacute phase after injury	65956
@NP	AdV vector-transduced OEG	65956
@NP	the subacute phase after injury	65985
@NP	the subacute phase	65985
@NP	injury	66010
@NP	the level of functional recovery	66032
@NP	the level	66032
@NP	functional recovery	66045
@NP	regeneration of the RST itself	66077
@NP	regeneration	66077
@NP	the RST itself	66093
@NP	the RST	66093
@NP	AdV vector-transduced OEG implants and RST regeneration Genetic modification	66109
@NP	AdV vector-transduced OEG implants	66109
@NP	AdV	66109
@NP	vector-transduced OEG implants	66113
@NP	RST regeneration Genetic modification	66148
@NP	RST regeneration	66148
@NP	Genetic modification	66165
@NP	us	66194
@NP	the growthpromoting properties of OEG	66211
@NP	the growthpromoting properties	66211
@NP	OEG	66245
@NP	In vitro , transduction ofOEGwith AdV-BDNF or AdV-NT-3	66250
@NP	In vitro	66250
@NP	transduction ofOEGwith AdV-BDNF	66260
@NP	AdV-NT-3	66295
@NP	a cell type that was more effective in promoting neurite growth	66316
@NP	a cell type	66316
@NP	neurite growth	66365
@NP	In vivo , only AdV-BDNFtransduced OEG	66381
@NP	In vivo	66381
@NP	only AdV-BDNFtransduced OEG	66390
@NP	a significant regenerative response of RST axons	66443
@NP	a significant regenerative response	66443
@NP	RST axons	66482
@NP	previous work	66496
@NP	ex vivo	66517
@NP	lentiviral vector-transduced OEG	66525
@NP	the marker protein green fluorescent protein to reliably track implanted cells	66569
@NP	the marker protein	66569
@NP	green fluorescent protein	66588
@NP	implanted cells	66632
@NP	we	66649
@NP	implanted OEG	66684
@NP	the lesioned spinal cord at least	66713
@NP	the lesioned spinal cord	66713
@NP	up to 4 months -LRB- Ruitenberg et al. , 2002 -RRB-	66747
@NP	up to 4 months	66747
@NP	Ruitenberg	66763
@NP	et al. , 2002	66774
@NP	et al.	66774
@NP	2002	66782
@NP	This	66789
@NP	these conditions	66815
@NP	the absence of elevated BDNF levels	66839
@NP	the absence	66839
@NP	elevated BDNF levels	66854
@NP	lesioned RST axons	66876
@NP	OEG implants	66922
@NP	date	66939
@NP	a number of axon populations	66945
@NP	a number	66945
@NP	axon populations	66957
@NP	OEG implants in different injury models	67010
@NP	OEG implants	67010
@NP	different injury models	67026
@NP	sensory axons	67061
@NP	the dorsal	67078
@NP	root axons	67089
@NP	Ramon-Cueto and Nieto-Sampedro , 1994 ; Navarro et al. , 1999	67101
@NP	Ramon-Cueto and Nieto-Sampedro	67101
@NP	1994 ; Navarro et al.	67133
@NP	1994	67133
@NP	Navarro et al.	67139
@NP	Navarro	67139
@NP	et al.	67147
@NP	1999	67155
@NP	serotonergic axons	67172
@NP	Ramon-Cueto et al. , 1998 , 2000 ; Lu et al. , 2001a , 2002	67192
@NP	Ramon-Cueto et al.	67192
@NP	Ramon-Cueto	67192
@NP	et al.	67204
@NP	1998 , 2000 ; Lu et al.	67212
@NP	1998 , 2000	67212
@NP	1998	67212
@NP	2000	67218
@NP	Lu et al.	67224
@NP	Lu	67224
@NP	et al.	67227
@NP	2001a , 2002	67235
@NP	2001a	67235
@NP	2002	67242
@NP	CST axons -LRB- Li et al. , 1998 ; Ramon-Cueto et al. , 2000 -RRB-	67252
@NP	CST axons	67252
@NP	Li	67263
@NP	et al. , 1998 ; Ramon-Cueto et al. , 2000	67266
@NP	et al.	67266
@NP	1998 ; Ramon-Cueto et al.	67274
@NP	1998	67274
@NP	Ramon-Cueto et al.	67280
@NP	Ramon-Cueto	67280
@NP	et al.	67292
@NP	2000	67300
@NP	Some controversy	67307
@NP	the regenerative response of the CST	67338
@NP	the regenerative response	67338
@NP	the CST	67367
@NP	others	67383
@NP	OEGinduced sprouting	67401
@NP	OEGinduced	67401
@NP	the proximal injury site	67437
@NP	the RST -LRB- Takami et al. , 2002 ; D.	67483
@NP	the RST -LRB- Takami et al.	67483
@NP	the RST	67483
@NP	Takami et al.	67492
@NP	Takami	67492
@NP	et al.	67499
@NP	2002 ; D.	67507
@NP	2002	67507
@NP	D.	67513
@NP	B.	67516
@NP	Levison , M.	67519
@NP	Levison	67519
@NP	M.	67528
@NP	J.	67531
@NP	Ruitenberg , G.	67534
@NP	Ruitenberg	67534
@NP	G.	67546
@NP	W.	67549
@NP	Plant , unpublished observations -RRB- .	67552
@NP	Plant	67552
@NP	observations	67571
@NP	It	67586
@NP	more insight	67622
@NP	both OEG cell biology and specific neurotrophic requirements	67638
@NP	OEG cell biology	67643
@NP	specific neurotrophic requirements	67664
@NP	the different spinal pathways	67702
@NP	Extended knowledge of proteins involved in regeneration of specific nerve tracts	67733
@NP	Extended knowledge	67733
@NP	proteins involved in regeneration of specific nerve tracts	67755
@NP	proteins	67755
@NP	regeneration of specific nerve tracts	67776
@NP	regeneration	67776
@NP	specific nerve tracts	67792
@NP	the development of more optimal bridging substrates via genetic engineering	67825
@NP	the development	67825
@NP	more optimal bridging substrates via genetic engineering	67844
@NP	more optimal	67844
@NP	substrates via genetic engineering	67866
@NP	substrates	67866
@NP	genetic engineering	67881
@NP	Intraparenchymal infusions ofBDNFinduce	67902
@NP	regeneration of supraspinal axons	67951
@NP	regeneration	67951
@NP	supraspinal axons	67967
@NP	the RST -LRB- Xu et al. , 1995 ; Kobayashi et al. , 1997 -RRB-	67996
@NP	the RST	67996
@NP	Xu	68005
@NP	et al. , 1995 ; Kobayashi et al. , 1997	68008
@NP	et al.	68008
@NP	1995 ; Kobayashi et al.	68016
@NP	1995	68016
@NP	Kobayashi et al.	68022
@NP	Kobayashi	68022
@NP	et al.	68032
@NP	1997	68040
@NP	a gene therapy-based strategy to deliver neurotrophins	68056
@NP	a gene therapy-based strategy	68056
@NP	neurotrophins	68097
@NP	several advantages	68115
@NP	the use	68139
@NP	osmotic minipumps	68150
@NP	review , see Dijkhuizen and Verhaagen , 1999	68173
@NP	review	68173
@NP	see Dijkhuizen and Verhaagen , 1999	68181
@NP	Dijkhuizen and Verhaagen , 1999	68185
@NP	Dijkhuizen and Verhaagen	68185
@NP	1999	68211
@NP	date	68221
@NP	engineered Schwann cells -LRB- Menei et al. , 1998 -RRB- and fibroblasts	68227
@NP	engineered Schwann cells -LRB- Menei et al. , 1998 -RRB-	68227
@NP	engineered Schwann cells	68227
@NP	Menei	68253
@NP	et al. , 1998	68259
@NP	et al.	68259
@NP	1998	68267
@NP	fibroblasts	68277
@NP	Liu	68290
@NP	et al. , 1999 ; Lu et al. , 2001b	68294
@NP	et al.	68294
@NP	1999 ; Lu et al.	68302
@NP	1999	68302
@NP	Lu et al.	68308
@NP	Lu	68308
@NP	et al.	68311
@NP	2001b	68319
@NP	BDNF	68352
@NP	the injured spinal cord	68360
@NP	Vigorous growth of RST axons	68385
@NP	Vigorous growth	68385
@NP	RST axons	68404
@NP	implantation of BDNF-secreting fibroblasts -LRB- Liu et al. , 1999 -RRB-	68433
@NP	implantation	68433
@NP	BDNF-secreting fibroblasts -LRB- Liu et al. , 1999 -RRB-	68449
@NP	BDNF-secreting fibroblasts	68449
@NP	Liu	68477
@NP	et al. , 1999	68481
@NP	et al.	68481
@NP	1999	68489
@NP	the present study	68499
@NP	only short-range BDNF-mediated sprouting	68518
@NP	only short-range	68518
@NP	This discrepancy	68573
@NP	experimental outcome between our study and the findings of Liu	68593
@NP	experimental outcome between our study	68593
@NP	experimental outcome	68593
@NP	our study	68622
@NP	the findings of Liu	68636
@NP	the findings	68636
@NP	Liu	68652
@NP	et al. -LRB- 1999 -RRB-	68656
@NP	et al.	68656
@NP	1999	68664
@NP	several differences	68693
@NP	treatment conditions	68716
@NP	i.e. , the duration of transgene expression and num - ber of implanted cells	68738
@NP	i.e.	68738
@NP	the duration of transgene expression and num - ber of implanted cells	68744
@NP	the duration of transgene expression and num	68744
@NP	the duration	68744
@NP	transgene expression and num	68760
@NP	ber of implanted cells	68790
@NP	ber	68790
@NP	implanted cells	68797
@NP	AdV vector-mediated transduction of OEG	68833
@NP	AdV vector-mediated transduction	68833
@NP	OEG	68869
@NP	a transient time course of transgene expression	68884
@NP	a transient time course	68884
@NP	transgene expression	68911
@NP	implantation	68938
@NP	the lesioned spinal cord -LRB- up to 30 d -RRB-	68954
@NP	the lesioned spinal cord	68954
@NP	30 d	68986
@NP	Ruitenberg	68993
@NP	et al. , 2002	69004
@NP	et al.	69004
@NP	2002	69012
@NP	persistent expression and thereby continuous neurotrophic support	69027
@NP	persistent expression	69027
@NP	continuous neurotrophic support	69061
@NP	engineered fibroblast grafts	69108
@NP	future studies	69141
@NP	it	69157
@NP	RST regeneration	69192
@NP	implantation	69215
@NP	stable transduced OEG	69231
@NP	lentiviral vector-mediated gene transfer	69266
@NP	persistent transgene expression -LRB- Ruitenberg et al. , 2002 -RRB-	69325
@NP	persistent transgene expression	69325
@NP	Ruitenberg	69358
@NP	et al. , 2002	69369
@NP	et al.	69369
@NP	2002	69377
@NP	those implants	69396
@NP	grafts of engineered fibroblasts	69423
@NP	grafts	69423
@NP	engineered fibroblasts	69433
@NP	neurotrophin expression	69467
@NP	modulation of neurite outgrowth -LRB- Blesch et al. , 2000 , 2001 -RRB-	69520
@NP	modulation	69520
@NP	neurite outgrowth -LRB- Blesch et al. , 2000 , 2001 -RRB-	69534
@NP	neurite outgrowth	69534
@NP	Blesch	69553
@NP	et al. , 2000 , 2001	69560
@NP	et al.	69560
@NP	2000	69568
@NP	2001	69574
@NP	entrapment	69592
@NP	axons	69606
@NP	areas with high neurotrophic factor expression -LRB- Kirik et al. , 2000 -RRB-	69615
@NP	areas	69615
@NP	high neurotrophic factor expression -LRB- Kirik et al. , 2000 -RRB-	69626
@NP	high neurotrophic factor expression	69626
@NP	Kirik	69663
@NP	et al. , 2000	69669
@NP	et al.	69669
@NP	2000	69677
@NP	Sprouting of RST axons	69684
@NP	Sprouting	69684
@NP	RST axons	69697
@NP	the interface of the lesion area and intact spinal cord	69737
@NP	the interface	69737
@NP	the lesion area and intact spinal cord	69754
@NP	the lesion area	69754
@NP	intact spinal cord	69774
@NP	This	69794
@NP	Liu	69820
@NP	et al. -LRB- 1999 -RRB-	69824
@NP	et al.	69824
@NP	1999	69832
@NP	the presence of elevated neurotrophin levels	69860
@NP	the presence	69860
@NP	elevated neurotrophin levels	69876
@NP	reactive glia	69906
@NP	an attractive area for lesioned axons	69931
@NP	an attractive area	69931
@NP	lesioned axons	69954
@NP	Kawaja and Gage	69978
@NP	1991	69995
@NP	RST axons	70017
@NP	the lesion core	70044
@NP	implanted OEG	70074
@NP	scar-associated cells -LRB- e.g. , meningeal cells -RRB-	70103
@NP	scar-associated cells	70103
@NP	e.g. , meningeal cells	70126
@NP	e.g.	70126
@NP	meningeal cells	70132
@NP	Several growth inhibitory molecules	70150
@NP	these cells	70212
@NP	RST axons	70246
@NP	this area	70261
@NP	review	70276
@NP	Fawcett and Asher , 1999 ; Pasterkamp et al. , 1999 ; De Winter et al. , 2002	70288
@NP	Fawcett and Asher , 1999 ; Pasterkamp et al. , 1999 ; De Winter et al.	70288
@NP	Fawcett and Asher , 1999	70288
@NP	Fawcett and Asher	70288
@NP	1999	70307
@NP	Pasterkamp et al. , 1999	70313
@NP	Pasterkamp	70313
@NP	et al. , 1999	70324
@NP	et al.	70324
@NP	1999	70332
@NP	De Winter et al.	70338
@NP	De Winter	70338
@NP	et al.	70348
@NP	2002	70356
@NP	Implantation of NT-3-producing OEG	70363
@NP	Implantation	70363
@NP	NT-3-producing OEG	70379
@NP	a growth response of axotomized RST axons	70413
@NP	a growth response	70413
@NP	axotomized RST axons	70434
@NP	the receptors for BDNFand NT-3 , TrkB and TrkC ,	70465
@NP	the receptors	70465
@NP	BDNFand NT-3 , TrkB and TrkC ,	70483
@NP	BDNFand NT-3	70483
@NP	TrkB and TrkC	70497
@NP	rubrospinal neurons	70531
@NP	these neurotrophins	70552
@NP	distinct roles	70585
@NP	injury	70606
@NP	NT-3	70614
@NP	injury-induced death	70642
@NP	newborn rats -LRB- Diener and Bregman , 1994 -RRB-	70666
@NP	newborn rats	70666
@NP	Diener and Bregman	70680
@NP	1994	70700
@NP	contrast to BDNF	70714
@NP	contrast	70714
@NP	BDNF	70726
@NP	regeneration-associated gene expression	70748
@NP	lesion-induced atrophy	70799
@NP	adulthood -LRB- Kobayashi et al. , 1997 -RRB-	70829
@NP	adulthood	70829
@NP	Kobayashi	70840
@NP	et al. , 1997	70850
@NP	et al.	70850
@NP	1997	70858
@NP	This	70865
@NP	a role	70879
@NP	NT-3 in survival of RST neurons	70890
@NP	NT-3	70890
@NP	survival of RST neurons	70898
@NP	survival	70898
@NP	RST neurons	70910
@NP	axonal regeneration	70934
@NP	opposite	70964
@NP	the CST	70977
@NP	BDNF	70995
@NP	survival but not regeneration -LRB- Lu et al. , 2001b -RRB-	71021
@NP	survival	71021
@NP	regeneration -LRB- Lu et al. , 2001b -RRB-	71038
@NP	regeneration	71038
@NP	Lu	71052
@NP	et al. , 2001b	71055
@NP	et al.	71055
@NP	2001b	71063
@NP	implantation of a peripheral nerve graft	71077
@NP	implantation	71077
@NP	a peripheral nerve graft	71093
@NP	regeneration of RST fibers	71119
@NP	regeneration	71119
@NP	RST fibers	71135
@NP	Richardson et al. , 1984	71165
@NP	Richardson	71165
@NP	et al.	71176
@NP	1984	71184
@NP	the fact that Schwann cells appear more potent growth promoters for RST axons	71199
@NP	the fact	71199
@NP	Schwann cells	71213
@NP	more potent growth promoters for RST axons	71234
@NP	more potent growth promoters	71234
@NP	RST axons	71267
@NP	evidence	71278
@NP	they	71304
@NP	a CNS environment	71335
@NP	inhibitory chondroitinsulfate proteoglycan expression	71368
@NP	astrocytes -LRB- Plant et al. , 2001 ; Takami et al. , 2002 -RRB-	71425
@NP	astrocytes	71425
@NP	Plant	71437
@NP	et al. , 2001 ; Takami et al. , 2002	71443
@NP	et al.	71443
@NP	2001 ; Takami et al.	71451
@NP	2001	71451
@NP	Takami et al.	71457
@NP	Takami	71457
@NP	et al.	71464
@NP	2002	71472
@NP	OEG	71490
@NP	better candidates	71503
@NP	cellular platforms for ex vivo gene transfer to repair the injured spinal cord	71524
@NP	cellular platforms	71524
@NP	ex vivo gene transfer to repair the injured spinal cord	71547
@NP	ex vivo gene transfer	71547
@NP	the injured spinal cord	71579
@NP	contrast	71620
@NP	genetically modified fibroblasts	71632
@NP	OEGare	71665
@NP	CNS origin	71675
@NP	a subset of factors that support neurite outgrowth	71707
@NP	a subset	71707
@NP	factors that support neurite outgrowth	71719
@NP	factors	71719
@NP	neurite outgrowth	71740
@NP	review , see Ramon-Cueto and Avila , 1998 ; Woodhall et al. , 2001	71763
@NP	review	71763
@NP	see Ramon-Cueto and Avila , 1998 ; Woodhall et al. , 2001	71771
@NP	Ramon-Cueto and Avila , 1998 ; Woodhall et al. , 2001	71775
@NP	Ramon-Cueto and Avila , 1998	71775
@NP	Ramon-Cueto and Avila	71775
@NP	1998	71798
@NP	Woodhall et al. , 2001	71804
@NP	Woodhall	71804
@NP	et al. , 2001	71813
@NP	et al.	71813
@NP	2001	71821
@NP	The combination of neural transplantation and neurotrophin delivery	71828
@NP	The combination	71828
@NP	neural transplantation and neurotrophin delivery	71847
@NP	a promising strategy	71911
@NP	regeneration and functional recovery	71943
@NP	spinal cord injury	71986
@NP	review	72010
@NP	Bunge , 2001 ; Blits et al. , 2002	72022
@NP	Bunge , 2001	72022
@NP	Bunge	72022
@NP	2001	72029
@NP	Blits et al. , 2002	72035
@NP	Blits	72035
@NP	et al. , 2002	72041
@NP	et al.	72041
@NP	2002	72049
@NP	We	72056
@NP	ex vivo transduction of OEG with BDNF - or NT-3-encoding AdV vectors	72076
@NP	ex vivo transduction	72076
@NP	OEG with BDNF - or NT-3-encoding AdV vectors	72100
@NP	OEG	72100
@NP	BDNF - or NT-3-encoding AdV vectors	72109
@NP	lesion size	72174
@NP	2	72188
@NP	the growth-promoting properties of these cells	72199
@NP	the growth-promoting properties	72199
@NP	these cells	72234
@NP	-LRB- 3 -RRB- improve functional recovery after implantation	72251
@NP	improve functional recovery	72255
@NP	implantation	72289
@NP	A limitation of AdV vector-transduced OEG implants	72303
@NP	A limitation	72303
@NP	AdV vector-transduced OEG implants	72319
@NP	they	72362
@NP	robust growth of RST axons	72382
@NP	robust growth	72382
@NP	RST axons	72399
@NP	the injury site , which is essential to restore damaged neural networks	72421
@NP	the injury site	72421
@NP	damaged neural networks	72468
@NP	Stable transduction of OEG with neurotrophin-encoding lentiviral vectors	72493
@NP	Stable transduction	72493
@NP	OEG with neurotrophin-encoding lentiviral vectors	72516
@NP	OEG	72516
@NP	neurotrophin-encoding lentiviral vectors	72525
@NP	the results obtained	72594
@NP	the results	72594
@NP	hope for the use of these modified cells in both acute and chronic spinal cord	72623
@NP	hope	72623
@NP	the use of these modified cells in both acute and chronic spinal cord	72632
@NP	the use	72632
@NP	these modified cells in both acute and chronic spinal cord	72643
@NP	these modified cells	72643
@NP	both acute and chronic spinal cord	72667
@NP	injury models	72702
@VP	* Giles W.	245
@VP	* Frank P.	265
@VP	encoding rat brain-derived neurotrophic factor -LRB- BDNF -RRB-	1169
@VP	Implanted animals	1422
@VP	received a total of 2x10 ^	1440
@VP	were filled with neurofilament-positive axons	1782
@VP	filled with neurofilament-positive axons	1787
@VP	enhanced regenerative sprouting of the rubrospinal tract	1905
@VP	sprouting of the rubrospinal tract	1927
@VP	were transduced with a BDNF	2191
@VP	transduced with a BDNF	2196
@VP	contributed to the level of functional recovery	2402
@VP	resulted in a cell that was more effective in promoting axonal outgrowth	2522
@VP	was more effective in promoting axonal outgrowth	2546
@VP	promoting axonal outgrowth	2568
@VP	lead to enhanced recovery after injury , possibly by sparing of spinal tissue	2610
@VP	occurs , resulting in a permanent loss of function and paralysis	2918
@VP	resulting in a permanent loss of function and paralysis	2926
@VP	inhibit or promote axon growth	3103
@VP	see Schwab and Bartholdi , 1996 ; Fournier and Strittmatter , 2001	3147
@VP	has been studied extensively to overcome inhibition	3242
@VP	been studied extensively to overcome inhibition	3246
@VP	studied extensively to overcome inhibition	3251
@VP	to overcome inhibition	3271
@VP	overcome inhibition	3274
@VP	see Jones et al. , 2001 ; Murray and Fischer , 2001	3424
@VP	known for their beneficial effects on neuroprotection and neurite outgrowth	3498
@VP	counteract pathological events	3611
@VP	deliver neurotrophins	3887
@VP	have been studied	3909
@VP	been studied	3914
@VP	studied	3919
@VP	have been used to induce regeneration after injury	4079
@VP	been used to induce regeneration after injury	4084
@VP	used to induce regeneration after injury	4089
@VP	to induce regeneration after injury	4094
@VP	induce regeneration after injury	4097
@VP	may have advantages over other cellular conduits	4219
@VP	have advantages over other cellular conduits	4223
@VP	see Franklin and Barnett , 2000 ; Plant et al. , 2000	4281
@VP	to elongate their axons into a CNS environment	4543
@VP	elongate their axons into a CNS environment	4546
@VP	thought to be related to the presence of OEG -LRB- Doucette , 1990 , 1991 -RRB-	4593
@VP	to be related to the presence of OEG -LRB- Doucette , 1990 , 1991 -RRB-	4601
@VP	be related to the presence of OEG -LRB- Doucette , 1990 , 1991 -RRB-	4604
@VP	related to the presence of OEG -LRB- Doucette , 1990 , 1991 -RRB-	4607
@VP	see Ramon-Cueto and Avila , 1998 -RRB-	4762
@VP	grow into OEG implants -LRB- Gudino-Cabrera et al. , 2000 -RRB-	5015
@VP	is low	5250
@VP	to create more conducive conditions for RST regeneration	5612
@VP	create more conducive conditions for RST regeneration	5615
@VP	was used to assess regeneration in animals over a 4 month observation period	6012
@VP	used to assess regeneration in animals over a 4 month observation period	6016
@VP	to assess regeneration in animals over a 4 month observation period	6021
@VP	assess regeneration in animals over a 4 month observation period	6024
@VP	has been described previously in detail	6368
@VP	been described previously in detail	6372
@VP	described previously in detail	6377
@VP	was isolated from adult rat brain	6472
@VP	isolated from adult rat brain	6476
@VP	were introduced in front of the translation startcodon ATG	6991
@VP	introduced in front of the translation startcodon ATG	6996
@VP	using the United States Biochemicals sequencing kit	7276
@VP	cloned in the AdV-targeting plasmid pAd309 dlE1.sl / SalI	7393
@VP	, yielding the plasmid pAd-BDNF	7450
@VP	yielding the plasmid pAd-BDNF	7452
@VP	encoding LacZ , BDNF , or NT-3	7507
@VP	were produced using standard procedures -LRB- Akli et al. , 1993 -RRB-	7795
@VP	produced using standard procedures -LRB- Akli et al. , 1993 -RRB-	7800
@VP	using standard procedures -LRB- Akli et al. , 1993 -RRB-	7809
@VP	was linearized by SalI digestion	7888
@VP	linearized by SalI digestion	7892
@VP	Linearized targeting plasmid	7922
@VP	targeting plasmid	7933
@VP	cotransfected with ClaI	7960
@VP	XbaI-digested Ad5 DNA into 911 producer cells -LRB- Fallaux et al. , 1996 -RRB-	7989
@VP	were overlain with 0.66 % agar-containing medium -LRB- Invitrogen -RRB-	8084
@VP	overlain with 0.66 % agar-containing medium -LRB- Invitrogen -RRB-	8089
@VP	were isolated and characterized by PCR	8171
@VP	isolated and characterized by PCR	8176
@VP	expanded on 911 cells	8259
@VP	harvested	8282
@VP	purified by two rounds of CsCl density gradient centrifugation	8297
@VP	collected from the gradient	8399
@VP	stored in small aliquots at 80 °C in TS buffer containing 10 % glycerol	8547
@VP	containing 10 % glycerol	8593
@VP	determined by a plaque assay on 911 cells	8642
@VP	expressed as plaque-forming units per milliliter -LRB- pfu/ml -RRB-	8688
@VP	used	8764
@VP	were in the range of 1010 pfu/ml	8769
@VP	described previously	8914
@VP	has been described previously -LRB- Yan et al. , 2001 -RRB-	9034
@VP	been described previously -LRB- Yan et al. , 2001 -RRB-	9038
@VP	described previously -LRB- Yan et al. , 2001 -RRB-	9043
@VP	decapitated	9243
@VP	were dissected	9276
@VP	dissected	9281
@VP	was then carefully removed under a microscope using fine Dumont forceps	9378
@VP	carefully removed under a microscope using fine Dumont forceps	9387
@VP	using fine Dumont forceps	9424
@VP	were dissected away from the rest of the bulb and cut into 1mm3 pieces	9507
@VP	dissected away from the rest of the bulb and cut into 1mm3 pieces	9512
@VP	dissected away from the rest of the bulb	9512
@VP	cut into 1mm3 pieces	9557
@VP	was then gently triturated and plated onto poly-L-lysinecoated 10 cm dishes	9953
@VP	gently triturated and plated onto poly-L-lysinecoated 10 cm dishes	9962
@VP	using the p75 neurotrophin receptor -LRB- p75NTR -RRB-	10135
@VP	were incubated with p75NTR monoclonal antibody -LRB- generously provided by Dr.	10399
@VP	incubated with p75NTR monoclonal antibody -LRB- generously provided by Dr.	10404
@VP	supplemented with 5 % FBS for 2 hr at 4 °C	10549
@VP	was removed by several washings with L-15 medium	10608
@VP	removed by several washings with L-15 medium	10612
@VP	detached by trypsinization	10697
@VP	pelleted by centrifugation	10725
@VP	resuspended in L-15 medium	10757
@VP	was plated onto pretreated dishes at a density of 4	10834
@VP	plated onto pretreated dishes at a density of 4	10838
@VP	10 ^ 5 cells per dish for 30 min at 4 °C	10888
@VP	were removed from the dishes during several washes with L-15 medium	10941
@VP	removed from the dishes during several washes with L-15 medium	10946
@VP	using a cell scraper -LRB- Sarstedt , Newton , NC -RRB-	11070
@VP	centrifuged	11115
@VP	resuspended in df-10S	11132
@VP	Purified	11155
@VP	seeded onto poly-Llysine - coated 10 cm dishes	11180
@VP	using AdV	11421
@VP	have been described recently -LRB- Ruitenberg et al. , 2002 -RRB-	11461
@VP	been described recently -LRB- Ruitenberg et al. , 2002 -RRB-	11466
@VP	described recently -LRB- Ruitenberg et al. , 2002 -RRB-	11471
@VP	fed overnight with df-10S supplemented with mitogens -LRB- see above -RRB-	11636
@VP	supplemented with mitogens	11662
@VP	see above	11690
@VP	to minimize OEG proliferation	11849
@VP	minimize OEG proliferation	11852
@VP	do not integrate into the host cell genome	11900
@VP	integrate into the host cell genome	11907
@VP	transduced OEG	11961
@VP	encoding betta-gal , BDNF , or NT-3	12094
@VP	cultured cells -LRB- Ruitenberg et al. , 2002 -RRB-	12245
@VP	Transduced OEG cultures	12438
@VP	were then subjected to nonradioactive in situ	12462
@VP	subjected to nonradioactive in situ	12472
@VP	described by Giger et al. -LRB- 1996 -RRB-	12535
@VP	labeled antisense cRNA probes specific for betta-gal , BDNF , or NT-3	12593
@VP	transduced OEG	12691
@VP	determine the levels of secreted AdV vector-derived BDNF and NT-3 via an ELISA	12772
@VP	secreted AdV vector-derived BDNF and NT-3 via an ELISA	12796
@VP	described by Woodhall et al. -LRB- 2001 -RRB-	12855
@VP	Transduced cultures of OEG	12892
@VP	were prepared as described above	12919
@VP	prepared as described above	12924
@VP	described above	12936
@VP	was refreshed	12992
@VP	refreshed	12996
@VP	were left for 24 hr , allowing determination of net production levels per day	13023
@VP	left for 24 hr , allowing determination of net production levels per day	13028
@VP	allowing determination of net production levels per day	13044
@VP	taken from control	13131
@VP	transduced OEG cultures were rapidly frozen in dry ice -- ethanol	13154
@VP	were rapidly frozen in dry ice -- ethanol	13178
@VP	frozen in dry ice -- ethanol	13191
@VP	stored at -80 °C until additional processing	13221
@VP	secreted neurotrophic factor	13483
@VP	derived from a transduced OEG culture -LRB- 10 5 cells -RRB- per day	13555
@VP	transduced OEG culture -LRB- 10 5 cells -RRB- per day	13570
@VP	To determine whether recombinant BDNF and NT-3 protein was biologically active	13672
@VP	determine whether recombinant BDNF and NT-3 protein was biologically active	13675
@VP	was biologically active	13727
@VP	described by Dijkhuizen et al. -LRB- 1997 -RRB-	13851
@VP	Purified	13890
@VP	seeded onto poly-L-lysine-coated 12 mm glass coverslips	13921
@VP	described above	14055
@VP	were removed from timed pregnant female rats	14154
@VP	removed from timed pregnant female rats	14159
@VP	were killed by an intraperitoneal overdose of Nembutal and decapitated	14247
@VP	killed by an intraperitoneal overdose of Nembutal and decapitated	14252
@VP	killed by an intraperitoneal overdose of Nembutal	14252
@VP	decapitated	14306
@VP	removed by Cesarean section and transferred to wet icecooled L-15 medium	14355
@VP	removed by Cesarean section	14355
@VP	transferred to wet icecooled L-15 medium	14387
@VP	aseptically dissected from rat embryos and pooled in ice-cold L-15 medium	14455
@VP	aseptically dissected from rat embryos	14455
@VP	pooled in ice-cold L-15 medium	14498
@VP	Isolated	14530
@VP	were subsequently transferred to DMEM/F -12 medium -LRB- 1:1 mixture -RRB-	14544
@VP	transferred to DMEM/F -12 medium -LRB- 1:1 mixture -RRB-	14562
@VP	was removed by aspiration	14642
@VP	removed by aspiration	14646
@VP	taken up in 50 l of DMEM/F -12 medium	14686
@VP	plated on top of AdV vector-transduced OEG monolayers	14727
@VP	were grown for an additional 24 hr in a CO2 incubator -LRB- 5 % -RRB- at 37 °C	14817
@VP	grown for an additional 24 hr in a CO2 incubator -LRB- 5 % -RRB- at 37 °C	14822
@VP	To visualize neurite outgrowth	14885
@VP	visualize neurite outgrowth	14888
@VP	were fixed with 4 % PFA in PBS for 30 min	14928
@VP	fixed with 4 % PFA in PBS for 30 min	14933
@VP	Fixed	14970
@VP	containing 0.3 % Triton X-100 and 5 % FBS	15121
@VP	washed three times with TBS	15394
@VP	mounted in Vectashield -LRB- Vector Laboratories , Burlingame , CA -RRB-	15578
@VP	coverslipped	15643
@VP	were prepared as described previously -LRB- Ruitenberg et al. , 2002 -RRB-	15909
@VP	described previously -LRB- Ruitenberg et al. , 2002 -RRB-	15926
@VP	containing 2 µg/ml of pituitary extract and 0.2 µM forskolin	16120
@VP	were left for 72 hr	16382
@VP	left for 72 hr	16387
@VP	dye -LRB- bis-benzimide ; Sigma -RRB-	16468
@VP	subsequently washed several times with L-15 medium	16499
@VP	were detached by trypsinization and washed twice in serum-free DMEM/F -12 medium	16567
@VP	detached by trypsinization and washed twice in serum-free DMEM/F -12 medium	16572
@VP	detached by trypsinization	16572
@VP	washed twice in serum-free DMEM/F -12 medium	16603
@VP	pelleted by low-speed centrifugation	16659
@VP	carefully resuspended	16697
@VP	to obtain a suspension of 105OEGper microliter , as determined by counting	16778
@VP	obtain a suspension of 105OEGper microliter , as determined by counting	16781
@VP	determined by counting	16829
@VP	counting	16843
@VP	determined by counting the percentage of dead cells using Trypan blue staining	16890
@VP	counting the percentage of dead cells using Trypan blue staining	16904
@VP	using Trypan blue staining	16942
@VP	was ≈ 95 %	17037
@VP	were kept cool on wet ice during surgery	17059
@VP	kept cool on wet ice during surgery	17064
@VP	were used in this experiment	17204
@VP	used in this experiment	17209
@VP	housed under standard conditions	17248
@VP	maintained in a 12 hr light/dark cycle	17282
@VP	had ad libitum access to water and food	17326
@VP	was monitored during the experiment as a general measure of health	17558
@VP	monitored during the experiment as a general measure of health	17562
@VP	were divided into six experimental groups	17634
@VP	divided into six experimental groups	17639
@VP	serves as a control	17714
@VP	received a similar spinal cord lesion but also an	17882
@VP	implant of either control or AdV vector-transduced OEG	17932
@VP	served as additional controls	18125
@VP	encoding BDNF or NT-3 before implantation	18228
@VP	subjected to infection with a 1:1 mixture of BDNF - and NT-3-encoding AdV vector	18418
@VP	subsequently implanted in the lesioned spinal cord -LRB- n = 12 -RRB-	18502
@VP	were tested weekly for 4 months for recovery of hind limb performance	18572
@VP	tested weekly for 4 months for recovery of hind limb performance	18577
@VP	were killed	18794
@VP	killed	18799
@VP	descending spinal pathways in general	18962
@VP	were taken from groups 3 -- 6 and evaluated for transgene expression	19044
@VP	taken from groups 3 -- 6 and evaluated for transgene expression	19049
@VP	taken from groups 3 -- 6	19049
@VP	evaluated for transgene expression	19075
@VP	involving the RST	19204
@VP	was described previously in detail -LRB- Ruitenberg et al. , 2002 -RRB-	19222
@VP	described previously in detail -LRB- Ruitenberg et al. , 2002 -RRB-	19226
@VP	To expose the spinal cord	19634
@VP	expose the spinal cord	19637
@VP	was made through both dura and pia mater using a sharpened 30 ga needle	19678
@VP	made through both dura and pia mater using a sharpened 30 ga needle	19682
@VP	using a sharpened 30 ga needle	19719
@VP	taking care not to damage the dorsal	19972
@VP	to damage the dorsal	19988
@VP	damage the dorsal	19991
@VP	resulted in complete transection of the RST projection area	20030
@VP	slightly damaged the spinal gray matter	20094
@VP	using a Harvard microinjection apparatus	20248
@VP	delivered 105 cells	20305
@VP	were closed in separate layers	20374
@VP	closed in separate layers	20379
@VP	to suppress pain	20627
@VP	suppress pain	20630
@VP	used for implantation	20713
@VP	ranged between 90 and 95 % , as determined by Trypan blue staining	20741
@VP	to recover for a period of 7 d before the assessment of locomotor capacity	20880
@VP	recover for a period of 7 d before the assessment of locomotor capacity	20883
@VP	were blinded to the treatment of the animal	21285
@VP	blinded to the treatment of the animal	21290
@VP	studying several aspects involved in the locomotion of quadrupedal animals	21423
@VP	involved in the locomotion of quadrupedal animals	21448
@VP	to assess behavioral deficits in partial spinal cord hemisection models	21524
@VP	assess behavioral deficits in partial spinal cord hemisection models	21527
@VP	was used to study more specific aspects such as posture and balance during gait	21621
@VP	used to study more specific aspects such as posture and balance during gait	21625
@VP	to study more specific aspects such as posture and balance during gait	21630
@VP	study more specific aspects such as posture and balance during gait	21633
@VP	was studied	21850
@VP	studied	21854
@VP	were required	21970
@VP	required	21975
@VP	was obtained	22118
@VP	obtained	22122
@VP	crossed the rope quickly with an occasional minor slip	22148
@VP	falls	22210
@VP	defined as follows	22316
@VP	follows	22327
@VP	cross the rope	22465
@VP	cross the rope	22630
@VP	slips , and falls	22655
@VP	slips	22655
@VP	falls	22666
@VP	To determine ratings	22673
@VP	determine ratings	22676
@VP	given two conditioning trials	22705
@VP	moved along the rope	22865
@VP	allowing us to determine the `` total error/step '' ratio	22949
@VP	to determine the `` total error/step '' ratio	22961
@VP	determine the `` total error/step '' ratio	22964
@VP	included counting the number of slips and falls during rope traverse	23038
@VP	counting the number of	23047
@VP	slips and falls during rope traverse	23070
@VP	slips	23206
@VP	falls	23226
@VP	was observed three times	23266
@VP	observed three times	23270
@VP	tracing	23505
@VP	described previously -LRB- Antal et al. , 1992 -RRB-	23563
@VP	was held in a stereotaxic frame	23874
@VP	held in a stereotaxic frame	23878
@VP	was subsequently delivered to the red nucleus using iontophoresis	23984
@VP	subsequently delivered to the red nucleus using iontophoresis	23988
@VP	using iontophoresis	24030
@VP	followed by 5 sec intervals for a period of 20 min	24318
@VP	was then switched off	24382
@VP	switched off	24391
@VP	was left in place for 5 min to allow diffusion ofBDAfrom the injection spot	24421
@VP	left in place for 5 min to allow diffusion ofBDAfrom the injection spot	24425
@VP	to allow diffusion ofBDAfrom the injection spot	24449
@VP	allow diffusion ofBDAfrom the injection spot	24452
@VP	to evaluate possible RST axon regeneration	24823
@VP	evaluate possible RST axon regeneration	24826
@VP	containing 0.315 mg/ml of fentanyl citrate and 10 mg/ml of fluanisone	25002
@VP	were repeated every 30 min after induction of the anesthesia	25092
@VP	repeated every 30 min after induction of the anesthesia	25097
@VP	intubated	25185
@VP	coordinates as for tracer delivery	25513
@VP	consisting of thin gold plates and with an interpolar distance of 5 mm	25634
@VP	were subsequently determined by slowly increasing the applied voltage	25723
@VP	determined by slowly increasing the applied voltage	25741
@VP	slowly increasing the applied voltage	25755
@VP	used for analysis	25803
@VP	were measured at twice the threshold value	25821
@VP	measured at twice the threshold value	25826
@VP	evoked potentials	25880
@VP	was transected at the level of vertebrae C3	26038
@VP	transected at the level of vertebrae C3	26042
@VP	was attributable to stimulation of the right red nucleus	26198
@VP	followed by 300 ml of ice-cold 4 % PFA in PBS	26373
@VP	stored in 0.1 % PFA in PBS containing 0.01 %	26513
@VP	containing 0.01 %	26539
@VP	were averaged to improve the signal/noise ratio	26631
@VP	averaged to improve the signal/noise ratio	26636
@VP	to improve the signal/noise ratio	26645
@VP	improve the signal/noise ratio	26648
@VP	was at least three times as large as the SD of the noise	26802
@VP	was discarded	27018
@VP	discarded	27022
@VP	were determined and included in the analysis	27034
@VP	determined and included in the analysis	27039
@VP	To evaluate transgene expression 7 d after implantation	27103
@VP	evaluate transgene expression 7 d after implantation	27106
@VP	cut on a cryostat	27218
@VP	subjected to standard in situ hybridization using DIGlabeled cRNA	27240
@VP	in situ hybridization using DIGlabeled cRNA	27262
@VP	were cut in PBS and collected in serial vials	27887
@VP	cut in PBS and collected in serial vials	27892
@VP	cut in PBS	27892
@VP	collected in serial vials	27907
@VP	washed three times	28294
@VP	incubated for 30 min	28317
@VP	supplemented with 5 % FBS and 0.3 % Triton X-100	28347
@VP	washed three times in TBS	28618
@VP	containing 0.01 % H2O2 to allow signal amplification	28717
@VP	to allow signal amplification	28739
@VP	allow signal amplification	28742
@VP	were washed again three times and incubated with ABC reagent for 1 hr at RT.	28779
@VP	washed again three times and incubated with ABC reagent for 1 hr at RT.	28784
@VP	washed again three times	28784
@VP	incubated with ABC reagent for 1 hr at RT.	28813
@VP	containing 0.01 % H2O2	28979
@VP	resulting in a dark purple precipitate	29035
@VP	graded series of ethanol , cleared in xylene ,	29116
@VP	cleared in xylene	29142
@VP	finally embedded in Entellan -LRB- Merck , Amsterdam , The Netherlands -RRB-	29165
@VP	were made	29432
@VP	made	29437
@VP	using DAB double staining as described previously	29572
@VP	described previously	29601
@VP	described above	29699
@VP	incubated overnight with ABC reagent	29719
@VP	to stain traced RST axons	29756
@VP	stain traced RST axons	29759
@VP	traced RST axons	29765
@VP	containing TBS to block peroxidase activity	29912
@VP	to block peroxidase activity	29927
@VP	block peroxidase activity	29930
@VP	were washed away with multiple washings in TBS	30104
@VP	washed away with multiple washings in TBS	30109
@VP	incubated with a horseradish peroxidaseconjugated secondary antibody	30165
@VP	were directed against rabbit immunoglobulins -LRB- 1:200 ; Dako -RRB-	30234
@VP	directed against rabbit immunoglobulins -LRB- 1:200 ; Dako -RRB-	30239
@VP	can be clearly distinguished from dark purple-stained RST axons	30470
@VP	be clearly distinguished from dark purple-stained RST axons	30474
@VP	clearly distinguished from dark purple-stained RST axons	30477
@VP	were mounted on gelatin-coated slides and dried overnight at RT.	30544
@VP	were mounted on gelatin-coated slides	30544
@VP	mounted on gelatin-coated slides	30549
@VP	dried overnight at RT.	30586
@VP	dehydrated in ethanol	30689
@VP	finally embedded in Entellan as described above	30716
@VP	described above	30748
@VP	to visualize regenerating axons in the lesion area	30932
@VP	visualize regenerating axons in the lesion area	30935
@VP	used as a general marker to visualize implantedOEGat the lesion site	31022
@VP	to visualize implantedOEGat the lesion site	31047
@VP	visualize implantedOEGat the lesion site	31050
@VP	combined with staining for NF or fibronectin	31095
@VP	may have invaded the lesion site -LRB- Pasterkamp et al. , 1999 -RRB-	31225
@VP	have invaded the lesion site -LRB- Pasterkamp et al. , 1999 -RRB-	31229
@VP	invaded the lesion site -LRB- Pasterkamp et al. , 1999 -RRB-	31234
@VP	containing 0.3 %	31364
@VP	to block nonspecific binding of antibodies	31404
@VP	block nonspecific binding of antibodies	31407
@VP	washed with TBS	31724
@VP	were mounted on slides and immersed in Vectashield	31909
@VP	mounted on slides and immersed in Vectashield	31914
@VP	mounted on slides	31914
@VP	immersed in Vectashield	31936
@VP	were captured using a Zeiss CLSM device	31989
@VP	captured using a Zeiss CLSM device	31994
@VP	using a Zeiss CLSM device	32003
@VP	To quantify regeneration or sprouting of traced RST axons	32082
@VP	quantify regeneration or sprouting of traced RST axons	32085
@VP	were counted as described by Blits et al. -LRB- 2000 -RRB-	32189
@VP	counted as described by Blits et al. -LRB- 2000 -RRB-	32194
@VP	described by Blits et al. -LRB- 2000 -RRB-	32205
@VP	was determined using a dark-field filter and considered as `` point 0	32278
@VP	determined using a dark-field filter and considered as `` point 0	32282
@VP	determined using a dark-field filter	32282
@VP	using a dark-field filter	32293
@VP	considered as `` point 0	32323
@VP	healthylooking spinal neurons , and a high density of small cells	32456
@VP	implanted OEG	32528
@VP	are known to invade spinal cord injury sites -RSB- as described previously	32595
@VP	known to invade spinal cord injury sites -RSB- as described previously	32599
@VP	to invade spinal cord injury sites	32605
@VP	invade spinal cord injury sites	32608
@VP	described previously	32644
@VP	was blinded to the treatment of the animals	33115
@VP	blinded to the treatment of the animals	33119
@VP	To correct for variability in the tracing results	33160
@VP	correct for variability in the tracing results	33163
@VP	to point 0	33354
@VP	point 0	33357
@VP	were determined using a computerized image analysis station	33534
@VP	determined using a computerized image analysis station	33539
@VP	using a computerized image analysis station	33550
@VP	used for RST axon quantification	33623
@VP	described above ; 50 % of total sections	33657
@VP	described above	33657
@VP	were studied under darkfield microscopy	33697
@VP	studied under darkfield microscopy	33702
@VP	was determined using the same criteria as described above	33773
@VP	determined using the same criteria as described above	33777
@VP	using the same criteria as described above	33788
@VP	described above	33815
@VP	were outlined while the observer was blinded to the experimental treatment	33851
@VP	outlined while the observer was blinded to the experimental treatment	33856
@VP	was blinded to the experimental treatment	33884
@VP	blinded to the experimental treatment	33888
@VP	subsequently imported into Microsoft -LRB- Seattle , WA -RRB- Excel , summed	34150
@VP	imported into Microsoft -LRB- Seattle , WA -RRB- Excel	34163
@VP	summed	34208
@VP	multiplied by the section thickness	34216
@VP	corrected for the total number of sections	34257
@VP	obtained from histological analysis	34328
@VP	using two-way ANOVA	34515
@VP	post hoc Newman -- Keuls tests	34539
@VP	were evaluated using nonparametric Kruskall -- Wallis ANOVA test	34639
@VP	evaluated using nonparametric Kruskall -- Wallis ANOVA test	34644
@VP	using nonparametric Kruskall -- Wallis ANOVA test	34654
@VP	were possible relationships between different outcome parameters	34769
@VP	were considered statistically significant if p 0.01	34838
@VP	considered statistically significant if p 0.01	34843
@VP	incorporated in the analysis	34902
@VP	were obtained from animals that survived the entire study	34931
@VP	obtained from animals that survived the entire study	34936
@VP	survived the entire study	34963
@VP	was analyzed for the presence of BDNF and NT-3 using ELISA techniques	35206
@VP	analyzed for the presence of BDNF and NT-3 using ELISA techniques	35210
@VP	using ELISA techniques	35253
@VP	indicate averages SEM -LRB- n = 4 -RRB-	35282
@VP	secreted in medium taken from control OEG cultures over a 24 hr time period	35378
@VP	taken from control OEG cultures over a 24 hr time period	35397
@VP	was not detectable -LRB- N.D. -RRB-	35468
@VP	secreted into the culture medium	35617
@VP	confirmed in a 24 hr coculture experiment of transduced OEG and E14 DRG explants	35794
@VP	transduced OEG and E14 DRG explants	35839
@VP	did not alter the growth-promoting properties of these cells	36216
@VP	alter the growth-promoting properties of these cells	36224
@VP	were secreted from OEG in biologically active form	36459
@VP	secreted from OEG in biologically active form	36464
@VP	transduced	36526
@VP	were more effective in promoting neurite outgrowth in culture	36541
@VP	promoting neurite outgrowth in culture	36564
@VP	-LRB- in E -RRB- B	36615
@VP	by transduced OEG after implantation in the lesioned spinal cord	36708
@VP	expressing high levels of BDNF and NT-3 mRNA	36812
@VP	were detected in the lesion area	36857
@VP	detected in the lesion area	36862
@VP	implanted with uninfected or AdV-LacZ-transduced OEG	36899
@VP	did not display such neurotrophin mRNA expression at the injury site	36971
@VP	display such neurotrophin mRNA expression at the injury site	36979
@VP	were nicely integrated in the host spinal cord bridging the injury site	37068
@VP	integrated in the host spinal cord bridging the injury site	37080
@VP	bridging the injury site	37115
@VP	implanted OEG.Someadditional labeling for p75 NTR -LRB- Schwann cells -RRB-	37296
@VP	dashed line	37462
@VP	surrounded by GFAP-positive reactive astrocytes	37616
@VP	to visualize scar-associated meningeal cells and fibroblasts in the lesion area	37836
@VP	visualize scar-associated meningeal cells and fibroblasts in the lesion area	37839
@VP	combined with immunohistochemistry for p75 NTR -LRB- red -RRB-	37920
@VP	expressed in the lesion area with only little immunoreactivity for p75 NTR	38073
@VP	were found to fill the lesion gap	38176
@VP	found to fill the lesion gap	38181
@VP	to fill the lesion gap	38187
@VP	fill the lesion gap	38190
@VP	was observed	38252
@VP	observed	38256
@VP	is a higher magnification of the outlined area	38357
@VP	may have migrated into the lesion area from the dorsal root	38410
@VP	have migrated into the lesion area from the dorsal root	38414
@VP	migrated into the lesion area from the dorsal root	38419
@VP	grafted	38645
@VP	did survive in the lesioned spinal cord	38659
@VP	survive in the lesioned spinal cord	38663
@VP	to visualize all axons present in this area	38957
@VP	visualize all axons present in this area	38960
@VP	displaying typical end bulb-like structures -LRB- arrowhead -RRB-	39097
@VP	aligning with bipolar p75 NTR-positive cells -LRB- arrows -RRB-	39247
@VP	were able to regenerate through the OEG implantation site	39371
@VP	to regenerate through the OEG implantation site	39381
@VP	regenerate through the OEG implantation site	39384
@VP	traced with BDA , which was iontophoretically applied 2 weeks before perfusion	39636
@VP	was iontophoretically applied 2 weeks before perfusion	39659
@VP	applied 2 weeks before perfusion	39681
@VP	to better visualize tissue cytoarchitecture	40011
@VP	better visualize tissue cytoarchitecture	40014
@VP	left	40070
@VP	is rostral -LRB- proximal to the injury -RRB-	40075
@VP	dashed lines indicate graft -- host interfaces	40116
@VP	indicate graft -- host interfaces	40129
@VP	Traced RST axons proximal to the lesion in an unimplanted control animal	40168
@VP	did not regenerate into the lesion area -LRB- asterisk -RRB-	40325
@VP	regenerate into the lesion area -LRB- asterisk -RRB-	40333
@VP	delineated by GFAP-positive astrocytes	40428
@VP	was observed	40637
@VP	observed	40641
@VP	outlined in B	40706
@VP	showing end bulb-like axon endings	40721
@VP	had been transduced with no or AdV-NT-3 vector before implantation	40873
@VP	been transduced with no or AdV-NT-3 vector before implantation	40877
@VP	transduced with no or AdV-NT-3 vector before implantation	40882
@VP	was observed	41078
@VP	observed	41082
@VP	determined using dark-field microscopy	41155
@VP	using dark-field microscopy	41166
@VP	inset ; asterisk , blood vessel ; wm , white matter	41195
@VP	Sprouting preferentially	41245
@VP	Traced RST axons deeper in the graft -LRB- arrows -RRB-	41423
@VP	showing undirectional growth of RST axons -LRB- arrow -RRB-	41582
@VP	leave the graft and extend distally into the host spinal cord -LRB- arrow -RRB-	41709
@VP	leave the graft	41709
@VP	extend distally into the host spinal cord -LRB- arrow -RRB-	41729
@VP	made of representative animals from each experimental group	42123
@VP	are shown	42183
@VP	shown	42187
@VP	contained both scar-associated cells and implanted OEG	42370
@VP	contained both scar-associated cells	42370
@VP	implanted OEG	42411
@VP	To compensate for variability in RST-tracing efficiency	42617
@VP	compensate for variability in RST-tracing efficiency	42620
@VP	were set as 100 %	42718
@VP	set as 100 %	42723
@VP	calculated	42757
@VP	were set as relative percentages	42768
@VP	set as relative percentages	42773
@VP	are presented as averages ± SEM	42807
@VP	presented as averages ± SEM	42811
@VP	implant	43387
@VP	transduced with both BDNF and NT-3-encoding AdV vectors	43612
@VP	counts	43678
@VP	prevented axonal dieback	43712
@VP	sprouting of axotomized RST axons into the lesion area -LRB- p < 0.0001 -RRB-	43749
@VP	axotomized RST axons into the lesion area -LRB- p < 0.0001 -RRB-	43762
@VP	indicating that coexpression of BDNF and NT-3 had no synergistic	43891
@VP	had no synergistic	43937
@VP	counteracting effect on RST outgrowth	43959
@VP	reduce lesion size after implantation in the lesioned rat spinal cord	44022
@VP	implanted animal using dark-field microscopy	44143
@VP	using dark-field microscopy	44160
@VP	invaded the injury site clearly defined the borders of the damaged area	44286
@VP	defined the borders of the damaged area	44318
@VP	showing the outlined damaged -LRB- shaded -RRB- area to determine lesion size	44403
@VP	outlined damaged -LRB- shaded -RRB- area to determine lesion size	44415
@VP	damaged -LRB- shaded -RRB- area to determine lesion size	44424
@VP	to determine lesion size	44446
@VP	determine lesion size	44449
@VP	showing lesion volumes in cubic millimeters -LRB- average ± SEM -RRB-	44533
@VP	was found in all OEG-implanted animals	44643
@VP	found in all OEG-implanted animals	44647
@VP	found only after implantation of AdV-BDNF - , AdV-NT-3 -	44724
@VP	AdV-BDNF plus AdV-NT-3-transduced OEG , respectively	44782
@VP	indicates the absence of robust and functional RST regeneration	45432
@VP	promote recovery of hindlimb function during horizontal rope walking	45548
@VP	showing experimental animals crossing the rope 4 months after injury	45664
@VP	crossing the rope 4 months after injury	45693
@VP	frequently observed in unimplanted lesioned controls	45788
@VP	slips and falls	45914
@VP	slips	45914
@VP	falls	45924
@VP	resulted in better general body posture during task performance	46042
@VP	left	46279
@VP	± SEM are presented from each experimental group up to 16 weeks after injury	46309
@VP	are presented from each experimental group up to 16 weeks after injury	46314
@VP	presented from each experimental group up to 16 weeks after injury	46318
@VP	occurred in all OEG-implanted animal groups during the first postoperative weeks	46642
@VP	was found	46785
@VP	found	46789
@VP	was present in all OEG-implanted animal groups -LRB- p ≤ 0.0002 -RRB-	46836
@VP	implanted rats -LRB- p = 0.99 -RRB-	46969
@VP	were observed between these groups -LRB- p > 0.53 -RRB-	47176
@VP	observed between these groups -LRB- p > 0.53 -RRB-	47181
@VP	slips and falls ; p < 0.0002	47374
@VP	slips	47374
@VP	falls ; p <	47384
@VP	falls	47384
@VP	was found in all OEG-implanted rats compared with unimplanted lesioned controls	47402
@VP	found in all OEG-implanted rats compared with unimplanted lesioned controls	47406
@VP	slips and no falls	47707
@VP	slips	47707
@VP	falls	47720
@VP	transduced OEG	47854
@VP	were observed between these groups -LRB- p > 0.64 -RRB-	47897
@VP	observed between these groups -LRB- p > 0.64 -RRB-	47902
@VP	correlates with lesion size	47996
@VP	plotted against accompanying lesion volumes	48077
@VP	determined by Pearson 's correlation test	48212
@VP	not shown	48546
@VP	served as control cultures or after hybridization with sense probe	48772
@VP	transduced	48864
@VP	using an ELISA assay 4 d after transduction with AdV vectors -LRB- Fig. 1A -RRB-	48949
@VP	taken from control -LRB- 0.45 ± 0.17 ng/105 cells per day -RRB- or AdVLacZ	49080
@VP	transduced OEG cultures -LRB- 0.57 ± 0.13 ng/105 cells per day -RRB-	49146
@VP	was not detectable	49219
@VP	secreted from transduced OEG was observed	49329
@VP	transduced OEG was observed	49343
@VP	was observed	49358
@VP	observed	49362
@VP	taken from AdV-NT-3-transduced OEG cultures	49405
@VP	was secreted from 105 cells per day	49504
@VP	secreted from 105 cells per day	49508
@VP	transduced with an AdV vector-encoding BDNF or NT-3 as compared with controls	49669
@VP	vectorderived BDNF and NT-3 was demonstrated in a coculture experiment	49775
@VP	was demonstrated in a coculture experiment	49803
@VP	demonstrated in a coculture experiment	49807
@VP	to determine the effect of transgenic neurotrophic factor production	49950
@VP	determine the effect of transgenic neurotrophic factor production	49953
@VP	were subsequently analyzed for neurite outgrowth	50023
@VP	subsequently analyzed for neurite outgrowth	50028
@VP	cocultured with uninfected or AdV-LacZ-transduced OEG -LRB- Fig. 1B , C -RRB-	50178
@VP	did not interfere with the growthsupporting properties of OEG	50369
@VP	interfere with the growthsupporting properties of OEG	50377
@VP	were transduced with an AdV vector-encoding BDNF or NT-3 -LRB- Fig. 1D , E -RRB-	50511
@VP	transduced with an AdV vector-encoding BDNF or NT-3 -LRB- Fig. 1D , E -RRB-	50516
@VP	were biologically active	50645
@VP	were secreted by transduced OEG as shown previously by ELISA	50713
@VP	secreted by transduced OEG as shown previously by ELISA	50718
@VP	transduced OEG as shown previously by ELISA	50730
@VP	shown previously by ELISA	50748
@VP	displaying typical bipolar OEG morphology	51003
@VP	were detected in the lesion area expressing high levels of BDNF or NT-3 mRNA	51045
@VP	detected in the lesion area expressing high levels of BDNF or NT-3 mRNA	51050
@VP	expressing high levels of BDNF or NT-3 mRNA	51078
@VP	not shown	51229
@VP	To determine the identity of BDNF - and NT-3	51241
@VP	determine the identity of BDNF - and NT-3	51244
@VP	expressing cells	51286
@VP	is a marker for OEG	51416
@VP	identifying them as being implanted OEG	51566
@VP	being implanted OEG	51586
@VP	implanted OEG	51592
@VP	bridging the injury site	51702
@VP	determined by GFAP staining that was used to visualize the developing glial scar	51730
@VP	was used to visualize the developing glial scar	51763
@VP	used to visualize the developing glial scar	51767
@VP	to visualize the developing glial scar	51772
@VP	visualize the developing glial scar	51775
@VP	indicating the presence of Schwann cells	51936
@VP	to visualize scar-associated cells , such as meningeal cells and fibroblasts ,	52052
@VP	visualize scar-associated cells , such as meningeal cells and fibroblasts ,	52055
@VP	implanted OEG , respectively	52133
@VP	was found in unimplanted animals delineating the scar	52224
@VP	found in unimplanted animals delineating the scar	52228
@VP	delineating the scar	52257
@VP	could be detected -LRB- Fig. 3A -RRB-	52324
@VP	be detected -LRB- Fig. 3A -RRB-	52330
@VP	detected -LRB- Fig. 3A -RRB-	52333
@VP	inset	52550
@VP	had migrated into the spinal cord after the injury	52615
@VP	migrated into the spinal cord after the injury	52619
@VP	were found to invade the spinal cord	53012
@VP	found to invade the spinal cord	53017
@VP	to invade the spinal cord	53023
@VP	invade the spinal cord	53026
@VP	presumably implanted OEG	53093
@VP	derived from the meningeal sheets -LRB- Pasterkamp et al. , 1999 -RRB-	53228
@VP	combined with axonal staining	53294
@VP	tracing	53583
@VP	result in robust long-distance regeneration of RST fibers under any condition	53633
@VP	penetrate into the central component of the scar tissue -LRB- Fig. 4A , C -RRB-	53909
@VP	implant of uninfected , AdV-LacZ - or AdV-NT-3-transduced OEG , respectively	54006
@VP	was observed compared with nonimplanted animals -LRB- Fig. 4B , D , E -RRB-	54136
@VP	observed compared with nonimplanted animals -LRB- Fig. 4B , D , E -RRB-	54140
@VP	sprouting of RST axons	54232
@VP	implant that was transduced with AdV-BDNF	54300
@VP	was transduced with AdV-BDNF	54313
@VP	transduced with AdV-BDNF	54317
@VP	was observed -LRB- Fig. 4G , I -RRB-	54557
@VP	observed -LRB- Fig. 4G , I -RRB-	54561
@VP	extending beyond the lesion and implantation site in the distal spinal cord	54681
@VP	were still in close proximity of the injury site -LRB- Fig. 4H , J -RRB-	54787
@VP	implant of uninfected OEG -LRB- p = 0.52 ; n = 9 -RRB- or AdVLacZ - transduced	55369
@VP	transduced	55426
@VP	transduced OEG	55523
@VP	induce growth of RST axons	55553
@VP	counteract axonal `` dieback '' -LRB- p ≥ 0.28 ; n = 7 -RRB-	55583
@VP	was observed	55698
@VP	observed	55702
@VP	sprouting	55765
@VP	seemed present in these OEG implanted groups	55775
@VP	implanted groups	55803
@VP	indicate that RST axons were not overly attracted by OEG implants	55832
@VP	were not overly attracted by OEG implants	55856
@VP	overly attracted by OEG implants	55865
@VP	did not evoke a regenerative response of RST axons	55975
@VP	evoke a regenerative response of RST axons	55983
@VP	expected from the histological observations	56030
@VP	sprouting of RST axons	56117
@VP	indicating that coexpression of BDNF and NT-3 had no synergistic	56331
@VP	had no synergistic	56377
@VP	counteracting effect on the level of RST axon sprouting	56399
@VP	sprouting	56445
@VP	was present in all OEG implanted rats compared with controls -LRB- Fig. 7 -RRB-	56558
@VP	implanted rats compared with controls -LRB- Fig. 7 -RRB-	56581
@VP	received OEG implants transduced with AdV vectors encoding BDNF	56917
@VP	transduced with AdV vectors encoding BDNF	56939
@VP	encoding BDNF	56967
@VP	represents the direct projection from the red nucleus	57430
@VP	involves the red nucleus	57819
@VP	data not shown	58012
@VP	did not reveal detectable functional deficits in the open field	58249
@VP	reveal detectable functional deficits in the open field	58257
@VP	to fully recover from the injury	58451
@VP	fully recover from the injury	58454
@VP	not shown	58514
@VP	stated previously	58701
@VP	slips of the hindlimb or even a fall from the rope -LRB- Fig. 9A -RRB-	58878
@VP	was not present during pretraining of the animals before spinal injury	58956
@VP	operated animals	59035
@VP	were observed	59119
@VP	observed	59124
@VP	scores was found -LRB- p ≤ 0.0002 -RRB- -LRB- Fig. 9B -RRB-	59204
@VP	was found -LRB- p ≤ 0.0002 -RRB-	59211
@VP	found -LRB- p ≤ 0.0002 -RRB-	59215
@VP	had a consistently improved locomotion	59287
@VP	slipped or fell from the rope less frequently than unimplanted control animals	59330
@VP	expected	59413
@VP	received an implant of uninfected or AdVLacZ - transduced OEG , respectively	59492
@VP	implant of uninfected or AdVLacZ	59504
@VP	transduced OEG , respectively	59538
@VP	using AdV vector-mediated gene transfer	59639
@VP	did not interfere with the behavioral outcome	59680
@VP	interfere with the behavioral outcome	59688
@VP	implant that was transduced with a neurotrophin-encoding AdV vector	59821
@VP	was transduced with a neurotrophin-encoding AdV vector	59834
@VP	transduced with a neurotrophin-encoding AdV vector	59838
@VP	made fewer errors during rope traverse	59941
@VP	control OEG implant	60147
@VP	implant	60159
@VP	were reflected in the significantly lower deficit scores	60198
@VP	reflected in the significantly lower deficit scores	60203
@VP	were found after the first month after surgery	60368
@VP	found after the first month after surgery	60373
@VP	occurred during the first 4 weeks after injury and OEG implantation	60467
@VP	Calculated total error/step ratios	60536
@VP	obtained from the deficit-scoring method -LRB- Fig. 9C -RRB-	60615
@VP	were found among the experimental groups	60707
@VP	found among the experimental groups	60712
@VP	resulting in significantly lower error scores	60829
@VP	slips or falls	60882
@VP	slips	60882
@VP	falls	60891
@VP	received an implant of either uninfected or AdVLacZ - transduced OEG	61063
@VP	implant of either uninfected or AdVLacZ	61075
@VP	transduced OEG	61116
@VP	Enhanced recovery	61132
@VP	subjected to transduction with neurotrophin-encoding AdV vector	61207
@VP	compared with AdVLacZ - transducedOEGimplanted rats	61277
@VP	were observed in animals implanted with AdV-BDNF-transduced OEG	61342
@VP	observed in animals implanted with AdV-BDNF-transduced OEG	61347
@VP	implanted with AdV-BDNF-transduced OEG	61367
@VP	did not reach statistical significance -LRB- p = 0.07 -RRB-	61421
@VP	reach statistical significance -LRB- p = 0.07 -RRB-	61429
@VP	were significantly less impaired than unimplanted lesioned controls	61794
@VP	performed well during horizontal rope walking	62091
@VP	to have relatively small lesions	62166
@VP	have relatively small lesions	62169
@VP	slipped or fell from the rope more frequently	62221
@VP	slipped	62221
@VP	fell from the rope more frequently	62232
@VP	had bigger lesion volumes -LRB- Fig. 9D -RRB-	62280
@VP	counteracting secondary degeneration	62387
@VP	would also be in line with the time course of recovery	62526
@VP	be in line with the time course of recovery	62537
@VP	showed that OEG did not induce major long-distance RST regeneration	63505
@VP	did not induce major long-distance RST regeneration	63521
@VP	induce major long-distance RST regeneration	63529
@VP	receiving an implant of neurotrophin-encoding AdV vector-transduced OEG	63958
@VP	implant of neurotrophin-encoding AdV vector-transduced OEG	63971
@VP	were not only attributable to a loss of rubral input	64337
@VP	contributed to these remaining deficits	64471
@VP	is a novel finding	64692
@VP	remained to be elucidated whether this also improved functional recovery	64851
@VP	to be elucidated whether this also improved functional recovery	64860
@VP	be elucidated whether this also improved functional recovery	64863
@VP	elucidated whether this also improved functional recovery	64866
@VP	transduced with neurotrophin-encoding AdV vectors	65005
@VP	indicates that BDNF and NT-3 counteracted secondary tissue degeneration	65061
@VP	counteracted secondary tissue degeneration	65090
@VP	was proposed previously	65176
@VP	proposed previously	65180
@VP	are partly caused by demyelination of spared axons	65708
@VP	caused by demyelination of spared axons	65719
@VP	appeared to influence impaired hindlimb performance	65811
@VP	to influence impaired hindlimb performance	65820
@VP	influence impaired hindlimb performance	65823
@VP	contributed to the level of functional recovery	66017
@VP	allowed us to manipulate the growthpromoting properties of OEG	66186
@VP	to manipulate the growthpromoting properties of OEG	66197
@VP	manipulate the growthpromoting properties of OEG	66200
@VP	resulted in a cell type that was more effective in promoting neurite growth	66304
@VP	was more effective in promoting neurite growth	66333
@VP	promoting neurite growth	66355
@VP	were capable of inducing a significant regenerative response of RST axons	66418
@VP	inducing a significant regenerative response of RST axons	66434
@VP	to reliably track implanted cells	66614
@VP	reliably track implanted cells	66617
@VP	survive in the lesioned spinal cord at least	66702
@VP	do not robustly respond to OEG implants	66895
@VP	respond to OEG implants	66911
@VP	to regenerate through OEG implants in different injury models	66988
@VP	regenerate through OEG implants in different injury models	66991
@VP	sprouting	67412
@VP	observed here for the RST -LRB- Takami et al. , 2002 ; D.	67465
@VP	involved in regeneration of specific nerve tracts	67764
@VP	bridging substrates via genetic engineering	67857
@VP	to deliver neurotrophins	68086
@VP	deliver neurotrophins	68089
@VP	see Dijkhuizen and Verhaagen , 1999	68181
@VP	have been used to deliver BDNF to the injured spinal cord	68326
@VP	been used to deliver BDNF to the injured spinal cord	68331
@VP	used to deliver BDNF to the injured spinal cord	68336
@VP	to deliver BDNF to the injured spinal cord	68341
@VP	deliver BDNF to the injured spinal cord	68344
@VP	sprouting	68549
@VP	was observed	68559
@VP	observed	68563
@VP	is likely	68670
@VP	is provided by engineered fibroblast grafts	69093
@VP	provided by engineered fibroblast grafts	69096
@VP	results in persistent transgene expression -LRB- Ruitenberg et al. , 2002 -RRB-	69314
@VP	compare those implants directly to grafts of engineered fibroblasts -RSB-	69388
@VP	allow modulation of neurite outgrowth -LRB- Blesch et al. , 2000 , 2001 -RRB-	69514
@VP	occurred along the interface of the lesion area and intact spinal cord	69722
@VP	was also observed by Liu et al. -LRB- 1999 -RRB-	69799
@VP	also observed by Liu et al. -LRB- 1999 -RRB-	69803
@VP	to grow -LRB- Kawaja and Gage , 1991 -RRB-	69969
@VP	grow -LRB- Kawaja and Gage , 1991 -RRB-	69972
@VP	also contains scar-associated cells -LRB- e.g. , meningeal cells -RRB-	70089
@VP	have been associated with these cells	70186
@VP	been associated with these cells	70191
@VP	associated with these cells	70196
@VP	may repel growing RST axons from this area	70228
@VP	repel growing RST axons from this area	70232
@VP	growing RST axons from this area	70238
@VP	did not elicit a growth response of axotomized RST axons	70398
@VP	elicit a growth response of axotomized RST axons	70406
@VP	are coexpressed on rubrospinal neurons	70512
@VP	coexpressed on rubrospinal neurons	70516
@VP	seem to have distinct roles after injury	70572
@VP	to have distinct roles after injury	70577
@VP	have distinct roles after injury	70580
@VP	elicit regeneration-associated gene expression	70741
@VP	was shown to promote survival but not regeneration -LRB- Lu et al. , 2001b -RRB-	71000
@VP	shown to promote survival but not regeneration -LRB- Lu et al. , 2001b -RRB-	71004
@VP	to promote survival but not regeneration -LRB- Lu et al. , 2001b -RRB-	71010
@VP	promote survival but not regeneration -LRB- Lu et al. , 2001b -RRB-	71013
@VP	has been observed -LRB- Richardson et al. , 1984 -RRB-	71146
@VP	been observed -LRB- Richardson et al. , 1984 -RRB-	71150
@VP	observed -LRB- Richardson et al. , 1984 -RRB-	71155
@VP	appear more potent growth promoters for RST axons	71227
@VP	is emerging that they do not interact well with a CNS environment	71287
@VP	emerging that they do not interact well with a CNS environment	71290
@VP	do not interact well with a CNS environment	71309
@VP	interact well with a CNS environment	71316
@VP	to repair the injured spinal cord	71569
@VP	repair the injured spinal cord	71572
@VP	express a subset of factors that support neurite outgrowth	71699
@VP	support neurite outgrowth	71732
@VP	see Ramon-Cueto and Avila , 1998 ; Woodhall et al. , 2001	71771
@VP	to augment regeneration and functional recovery after spinal cord injury	71932
@VP	augment regeneration and functional recovery after spinal cord injury	71935
@VP	see Bunge , 2001 ; Blits et al. , 2002	72018
@VP	did	72144
@VP	reduce lesion size	72167
@VP	is essential to restore damaged neural networks	72444
@VP	to restore damaged neural networks	72457
@VP	restore damaged neural networks	72460
@VP	obtained	72606
